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Osteosarcoma is the most common primary malignancy of the bone with an extremely 
high propensity for aggressive growth and metastasis. While the precise molecular 
mechanism underlying the disease is poorly understood, emerging evidence has 
implicated the canonical Wnt/β-catenin signaling pathway. The overall goal of this study 
is to develop novel Wnt-targeted therapies for the treatment of osteosarcoma. We 
hypothesized that osteosarcoma progression may be delayed by disrupting the Wnt/β-
catenin pathway either by using small molecule inhibitors or by manipulating the levels 
of the endogenous antagonists, the family of secreted frizzled-related proteins (SFRPs).  
 
To test our hypothesis, we explored three specific aims: 
(1)    Assess the role and mechanism of action of small molecule Wnt/β-catenin 
inhibitors in regulating osteosarcoma cell proliferation, motility and invasion.  
(2)    Synthesize and evaluate a set of lead compounds with improved potency and 
selectivity as Wnt/β-catenin antagonists; identify the critical structural motifs for 
Wnt inhibitory activity and examine the underlying mechanism of Wnt inhibition 
of selected curcumin analogues 
(3)    Examine the functional roles and mechanism of SFRPs as tumor suppressors in 
regulating osteosarcoma cell proliferation, motility and invasion.    
 
In Aim (1), we successfully showed that curcumin, PKF118-310 and artemisinin 






inhibited U2OS cell invasion and migration. The observed anti-invasion effects were 
associated with a decrease in the expression and activities of Matrix Metalloproteinase-9, 
a Wnt target gene. We further demonstrated that the anti-proliferative effect of PKF118-
310 is attributed to PKF118-310-induced apoptosis and G2/M phase arrest, with a 
corresponding decrease in proliferation-associated Wnt target oncogenes such as cyclin-
D1, c-Myc, and survivin. In Aim (2), using curcumin as a lead, we next synthesized and 
identified several analogues that were not only up to 60 times more potent than curcumin 
as Wnt antagonists, but were also highly selective with limited cytotoxicity. Further 
structure-activity-relationship analysis of these analogues suggested that conformation 
restriction around the dienone moiety, as well as the introduction of suitable alkoxyl and 
hydroxyl group substitutions on the aromatic rings of curcumin structure, dramatically 
enhanced Wnt-inhibitory activity. Using the Human Wnt Signaling Pathway RT2 
ProfilerTM PCR array, we observed down-regulation of several Wnt target oncogenes 
such as FOSL1, PITX2 and WISP1 in U2OS cells following treatment with the most 
potent analogue (3-3), in correspondence to its anti-invasive effects. In Aim (3), we 
found that restoration of SFRPs expressions in U2OS cells suppressed the transcriptional 
activity of the β-catenin/TCF complex and significantly inhibited anchorage-dependent 
growth, colony formation efficiency and osteosarcoma cell invasion. On the other hand, 
differential effects on cell migration in U2OS stable transfectants were observed. These 
anti-proliferative effects may be attributed to GO/G1 and/or G2/M phase arrests and 
perturbations of major Wnt target proliferation-associated oncogenes including cyclin-
D1, c-Myc and survivin in the U2OS transfectants. Lastly, using the Human Wnt 






such as WISP1, Brachyury, SLC9A3R1 and JUN that might play a significant role in 
regulating osteosarcoma tumorigenesis and metastasis with over-expressions of SFRP2 or 
SFRP5. This analysis of gene perturbations provided valuable insights on the interactions 
of SFRPs with the Wnt pathway and may aid us in designing more effective SFRPs-based 
therapeutics. In conclusion, our findings not only provided deeper insights into the 
contributory role of aberrant canonical Wnt/β-catenin signaling in osteosarcoma disease 
progression, but also a greater understanding of the potential of small molecules and 
SFRPs as Wnt antagonists in osteosarcoma. These knowledge may be useful for the 
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CHAPTER 1. Introduction 
 
1.1  Osteosarcoma 
Osteosarcoma is the most frequent malignancy of the bone which predominantly affects 
rapidly growing bones such as the metaphyses of long tubular bones, especially the distal 
femur or proximal tibia in adolescents and children, and there is no sex- or race-based 
predilection [1].  High grade central osteosarcoma is by far the most frequent sub-type, 
comprising up to 80 % of all osteosarcomas. The other osteosarcoma variants, which 
differ in site, histology or biological behavior, include small cell osteosarcoma, 
osteosarcoma occurring as secondary malignancy, extra skeletal osteosarcoma, surface 
osteosarcoma and craniofacial osteosarcoma. Risk factors for osteosarcoma include states 
associated with increased osteoblast proliferation such as chronic osteomyelitis, Paget’s 
disease of bone, ionizing radiation and various rare inherited syndromes such as 
retinoblastoma and multiple exostoses [2].   
 
Osteosarcoma is a mesenchymal neoplasm characterized by locally aggressive growth 
and early metastatic potential as a result of morphologically abnormal osteoblastic cells 
producing defective immature bone (osteoid). An alarming high proportion of 20-25 % of 
patients presents with clinically detectable distant metastases at the time of diagnosis.   
The rest has a 50-60 % risk of developing metastases and often microscopic subclinical 
metastases are detected at first presentation. Effective treatment options are very limited 
for osteosarcomas that have metastasized [3, 4]. The presence of metastatic disease is the 






these patients have a disease-free survival at five years [5, 6]. Furthermore, loss of 
differentiation occurs in more than 80 % of osteosarcoma, correlates with higher grade 
and confers a 10 % to 15 % decrease in survival.   
 
The current standard treatment for osteosarcoma uses a multi-modal treatment approach 
consisting of preoperative neo-adjuvant systemic polychemotherapy, local surgical 
resection to safely remove the tumor yet preserve as much extremity as possible, 
followed by post-operative adjuvant chemotherapy. Chemotherapeutic agents aimed at 
eradicating clinically detectable metastases in osteosarcoma include doxorubicin, 
cisplatin, high-dose methotraxate and ifosfamide, which are generally given in 
combination over six to 12 months. With this standard multi-modal regimen, the five-
year relapse-free survival rates of patients with non-metastatic osteosarcoma remains low 
at approximately 60-70 % while the survival rate for patients with distance metastasis is 
less than 20 % [1]. Further, exploitation of the most commonly used chemotherapeutic 
agents against osteosarcoma has been hampered by severe and life-threatening side 
effects including antracyclin-induced cardiomyopathy, glomerular dysfunction and 
secondary cancers such as treatment-related leukemia particularly after high-dose 
cisplatin, hemorrhagic cystitis caused by ifosamide as well as renal dysfunction with 
methotrexate. At present, there is no standard chemotherapy treatment regimen for 
osteosarcoma which relapses following multi-modal first-line treatment [7, 8]. Despite 
significant clinical improvements through the use of combination intensive chemotherapy 
and surgical resection over the past few decades, prognosis for osteosarcoma patients 






metastases are very common events and the major cause of death in these patients [5, 9]. 
Moreover, effective therapeutic options available for patients who either relapse 
following administration of currently approved chemotherapeutic agents or suffer 
intolerable acute and long term toxicities from chemotherapy treatments are seriously 
lacking. Therefore, more effective treatment strategies are urgently needed to prevent or 
reduce osteosarcoma disease progression and improve patient survival rates. 
 
 
1.2  Molecular mechanisms involved in osteosarcoma tumor progression  and 
metastasis 
Identifying molecular signaling mechanisms involved in osteosarcoma tumorigenesis and 
metastasis may be the key to designing novel, safe and effective treatment therapies 
against this malignant phenotype. While the precise molecular mechanisms that regulate 
osteosarcoma disease progression and metastasis are poorly understood,  numerous 
reports on the involvement of multiple interacting and cross talked molecular signaling 
pathways associated with Cyclooxygenase-2 (COX-2), Nuclear Factor Kappa-light-
chain-enhancer of activated B cells (NF-κB) and several receptor tyrosine kinase 
signaling have expanded our understanding of the pathogenesis of osteosarcoma. For 
instance, both in vivo and in vitro studies showed that treatments with COX-2 inhibitors 
abrogated enhanced cell invasiveness and motility in osteosarcoma over-expressing 
COX-2 [10, 11]. NF-κB signaling is implicated in osteosarcoma metastasis as 
demonstrated by Harimaya et al. who found that forced expression of NF-κB decoy 
attenuated Tumor Necrosis Factor-α (TNF-α)-induced motility and invasiveness of 






over-expressed in osteosarcoma cells, and the inhibition of ET receptors effectively 
suppressed both basal and ET-1-induced osteosarcoma cell invasion through a NF-κB-
dependent mechanism [13]. Moreover, using microarray analysis studies, osteosarcoma 
cultured cell lines and tissues samples were found to over-express multiple cell-signaling 
related genes, ligands, receptors and downstream signaling molecules of the receptor 
tyrosine kinase family, and their over-expressions were closely associated with high 
potential for metastasis and bad prognosis. Examples include the Vascular Endothelial 
Growth Factor (VEGF) [14], Insulin-like Growth Factor (IGF) [15], Endothelial Growth 
Factor (EGF) [16], Signal Transducer and Activator of Transcription 3 (STAT3) [17, 18], 
Mitogen-Activated Protein Kinase (MAPK) [19], Mammalian Target of Rapamycin 
(mTOR) [20], Orphan receptor tyrosine kinase (ROR2) [21, 22] and Minibrain-Related 
Kinase (MIRK) [23].  
 
Many other genes in a myriad of tumorigenic pathways are continuously being identified 
in microarray profiling studies in the examination of causal biomolecular processes and 
novel pathways associated with osteosarcoma pathogenesis. Examples include genes that 
regulate growth and cell cycle progression (cyclins and cyclin dependent kinases), 
apoptosis (Fas, MAPKKK5), invasion and motility (AXL, chemokine receptor CXCR4, 
collagen VII, ezrin, galectin-3, Her-2/neu, MKK6, thrombospondin, fibronectin), 
angiogenesis (VEGF), DNA replication and transcription (E2F4, E2F5, Runx2) as well as 







Recently, accumulating evidence has implicated the canonical Wnt/β-catenin signaling 
pathway in osteosarcoma tumorigenesis and metastasis. Although its role has been well 
studied in many other types of malignancies, there are limited reports on the contributory 
role of aberrant Wnt/β-catenin signaling in osteosarcoma disease progression, and even 
fewer reports, if any, on the application of Wnt therapeutics in osteosarcoma treatment, 
thus there lies the potential and scope for novel research.  
 
1.3 Overview of Wnt/β-catenin signaling pathway and its implication in oncology 
The term ‘Wnt’ was coined from a combination of the Drosophila segment polarity gene 
Wingless, which is involved in segment polarity during development [29] and the murine 
proto-oncogene Int-1, that is required for the development of the forebrain, midbrain, 
cerebellum and neural crest [30, 31]. The Wnt-dependent signaling pathway is highly 
conserved among Drosophila, Dictyostelium, C. elegans, Xenopus and mammals [32, 33]. 
Wnt signaling plays pivotal roles in the regulation of body axis formation, cell 
proliferation and organogenesis in many organisms, and are important for homeostatic 
self-renewal in various tissues. Given the critical and pleiotropic roles of Wnt, it is not 
surprising that perturbations in Wnt signaling have been implicated in a range of human 
diseases and cancers [34-36]. Wnt proteins are secreted glycoproteins that act on target 
cells by binding to Frizzled receptors (FZD) and low-density lipoprotein receptor-related 
protein 5/6 (LRP5/6) co-receptors. To date, a total of 19 Wnt genes and 10 different FZD 







The complexity of molecular players on the cell surface is further illustrated inside the 
cell by the existence of at least four Wnt-dependent downstream pathways whose 
activation is dependent on the specificity of the Wnt ligands and FZD receptors, as well 
as other cellular components. These four signaling pathways include: (1) the canonical 
Wnt/β-catenin pathway that regulates the expression of Wnt target genes through TCF/β-
catenin; (2) the planar cell polarity (PCP) pathway that establishes asymmetric cell 
polarities and coordinates cell shape changes and cellular movements; (3) Wnt/Ca2+ 
pathway which controls cell adhesion and motility [39]; and (4) the most recently 
discovered Protein kinase A pathway that plays a role in myogenesis [40]. More than 50 
signaling component proteins have since been identified to transduce these Wnt signals to 
mediate diverse cellular responses. Among these four known Wnt pathways, the 
canonical Wnt/β-catenin signaling pathway is the best understood and has been identified 
as the main culprit in the cellular events that leads to cancer, whereas the role of the non-
canonical Wnt pathway is poorly understood and difficult to address. At least six of the 
19 Wnt ligands, including Wnt 1, Wnt 2, Wnt 3, Wnt 3a, Wnt 8 and Wnt 8b, have been 
reported to activate the canonical Wnt/β-catenin pathway while Wnt 4, Wnt 5a and Wnt 
11 can activate the non-canonical Wnt signaling. As presented in Table 1-1, various 
Wnt/β-catenin pathway components contributing to a wide spectrum of cancer types have 
been identified. This list continues to be added onto, giving it many layers of complexity 




















colon cancer,  breast cancer,  melanoma,  head and 
neck cancer, non-small-cell lung cancer,  gastric 
cancer, mesothelioma, osteosarcoma  
[41-48] 
FZD Increased expression 
 
colon cancer, breast cancer, head and neck cancer, 
gastric cancer 
[43, 44, 47, 49, 
50] 
LRP5  Gain-of-function mutation, 
Increased expression 




Reduced expression osteosarcoma,  non-small-cell lung cancer, 
mesothelioma, chronic lymphatic leukemia, gastric, 
breast, esophageal adenocarcinoma 
[49, 54-62] 





Reduced expression colon cancer, breast cancer,  prostate cancer, lung 




Within the cytoplasm 
DVL Increased expression  mesothelioma, non-small-cell lung cancer, cervical 
cancer 
[70-72] 
β-catenin Gain-of-function mutations 
Increased expression 
colon cancer,  osteosarcoma, Lung cancer, liver, 
endometrial ovarian cancer, pilomatricoma skin 








APC  Loss-of-function mutations/ 
Reduced expression 
colon cancer [79-81] 
Axin 1 Loss-of-function mutations 
 
liver cancer medulloblastomas , esophageal 
squamous cell carcinoma 
[82-84] 
Axin 2 Loss-of-function mutations colon cancer, hepatocellular cancer [85-87] 
Tyrosine kinases,  
Met  
Over-expressions colorectal cancer [88] 
Tyrosine phosphatase 
genes 
Mutations colorectal cancer [89] 
 
BCL9-2 Increased expression 
Rearrangement of the BCL9-2 
loci 
colon cancer, acute myeloid leukemia, acute 
lymphoid leukemia, advanced colon carcinoma 
[90-92]   
 
In the nucleus 









Increased function/ expression colorectal cancer [96] 
Wnt target oncogenes  
 
Increased function/ expression breast cancer, colorectal  cancer. 
intestinal cancer,  liver cancer,  
[60, 97-103] 
 
Abbreviations: APC: Adenomatous polypopsis coli; BCL9-2: B-cell lymphoma 9-2; CBP: Camp response element binding protein DKK: 
Dickkopf; DVL: Dishevelled; FZD: Frizzled receptor; HBP1: High-mobility-group-box transcription factor 1; HDAC: Histone deacetylase; 






On the cell surface: Initiation of Wnt/β-catenin signaling cascade 
Canonical Wnt/β-catenin signaling pathway is initiated when both the FZD and LRP5/6 
co-receptors complex with Wnt ligands [37, 38] (Figure 1-1). However, the binding 
affinities of native FZD-Wnt complexes remained undetermined due to the lack of 
purified Wnt ligands. During development, Wnt/β-catenin signaling plays an important 
role in cell fate specification, tissue patterning and control of asymmetrical cell division 
where the expression of the Wnt genes is developmentally regulated in a coordinated 
temporal and spatial manner. Activation of Wnt/β-catenin signaling is also tightly 
regulated by four families of Wnt antagonists that can be classified into two sub-groups 
according to their mode of action: the Secreted Frizzled-Related Protein (SFRP) family, 
Wnt Inhibitory Factor-1 (WIF-1) and Cerberus act as Wnt antagonists by directly 
squelching Wnt ligands, thus preventing FZD-Wnt binding, while the Dickkopf (DKK) 
family inhibits Wnt signaling by binding to LRP and Kremen receptors, and sterically 
hindering Wnt interaction with LRPs [54, 104]. The formation of the LRP-DKK-Kremen 
ternary complexes disengages the LRP receptor from the Wnt-FZD complex, precluding 
signal transduction by Wnt [104, 105]. The loss of this coordinated control in Wnt/β-
catenin signaling, however, subsequently drives the formation of numerous diseases 
including human cancers (Table 1-1). 
 
Indeed, epigenetic silencing of genes encoding endogenous Wnt antagonists such as 
SFRPs [49, 54, 55, 57-62] and WIF-1 [64-69], or increased expression of pathway 
components including Wnt ligands [41-48], FZD [43, 44, 47, 49, 50], Dishevelled (DVL) 






activation of Wnt signaling observed in many human malignancies (Table 1-1). 
Dysregulation of modulators of the Wnt pathway such as proteases activator receptor-1 
and Frat proteins which function as activators as well as Idax and Naked which inhibits 
Wnt signaling may also be implicated with cancer progression [106-108].  
 
 
Within the cytoplasm: Stabilization of β-catenin 
Stabilization of the β-catenin protein within the cytoplasm is the key to the activation of 
canonical Wnt/ β-catenin signaling (Figure 1-1). Upon binding of the Wnt ligand to the 
LRP/FZD complex, DVL is phosphorylated and through its association with Axin and 
Adenomatous Polyposis Coli (APC) tumor suppressor, prevents Glycogen Synthase 
Kinase-3β (GSK-3β) and Casein Kinase-1α (CK-1α) from phosphorylating β-catenin 
[109, 110]. Unphosphorylated β-catenin is stabilized by escaping recognition by the β-
Transducin Repeat-Containing Protein (β-TrCP), a component of an E3 ubiquitin ligase 
complex, and subsequently translocates to the nucleus where it interacts with the T-Cell-
specific Transcriptional Factor/Lymphoid Enhancer Binding Factor (TCF/LEF) to 
activate the expression of Wnt target genes [77, 111, 112]. Mutations of oncogenes and 
tumor suppressor genes including APC, Axin and β-catenin in Wnt signaling not only 
initiate events in cancer formation, but also facilitate their progression into malignant, 
invasive and metastatic cancers (Table 1-1). Approximately 90% of colon cancers 
showed aberrant Wnt signaling, usually as a result of mutation in APC (80 %) [79-81], 
and less frequently due to mutations in β-catenin [76, 77] or Axin [85, 86]. Mutations of 
the conserved serine/threonine phosphorylation sites of β-catenin block its targeted 









Figure 1-1. The Wnt/β-catenin signaling cascade. Left: In the absence of Wnt ligands 
and/or when secreted endogenous antagonists such as Cerberus, Wnt Inhibitory Factor-1 
(WIF-1), Secreted Frizzled-Related Proteins (sFRPs) or Dickkopf (DKKs) are present, β-
catenin levels are tightly regulated by a degradation complex comprising of Axin, 
Adenomatous Polyposis Coli (APC) and Glycogen Synthase Kinase-3β (GSK-3β). 
Transcription of TCF/LEF target genes is effectively repressed by Groucho, histone 
deacetylases (HDAC) and HMG-box transcription factor 1 (HBP1) transcriptional co-
repressors. Right: The binding of Wnt ligands to Frizzled receptor (FZD) and low-density 
lipoprotein receptor-related protein 5/6 (LRP5/6) co-receptor hyperphosphorylates 
Dishevelled (DVL), leading to inhibition of the β-catenin degradation complex. The 
resultant effect is β-catenin translocation to the nucleus where it activates the 
transcription of target genes by directly displacing the transcriptional repressors and 
recruiting an array of co-activator proteins including Pygopus (Pygo), SWI/SNF 
chromatin-remodeling complex member (Brg1), histone acetylase CREB-binding protein 






or Axin 1 compromises their functions as the APC-Axin-GSK3β β-catenin destruction 
complex. Axin 2 is an axin homologue that shows 45 % homology to Axin 1, with similar 
biochemical properties. Whereas Axin 1 is a constitutively expressed component of the β-
catenin degradation complex, Axin 2 is up-regulated in response to increased β-catenin 
concentrations and functions to limit the duration and intensity of Wnt signaling. In 
contrast to colorectal cancers, frequent mutation of β-catenin that results in Wnt signaling 
dysfunction have been detected in many non-colorectal cancers such as liver cancer 
(hepatocellular and hepatoblastoma), endometrial ovarian cancer, pilomatricoma skin 
cancer, prostate cancer, melanoma and Wilms tumor [73-78]. Mutations of Axin 1 and 
Axin 2 were observed in some liver cancers, esophageal squamous cell carcinoma and 
medulloblastomas [82-84, 87] while non-colon cancers are very rarely due to loss of APC 
function.   
 
Cellular re-distribution of β-catenin within the cytoplasm  
In addition to its role in gene regulation, β-catenin is involved in regulating cell-cell 
adhesion by acting as a structural adaptor protein linking E-cadherin to the actin 
cytoskeleton in the plasma membrane [97, 113-117] (Figure 1-1). Both functions of β-
catenin are deregulated in several cancers, thus leading to the loss of β-catenin/E-
cadherin-mediated cell adhesion and a corresponding increase in β-catenin-dependent 
transcription. The switch between these two functions, which directly controls the 
shuttling of β-catenin between the plasma membrane and nucleus, is tightly regulated by 
several factors including the presence of E-cadherin-mediated cell adhesion, interaction 






phosphorylation of β-catenin [118, 119]. Phosphorylation of tyrosine residue 654 of β-
catenin by either c-scr or the epidermal growth factor receptor leads to the loss of E-
cadherin binding while the tyrosine kinases Fer, Fyn or Met are capable of inducing 
phosphorylation of tyrosine residue 142 of β-catenin to disrupt interaction with α-catenin 
but promotes binding of β-catenin to the nuclear co-factor B-Cell Lymphoma 9-2 (BCL9-
2) [118-123]. The β-catenin-BCL9-2 complex subsequently localizes to the nucleus and 
regulates the transcription of crucial target oncogenes upon interaction with the TCF/LEF 
DNA binding proteins [120]. Accordingly, over-expressions of tyrosine kinases and 
mutations in tyrosine phosphatase genes that might catalyze these phosphorylation 
processes have been reported in colorectal cancers [88, 89] (Table 1-1). BCL9-2 
expression was found to be elevated in a series of human colon cancer samples [124]. 
Moreover, BCL9-2 gene is located in a region where frequent amplifications, deletions, 
loss of heterozygosity or gene rearrangement have been reported in several cancers 
including acute myeloid leukemia, acute lymphoid leukemia and advanced colon 
carcinoma, indicating that rearrangement of the BCL9-2 loci is involved in tumor 
formation and progression [90-92]. APC also plays an important role in switching the 
function of β-catenin between cell adhesion and Wnt signaling. APC binds directly with 
β-catenin, α-catenin and actin filament in the cell-cell adhesion complex linked with E-
cadherin [125, 126]. As such, APC loss-of-function potentially couples loss of cell 
adhesion to activated Wnt signaling, in a similar manner as Y142 phosphorylation of β-
catenin which shifts β-catenin from adherens junctions to the nucleus.  In addition, this 
preferential movement of β-catenin can be influenced by distinctive conformational 






promotes the formation of a monomeric form of β-catenin that preferentially interacts 
with TCF/LEF proteins in the nucleus while another distinctive form that exists as a β-
catenin-α-catenin dimer preferentially binds to E-cadherin at the plasma membrane [127].  
 
In the nucleus: Wnt/β-catenin-mediated gene transcriptional activity 
The human TCF/LEF proteins, consisting of TCF-1, LEF-1, TCF-3 and TCF-4, belong to 
a family of transcriptional factors that bind DNA in a sequence-specific manner through 
their High Mobility Group (HMG) domains, but lack the capability to activate gene 
transcription independently [128]. In the absence of Wnt ligands, levels of nuclear β-
catenin remain low, which in turn allow the DNA binding TCF/LEF protein to interact 
with transcriptional co-repressors such as Groucho, Histone Deacetylases (HDAC) and 
HMG-Box Transcription Factor 1 (HBP1), thus blocking target gene transcription [95, 
129, 130] (Figure 1-1). Although activating mutations in TCF/LEF genes are rare in 
human cancers, Duvel et al. has recently reported a frequent frame shift mutation in TCF-
4 in human colorectal cell lines [93]. 
 
Besides regulation through the transcriptional co-repressors, nuclear APC plays a critical 
role in the control of nuclear β-catenin levels and activity by binding to β-catenin and 
inducing its nuclear export [131, 132]. Nuclear translocation of β-catenin converts the 
TCF/LEF protein into a potent transcriptional activator by directly displacing the 
transcriptional repressors and recruiting an array of co-activator proteins including 
histone acetylase cAMP Response Element Binding Protein (CBP/p300), SWI/SNF 






Homeodomain 2 (PITX2), Pygopus (Pygo), mediator and Hyrax/parafibromin (a member 
of the polymerase-associated factor complex) to activate transcription of at least 300-400 
Wnt target genes with diverse functions [133-141]. Notorious examples of Wnt target 
genes include oncogenes that are involved in cancer cell proliferation (cyclin-D1, c-Myc, 
survivin) [97, 98, 142], adhesion (E-cadherin, neuronal cell adhesion molecule) [143], 
tumor metastasis (Matrix Metalloproteinases (MMPs) [99-101], keratin 1 [102], 
Urokinase Plasminogen Activated Receptor (uPAR) [103], CD44 [144], VEGF [145] 
WNT1-Induced Secreted Protein 1 (WISP-1) [146]) and cell differentiation (siamois, 
brachyury T gene) [147, 148]. Other Wnt responsive genes comprise of components of 
the Wnt pathway itself such as LRPs, Axin2, β-TrCP and TCF/LEF, suggesting an auto-
regulation of Wnt signaling. The list of downstream target oncogenes will undoubtedly 
be expanded and it would be very useful to elucidate the relevance of these genes in 
human cancer. 
 
Wnt/β-catenin signaling pathway in the disease progression of osteosarcoma 
Although its role has been well studied in many other types of malignancies, the 
knowledge of the Wnt/β-catenin signaling in osteosarcoma is limited. Specifically, over-
expression of numerous Wnt components including Wnt ligands and Frizzled receptors, 
as well as the epigenetic silencing of genes encoding endogenous Wnt pathway inhibitors 
such as SFRP3 and WIF-1, highlighted the implications of aberrant Wnt/β-catenin 
signaling in the development and progression of this malignant phenotype [47, 56, 65]. 
Elevated levels of cytoplasmic and nuclear β-catenin have also been reported in 






LRP5, in osteosarcoma specimens correlated significantly with metastatic events [47] 
while Wnt10b ligand induced osteosarcoma chemotaxis and its expression correlated 
with reduced survival [48]. Dominant-negative LRP5 (DN-LRP5) has also been shown to 
inhibit both in vitro and in vivo osteosarcoma growth and metastasis by down-regulating 
MMPs, Twist, Slug, Snail and N-cadherin [51, 52]. Furthermore, DKK-3, an endogenous 
inhibitor of the pathway, inhibited the motility and invasiveness of osteosarcoma cells by 
affecting intracellular β-catenin [63]. Kansara et al. has also found that WIF-1 is silenced 
in human osteosarcoma and when deleted in mice, accelerates radiation-induced 
osteosarcoma formation [65]. Most recently, Rubin et al. reported that restoration of 
WIF-1 markedly reduced the number of lung metastasis in vivo in an orthopedic mouse 
model of osteosarcoma [149]. Given these observations, disruption of the Wnt/β-catenin 
signaling pathway is an attractive approach for developing effective therapies for 
osteosarcoma. It is thus our goal to perturb critical nodal points in the Wnt/β-catenin 
pathway with the aim of developing novel Wnt-targeted therapies to prevent or reduce 
osteosarcoma disease progression.  
 
 
1.4 Strategies in inhibiting the Wnt/β-catenin signaling pathway 
Overwhelming evidence implicates aberrant activation of Wnt signaling in oncogenesis 
and cancer progression. Given the complexity of the canonical Wnt/β-catenin signaling 
pathway and its tight regulation at multiple cellular levels, the pathway offers ample 
targeting nodal points for rationale drug development to treat cancer. Wnt therapeutic 
interventions can be targeted at many junctures to: (1) disrupt receptor-ligand interactions 






enhance proteosomal degradation of cytoplasmic β-catenin; (4) interrupt β-catenin/TCF 
complexation and/or (5) inactivate Wnt target oncogenes transcription within the nucleus. 
Despite intense efforts and interest by pharmaceutical and biotechnology sectors in 
developing effective Wnt signaling pathway antagonists, drug development specifically 
targeting the aberrant Wnt/β-catenin pathway is still in its infancy, with no drugs 
currently in late-stage clinical trials.  Nevertheless, numerous in vitro and in vivo reports 
on the effective use of Wnt therapeutics on cancer caused by aberrant Wnt activation are 
extremely encouraging and should motivate the accelerated discovery of yet more potent 
and novel Wnt therapeutics. 
 
 
1.4.1 Existing drugs as Wnt therapeutics 
 
A number of drugs that are either already on the market or are currently being evaluated 
for use in other diseases such as Non-Steriodal Anti-Inflammatory Drugs (NSAIDs) and 
vitamin derivatives have been reported to target Wnt signaling. NSAIDs, which are used 
worldwide for the treatment of pain, inflammation and fever, have recently been shown 
to dampen the Wnt signaling pathway in colorectal cancers and curb tumor growth in 
vivo [150]. Increasing evidence showed that the activities of the COX and Wnt signaling 
pathways might be inextricably linked in colon cancers and could be subject to concerted 
regulation in vivo by NSAIDS [151, 152]. A direct support for this was provided in study 
describing the substantial reduction of nuclear β-catenin levels in polyps of Familial 
Adenomatous Polyposis (FAP) patients treated for six months with the NSAID sulindac 
sulphide [150]. Furthermore, elevated COX activity in colon cancer was demonstrated to 






by interfering with the capacity of cells to degrade β-catenin [151, 152]. Thus the 
reduction of prostaglandin levels by inhibition of COX activity in the tumors could 
account for the observed ability of NSAIDS to dampen the Wnt signaling pathway and 
curb tumor growth. Most recently, celecoxib (a COX-2 inhibitor) was also shown to 
inhibit β-catenin-dependent survival of MG-63 osteosarcoma cell line [153].  
 
Unfortunately, the clinical use of NSAIDs is limited by severe intestinal bleeding and/or 
kidney failure caused by COX-1 inhibitors and potential cardiovascular side effects of 
COX-2 inhibitors. Vitamin derivatives such as retinoids are reported to inhibit colon 
cancer growth in vitro and in animal models by reducing TCF-β-catenin complex 
formation [154, 155]. However, a more recent study recorded increased intestinal tumor 
growth in mice treated with retinoic acid and raised some doubts regarding their 
therapeutic potential [156]. 
 
1.4.2  Novel approaches in Wnt therapeutics  
Although existing drugs in the market such as NSAIDs and vitamin derivatives seemed 
promising in in vitro and limited in vivo assays, their clinical potential is limited by their 
inability to reduce adenoma formation in approximately 50 % of treated patients and 
unwanted side effects. Therefore there is an urgent need to continuously develop more 
effective and selective Wnt inhibitors, and several of the promising approaches that are 
currently being explored in persuit of these inhibitors targeting Wnt-activated cancers are 








Antibodies against over-expressed membrane Wnt components such as Wnt ligands and 
FZD proteins are particularly useful for a range of human cancers without mutations in 
APC, Axin or β-catenin, but instead have increased expression of more upstream pathway 
components. For instance, WNT1 and WNT2 monoclonal antibodies effectively 
suppressed Wnt signaling in several cancers over-expressing these Wnt ligands including 
breast [157], head and neck [44], non-small cell lung carcinoma [157], gastric [41], colon, 
melanoma [158], mesothelioma [157] and sarcoma [157] (Table 1-2). FZD1 and FZD2 
receptors, highly expressed in breast [43] and colon cancers [159] compared to normal 
tissues, represent alternative targets for antibody-based therapies. Most recently, the 
development of antibody-based therapeutics were made even more attractive by the 
discovery that treatment with WNT1 antibody strongly induced apoptosis in colon 
cancers cell lines that over-expressed this ligand even in the presence of additional 
downstream mutations [61, 160]. Membrane proteins encoded by Wnt target genes are 
also excellent potential therapeutic targets for antibody-based therapies. 
 
Viral-based therapeutics 
The biggest advantage of viral-based therapies is their high therapeutic efficacy and 
selectivity. This is typically achieved by oncolytic virus which target the cancer cells by 
either restricting infection and replication of cell-destroying virus to the cancer cells or by 
selective expression of virally encoded genes that produce toxins or prodrug-converting 
enzymes in these cells [161] (Table 1-2). The oncolytic viral approach has been used 






FADD (Fas-associated via death domain) gene or cytotoxic genes encoding diphtherin 
toxin A in colon cancer cell lines with hyperactive TCF/β-catenin signaling [162, 163]. 
Similarly, other examples that selectively target tumor cells which exhibit aberrantly high 
TCF/β-catenin activity include the development of replicating adenovirus that expressed 
tumor-selective viral E1B, E1A, E2 and E4 genes from promoters controlled by the TCF- 
4 transcriptional factor [164, 165]. Furthermore, several recombinant adenoviruses in 
combination with prodrug treatment have been shown to effectively and selectively kill 
cancer cells with active TCF/β-catenin activity, but spare the control normal cells. One 
example is the effective use of an adenovirus expressing the thymidine kinase gene under 
the control of a TCF-responsive promoter which selectively killed colon cancer cells with 
hyperactive TCF/β-catenin signaling following treatment with the prodrug ganciclovir 
[166]. Recent examples include selectively replicating adenovirus expressing genes 










Approaches Tumor targeted  References 
 
Extracellular and membrane 
Wnt ligands Antisense  
Monoclonal antibodies 
Breast, Colon, Head and neck, NSCLS, gastric, 
Melanoma, Mesothelioma, soft tissue sarcoma  
[41, 44, 157, 158]  
FZD Antisense  
Monoclonal antibodies 
Breast, Colon  [43, 159] 
SFRPs sFRPs over-expression 
Therapeutic proteins  
Breast, Cervical, Colorectal, Gastric, Mesothelioma, 
Liver,  Lung, osteosarcoma Tetratocarcinoma, 
[55, 61, 167] 
WIF sFRPs over-expression 
Therapeutic proteins  








[63, 168, 169]. 
 
Within the Cytoplasm 
APC wt-APC over-expressions  Colon  [170] 
Axin 
 
wt-Axin over-expressions Colon, hepatocellular carcinoma [83] 
β-catenin Antisense oligos 
RNA interference 
Protein knockdown 
Breast, Colon, NSCLS, Esophageal, 
squamous cell carcinoma 
[171-175].   
COX-2 COX-2 Inhibitors Breast, Colon, NSCLS [150, 176, 177] 
 
In the Nucleus 
TCF/LEF Retinoids 
Apoptotic/Suicide HSV-








Small molecule inhibitor 
Oncolytic virus 
CBP Inhibition of CBP Colon [179] 
c-MyC Antisense oligos 
 
Breast, Colon 
Liver, Prostate, Melanoma, 
[182, 183] 
CyclinD1 Cdk inhibitor Breast, Colon, Glioblastoma, Leukemia, Lymphoma, 
Melanoma, NSCLS,  Prostate, renal cell carcinoma, 
squamous cell carcinoma, soft tissue sarcoma, Uterine,   
[184, 185] 
 
Abbreviations: APC: Adenomatous polyposis coli; CBP: Camp response element binding protein; COX-2: Cyclooxygenase-2; DKK: Dickkopf; 
FZD: Frizzled receptor; SFRP: Secreted frizzled-related protein; WIF: Wnt inhibitory factor; NSCLC: non-small cell lung cancer; TCF/LEF: T-









toxic drug 5-fluorouracil [180], and Escherichia coli nitroreductase which activates the 
prodrug CB1954 [181].  
 
Recombinant adenoviruses are also used to constitutively express Wnt components that 
are suppressed due to genetic mutations. For example, adenoviruses (Ad-CBR) that 
constitutively expressed APC induced apoptosis and growth arrest by blocking TCF-β-
catenin transcriptional activity in colorectal cancer cell lines with mutant APC [170]. 
Similarly, adenovirus-mediated gene transfer of wild-type Axin-1 promoted apoptosis in 
colorectal and hepatocellular cancer cells that have aberrant Wnt activation due to Axin-1 
mutation [83].  
 
Nucleic-acid-based therapeutics (vaccines, antisense and small interfering RNA) 
Antisense oligonucleotides are single stranded DNA, RNA or chimeric RNA/DNA that 
are designed to specifically hybridize to a target mRNA and subsequently prevent protein 
synthesis. As many human cancers with aberrant Wnt signaling ultimately results in 
increased β-catenin levels, direct targeting of this key protein using anti-sense and RNA 
interference (RNAi) strategies have attracted a lot of attention. Several studies using 
antisense oligonucleotides have demonstrated decreased β-catenin levels and inhibition of 
cell proliferation, adhesion, invasiveness and anchorage-dependent growth in various 
cancer cells and in vivo xenograft models [171-173] (Table 1-2). Other studies have 
developed and evaluated the therapeutic potential of RNAi targeting β-catenin: Van et al. 
created an inducible vector system expressing β-catenin small interfering RNA (siRNA) 






cell lines [174]. In another study, siRNA against β-catenin suppressed in vitro and in vivo 
tumor growth of colon cancer [175]. 
 
Microarray analyses of TCF-dependent gene expressions in human cancer cells suggest 
that there are currently at least 300-400 oncogenes that regulate cancer cell proliferation, 
differentiation, migration, apoptosis and other processes that leads to cancer initiation and 
progression [186]. Given that some of these targets such as c-Myc and cyclin D1 are 
directly implicated in driving cancer formation, current therapeutic approaches use RNAi 
or small membrane-permeable antisense molecules to reduce c-Myc and cyclin D1 RNA 
levels [183]. AVI-4126 is an example of a c-Myc specific antisense molecule that 
effectively suppressed growth in various cancer xenograft murine models including 
breast, prostate, melanoma and liver [182].  
 
Small molecule inhibitors 
Drugs developed to disrupt TCF-β-catenin signaling activity undoubtedly have great 
potential as effective cancer therapeutics, given that a common feature of almost all 
cancers with aberrant activation of Wnt/β-catenin pathway is the constant presence of 
TCF-β-catenin complexes in the nuclei. Although no small-molecule inhibitors of the 
TCF-β-catenin has yet been identified by High Throughput Screening (HTS) of large 
synthetic compound libraries, three natural occurring compounds (PKF115-584, PKF222-
815 and CPG049090) from a HTS of natural compounds consistently scored as effective 
antagonists of  TCF-β-catenin complexation by binding to either TCF or β-catenin [178] 






include development of small molecule inhibitors that prevent interaction of β-catenin 
with crucial transcriptional co-activator proteins such as CBP and BCL-9/pygopus. For 
instance, ICG-001 was found to inhibit growth of colon cancer cell lines and xenografts 
mouse models by selectively binding CBP, thus preventing interaction with β-catenin 
[179]. Small molecule inhibitor of the interaction between BCL-9 and β-catenin has also 
been developed. Low-molecular weight compounds that target other transcriptional co-
activators such as BRG-1, Pygopus, Hyrax and components of the Mediator complex are 
also under scrutiny for potential therapeutic applications [187].  
 
In addition, the increasing availability of detailed crystal structures of various 
components of the Wnt pathways down the whole signaling cascade, ranging from β-
catenin, Axin, APC, DVL and their complexes should allow future design and testing of 
small molecule compounds that interfere with their activity [125, 188-191]. To this end, 
Shan et al. has recently developed a small molecule, NSC668036, which binds to DVL 
and blocks its interaction with FZD; NSC668036 is of great therapeutic value to prevent 
or minimize signaling relay and amplifications [192].  
 
Natural products are traditionally excellent sources of lead compounds in the drug 
discovery and development process, and are gaining prominence as effective antagonists 
of the Wnt/β-catenin signaling pathway. Indeed, a wide variety of natural compounds 
ranging from phytochemicals, microorganisms, fungi, slime molds to bacteria have been 






In fact, we have recently written a review entitled ‘Natural compounds as antagonists of 
canonical Wnt/β-Catenin Signaling’ published in Current Chemical Biology (2010). In 
this review, we provided a comprehensive summary on the current use of natural 
compounds as Wnt therapeutics and the development of more efficacious analogues 
using these compounds as lead structures. Increasing evidence of natural products as rich 
and diverse sources for lead compounds would inspire more concerted efforts to harness 
this largely untapped ‘reservoir’ for ‘drug-like’ molecules and accelerated their 
development as effective Wnt therapeutics. To this end, , we have examined the role and 
mechanism of actions of small molecule drugs derived from natural sources as Wnt/β-
catenin inhibitors in regulating osteosarcoma cell proliferation, motility and invasion in 
this thesis.   
 
Therapeutic proteins 
Therapeutic proteins of endogenous Wnt antagonists such as SFRPs, WIF-1 and DKK 
have great therapeutic potential for the treatment of human oncology as a result of 
epigenetic inactivation of these secreted negative regulators. Significant transcriptional 
down-regulation of SFRPs gene family via hypermethylation has been observed in many 
human malignancies including breast, lung, cervical, liver, gastric, colorectal and 
osteosarcoma, just to name a few [55] (Table 1-2). Restoration of SFRP functions in 
these tumor types have shown to effectively attenuate Wnt signaling even in the presence 
of downstream mutation [61], highlighting the great potential of using SFRPs as a 







Indeed, sFRPS therapeutic proteins, which functions as Wnt antagonist are currently been 
developed and evaluated in preclinical tumor models [167]. It is also one of our research 
objectives to examine the functional roles and mechanisms of SFRPs as tumor 
suppressors in regulating osteosarcoma cell proliferation, motility and invasion. Several 
recent studies have explored the anti-cancer potential of WIF-1 proteins, another group of 
antagonist which blocks Wnt signaling in a similar manner as SFRPs by directly 
squelching Wnt ligands, thus preventing FZD-Wnt binding. WIF-1 is down-regulated in 
prostate, mesothelioma, breast, lung, and bladder cancer, as well as osteosarcoma, and 
restoration of WIF-1 expression would in a similar manner prevent or reduce 
tumorigenesis and metastasis in these cancers [64-69]. DKK-3 is the third class of natural 
Wnt antagonist which has been reported to be down-regulated in many immortalized and 
tumor derived cell lines. However, forced expression of DKK-3 significantly inhibited 
cell growth and invasion in non-small cell lung cancer and osteosarcoma cells 
respectively [63, 168, 169]. Accordingly, exogenous proteins of these Wnt antagonists 
that are down-regulated in numerous cancers hold great promise as therapeutic agents for 






CHAPTER 2. Hypothesis and Aims  
 
Evidence that implicates aberrant activation of the canonical Wnt/β-catenin signaling 
pathway in osteosarcoma has only recently emerged. There are very limited, if any, 
reports on the use of Wnt therapeutics in the treatment of osteosarcoma and there lies the 
potential and scope for novel research. The overall goal of this study is thus to perturb 
critical nodal points in the Wnt/β-catenin signaling pathway both pharmacologically and 
genetically with the aim of developing novel Wnt-targeted therapies to prevent or reduce 
osteosarcoma progression and metastasis, thereby improving the clinical outcomes of this 
disease.  
 
We hypothesized that osteosarcoma progression may be delayed by disrupting the Wnt/β-
catenin signaling pathway either by using small molecule inhibitors or by manipulating 
the levels of the endogenous antagonists, SFRPs. Our hypothesis was based on several 
observations: Firstly, numerous Wnt signaling components including Wnt ligands and 
Frizzled receptors were found to be over-expressed in osteosarcoma [47, 56, 65], while 
many genes encoding endogenous Wnt antagonists such as SFRP3 and WIF-1 were 
epigenetically silenced [47, 56, 65]. Secondly, accumulation of cytoplasmic and nuclear 
β-catenin was commonly observed in osteosarcoma and nuclear translocation of β-
catenin protein correlated with osteosarcoma metastasis [73, 74]. Others have also 
reported that high expression of the Wnt co-receptor, LRP5, in osteosarcoma specimens 
associated with decreased patient survival [47] while increased expression of Wnt10b 






the other hand, blocking Wnt signaling using DN-LRP5 and DKK3 resulted in inhibitions 
of both osteosarcoma growth and metastasis through down-regulating Wnt-responsive 
oncogenes including MMPs, Twist, Slug, Snail and N-cadherin [51, 52], Lastly, Kansara 
et al reported that WIF-1 was silenced in human osteosarcoma and when deleted in mice, 
accelerated radiation-induced osteosarcoma formation [65]. These studies were later 
supported by  Rubin et al. who showed  that restoration of WIF-1 markedly reduced the 
number of lung metastasis in an orthopedic mouse model of osteosarcoma [149]. Given 
these observations, disruption of the Wnt/β-catenin signaling pathway is an attractive 
approach for developing effective therapies for osteosarcoma. 
 
To test our hypothesis, we explored three specific aims: 
(1) Assess the role and mechanism of actions of small molecules Wnt/β-catenin 
inhibitors in regulating osteosarcoma cell proliferation, motility and invasion.  
(2) Synthesize and evaluate a set of lead compounds with improved potency and 
selectivity as Wnt/β-catenin antagonists; identify critical structural motifs for Wnt 
inhibitory activity; and examine the underlying mechanism of Wnt inhibition of 
selected curcumin analogue. 
(3) Examine the functional roles and mechanisms of SFRPs as tumor suppressors in 
regulating osteosarcoma cell proliferation, motility and invasion.   
 
Work done to address these specific aims was included in the following chapters: In 
Chapter 3, we provided important in vitro proof-of-concept for the potential use of small 






(Aim 1).  In Chapter 4, we evaluated and identified curcumin analogues with enhanced 
Wnt inhibitory potency and reported critical structural motifs for Wnt inhibitory activity 
using structure-activity–relationship analysis (Aim 2).  In Chapter 5, we reported the role 
of SFRPs as tumor suppressors in delaying osteosarcoma disease progression (Aim 3). 
Lastly, the thesis is concluded with a summary and perspectives on the subject matter 
(Chapter 6).  
 
Achieving the above aims not only provided deeper insights into the contributory role of 
aberrant canonical Wnt/β-catenin signaling in osteosarcoma disease progression and 
metastasis, but a greater understanding of the role and functions of small molecule Wnt 
antagonists and SFRPs in osteosarcoma. These knowledge maybe useful for the 
subsequent discovery and development of novel molecular Wnt-targeted therapy for the 





CHAPTER 3. Antitumor activity of natural small molecule compounds as 
Wnt/β-catenin antagonists against human osteosarcoma cells  
 
3.1 Introduction 
Aberrant activation of the canonical Wnt/β-catenin signaling pathway has been 
implicated in tumorigenesis and cancer progression in many human malignancies [47, 48, 
51, 52, 63, 193]. Small molecule inhibitors of Wnt/β-catenin signaling pathway clearly 
hold great promise as an effective therapeutic strategy for the delay of disease 
progression in these malignancies. While intense efforts from screening diverse natural 
compound libraries made in this quest for effective Wnt antagonists has led to the 
discovery of numerous effective candidates, drug development in this area is still in its 
infancy, with no drugs currently in late-stage clinical trials. Particularly, evidence of 
deregulated Wnt/β-catenin signaling in osteosarcoma has only recently emerged; there 
are thus limited, if any, reports on the use of such small molecule inhibitors derived from 
natural sources in delaying osteosarcoma disease progression and there lies the potential 
and a great scope for novel research.  
 
Our first aim of this thesis is to assess the role and mechanism of actions of small 
molecule Wnt/β-catenin inhibitors in regulating osteosarcoma cell proliferation, motility 
and invasion. The goal of this part of the dissertation is to provide important in vitro 
proof-of-concept for the potential use of small molecule Wnt/β-catenin inhibitors to delay 




inhibitory activities may then be modified by medicinal chemistry to increase the potency 
and selectivity.  
 
Our data demonstrated that curcumin significantly inhibited Wnt/β-catenin signaling and 
reversed Wnt/β-catenin-induced cell invasiveness and MMP-9 expression in U2OS cells. 
Furthermore, another natural compound, PKF118-310, inhibited osteosarcoma cell 
invasion, migration and proliferation, as well as induced apoptosis and G2/M phase cell 
cycle arrest, through down-regulating Wnt target genes including MMP-9, cyclin D1, c-
Myc and survivin. Our results strongly suggest that curcumin and PKF118-310 may be 
promising candidate drugs for development, given the limited chemotherapeutic options 
available for the treatment and prevention of osteosarcoma. Building on these promising 
results, we then developed analogues with increased potency and selectivity using 
curcumin as our lead compound in our second aim detailed in the next chapter.    
 
3.2 Experimental Methods 
3.2.1  Cell culture, transfections and plasmids 
The human osteosarcoma cell lines U2OS, SaOS-2 and HOS were purchased from 
American Tissue Culture Collection (Rockville, MD) while CRL11226, CRL1423, OS1, 
OS2 and OS3 have been described previously [194] and were kindly provided by Dr 
Saminathan S. Nathan (Department of Orthopaedic Surgery, Yong Loo Lin School of 
Medicine, National University of Singapore). All cell culture reagents were purchased 
form Sigma Chemical Co. (St Louis, MO) unless otherwise stated. U2OS, SaOS-2 and 




cells were maintained in DMEM, RPMI and RPMI: DMEM 9:1 medium respectively. All 
media were supplemented with 10-15 % fetal bovine serum (FBS) (Invitrogen, Carlsbad, 
CA), 10U/ml penicillin G and 100μg/ml streptomycin. The cells were cultured in a 
humidified atmosphere at 37 ºC containing 5 % CO2. TOPglow and FOPglow reporters 
used in the luciferase reporter gene assays were purchased from Upstate Biotechnology 
(Lake Placid, NY). The pSV-β-galactosidase control vector and pcDNA3.1 empty 
plasmids were purchased from Promega (Madison, WI) and Invitrogen (Carlsbad, CA) 
respectively. The plasmids for wild-type (pcDNA β-catenin) and mutant S33Y β-catenin 
(pcDNA S33Y) were kindly provided by Dr Georges Rawadi (Galapagos SASU, 
Romainville, France) and have been described previously [76]. PKF118-310 (Asinex, 
Winston-Salem, NC), curcumin (Sigma Chemical Co., St Louis, MO), quercetin (Sigma 
Chemical Co., St Louis, MO), artemisinin (Sigma Chemical Co., St Louis, MO), 
artesunate (Sigma Chemical Co., St Louis, MO), LiCl (Sigma Chemical Co., St Louis, 
MO), BIO (Merck, Darmstadt, Germany) and SB216763 (Sigma Chemical Co., St Louis, 
MO) were dissolved in Dimethyl Sulfoxide (DMSO) before use. The final concentration 
of DMSO did not exceed 0.1 % in all instances. 
 
3.2.2  Cell proliferation assay 
The effects of test compounds on the proliferation of U2OS, SaOS-2 and HOS cells were 
examined using 3-(4, 5 dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
assays. U2OS, SaOS-2 and HOS cells were seeded into 96-well plates at a density of 9 x 
103 cells/well, 10 x 103 cells/well and 5.5 x 103 cells/well respectively and cultured for 24 




DMSO (vehicle control) for 72 h. For time-response assays, U2OS cells were treated in 
the same manner for 24 h and 48 h. After treatment, cell growth was analyzed by adding 
100 μl of 1 mg/ml MTT (Sigma Chemical Co., St Louis, MO). Following an incubation 
period of 4 h, DMSO was added to lyse the cells and dissolve the purple formazan 
crystals. The absorbance of the formazan product was determined at λmax of 595 nm 
using a Tecan Spectra Fluor spectrophotometer (MTX Lab Systems Inc., Vienna, VA). 
The IC50 values were obtained from the sigmoidal curve by plotting the percentage 
survival of cells against the concentration of curcumin or PKF118-310 using GraphPad 
Prism version 4.0 for Windows, GraphPad Software (San Diego, CA). 
 
3.2.3  Luciferase reporter gene assay 
U2OS cells (1.0 x 105/well) grown to 90–95% confluency in 24-well plates were 
transiently co-transfected with either 0.3µg TOPglow, a luciferase reporter construct 
containing four TCF consensus binding sites upstream of the firefly luciferase cDNA, or 
0.3 µg FOPglow, a negative control plasmid with mutated TCF binding sites, and 0.1 µg 
pSV-β-galactosidase plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 
according to the manufacturer’s instructions. For the extrinsic activation of the canonical 
Wnt/β-catenin signaling pathway, U2OS cells were co-transfected with one other gene, 
the wild-type (pcDNA β-catenin) or mutant S33Y β-catenin gene (pcDNA S33Y). The 
amount of DNA in each transfection was kept constant by the addition of an appropriate 
amount of the empty expression vector (pcDNA3.1). Five to twenty hours post-
transfection, cells were treated with compounds at various concentrations for 24 h before 




molecule GSK-3β inhibitors, U2OS cells were incubated with 5 μM BIO or 50 μM 
SB216763 with various concentrations of curcumin or PKF118-310 for 24 h before cells 
were lysed using the Reporter Lysis Buffer (Promega, Madison, WI). Luciferase assays 
were performed with the Luciferase assay systems kit (Promega, Madison, WI) according 
to the manufacturer’s instructions. Cell lysates (20 µl) were incubated with 50 µl of β-
galactosidase assay buffer (Promega, Madison, WI) at 37 ºC for 40 mins and absorbance 
at λmax of 420 nm was measured in a Tecan Spectra Fluor spectrophotometer (MTX Lab 
Systems Inc., Vienna, VA) to determine β-galactosidase activity. For luciferase activity, 
20 µl cell lysate was mixed with luciferin (100 µl) and the light output was determined in 
a luminometer (Tecan, MTX Lab Systems Inc., Vienna, VA). Results were expressed as 
mean ± Standard Error Mean (SEM) of normalized ratios of luciferase and β-
galactosidase activities for each triplicate sets. Reporter activities in compound-treated 
cells were expressed as the percentage of DMSO-treated samples.  
 
3.2.4  Cell migration and invasion assays 
U2OS cell migration and invasion were determined using the wound healing and 
Matrigel invasion assays as previously described [195]. Briefly, for wound healing assays, 
equal number of U2OS cells (5.0 x 105/well) were seeded and grown overnight to 90–
95 % confluence in 6-well plates before wounds of similar size were introduced into the 
monolayer by a sterile pipette tip. The monolayers were rinsed with Phosphate Buffer 
Saline (PBS) to remove detached cells and then cultured in medium containing various 
concentrations of compounds. The speed of wound closure was documented 12 h and 24 




invasion assays, on the other hand, were performed using 8 µm pore size polyethylene 
terephthalate membrane inserts (BD Bioscience, San Jose, CA) precoated with 30 µg 
Matrigel (an extracellular matrix gel from Engelbreth Holm-Swarm mouse sarcoma) (BD 
Bioscience, San Jose, CA). Briefly, cells that were untransfected or transfected with the 
respective control vector or β-catenin plasmids were treated with compounds at various 
concentrations for 24 h.  Next, viable cells (1.5 x 105/ 200 µl, confirmed by trypan blue 
exclusion) were seeded in serum-free medium onto the upper wells of the precoated 
membrane inserts, while McCoy’s 5A medium supplemented with 15 % FBS was added 
in the lower compartment as a chemoattractant. Control wells contained serum-free 
medium in the lower chamber instead. Cells were allowed to invade through the 
precoated inserts for a period of 48 h, after which non-invasive cells were removed from 
the upper membrane using a cotton swab. Cells that have invaded to the lower surface of 
the membrane were then fixed with 70 % ethanol and stained with 0.2 % w/v crystal 
violet before they were counted using the Nikon Eclipse TE2000U microscope (Melville, 
NY). Invaded cells from ten random microscopic fields (200 x magnifications) were 
enumerated and all experiments were performed in triplicates at least.   
 
3.2.5  Western blot analysis 
Western blotting was used to examine the protein expression levels of β-catenin, active β-
catenin, MMP-9, cyclin D1, c-Myc and survivin before and after 24 h treatment of 
curcumin or PKF118-310. The primary antibodies for β-catenin, MMP-9, cyclin D1, c-
Myc and survivin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), 




Biotechnology (Lake Placid, NY), Sigma Chemical Co. (St Louis, MO) and BD 
Bioscience (San Jose, CA) respectively. Anti-mouse (BioRad, Hercules, CA) and anti-
rabbit (Santa Cruz, CA) IgG horseradish peroxidase were used as the secondary 
antibodies. Cells were harvested and lysed in lysis buffer containing 1 % Triton with 
protease inhibitor (Roche, Mannheim, Germany). The protein concentration of the 
soluble extracts was determined by Bradford protein assay (Sigma Chemical Co., St 
Louis, MO). For the collection of proteins from the cytosolic and nuclear fractions, the 
NE-PER cytoplasmic and nuclear protein extraction kit (Pierce, Rockford, IL) was used 
according to the manufacturers’ protocol. Proteins (10-50 µg) were separated by 
electrophoresis on 8-10 % SDS-polyacrylamide gels and blotted onto nitrocellulose 
membranes (BioRad, Hercules, CA). Membranes were then blocked overnight at room 
temperature in Tris-buffered saline containing 0.1 % (v/v) Tween 20 and 5 % (w/v) fat-
free dry milk and then incubated with the respective primary antibodies, followed by the 
secondary antibody according to the manufacturer’s directions. After incubation with the 
antibodies, membranes were washed and incubated with the West Femto or West Pico 
luminal/enhancer solution (Pierce, Rockford, IL) and stable peroxide solution (Pierce, 
Rockford, IL) before being exposed to an X-ray film (ThermoFisher Scientific, Waltham, 
MA). Bands were quantified using Quantity One software (BioRad, Hercules, CA), 
normalized to either α-tubulin or lamin A/C loading controls, before bands in treatment 
group are expressed relative to DMSO control (set as 100%). 
 




The effects of curcumin and PKF118-310 on the gelatinolytic activity of MMP-9 were 
examined by gelatin zymography as detailed previously [195, 196]. U2OS cells that were 
untransfected or transfected with the respective control vector or β-catenin plasmids were 
treated with the indicated concentrations of curcumin or DMSO for 72 h in serum-free 
medium. U2OS cells were treated with PKF118-310 in a similar manner for 24 h. After 
treatment, serum-free conditioned media were harvested and centrifuged at 170 g to 
remove cellular debris. The supernatant was then concentrated using Amicon Ultra-4 
centrifuge filter devices (Millipore, Billerica, MA) and stored at -80 °C until use. Protein 
content in the supernatant was quantified using the Bradford protein assay (Sigma 
Chemical Co., St Louis, MO). An equal amount of protein (25 µg) from each treatment 
was diluted with the loading buffer (4x) and applied to a 7.5 % sodium dodecyl sulfate 
(SDS)-polyacrylamide gel co-polymerized with 0.2% gelatin A (Sigma Chemical Co., St 
Louis, MO). After electrophoresis, the gels were stained with 0.1 % Coomassie brilliant 
blue (BioRad, Hercules, CA) and destained with 45 % methanol, 10 % (v/v) acetic acid 
until clear bands suggestive of gelatin digestion were present. Bands were quantified 
using Quantity One software (BioRad, Hercules, CA). 
 
3.2.7  Apoptosis assay 
The effect of PKF118-310 on U2OS cell apoptosis was assessed using an annexin-V-
fluorescein/ Propidium Iodide (PI) apoptosis assay kit (Invitrogen, Carlsbad, CA) 
accordingly to the manufacturers’ protocol. Briefly, U2OS cells (0.2 x 106 cells/well) 
were seeded into 6-well plates and allowed to adhere overnight. On the following day, 




which the cells were washed with 1x PBS and trypsinized. U2OS cells were then 
incubated for 15 mins at room temperature in 1x annexin-binding buffer (100 μl) 
containing annexin-V and PI. After incubation, 400μl 1x annexin-binding buffer was 
added and the stained cells were analyzed using a CyAn ADP flow cytometer (Beckman 
Coulter, Inc. Fullerton, CA). 
 
3.2.8  Cell cycle analysis 
The effect of PKF118-310 on the cell cycle distribution was assessed by flow cytometry 
after staining the cells with PI as described earlier [195]. U2OS cells (1.5 x 105 cells/well) 
were seeded and cultured for 24 h. Cells were then treated with PKF118-310 at various 
concentrations or DMSO (vehicle control). Following treatment for 24 and 48 h, both 
floating and adherent cells were collected and washed with 1x PBS. After which, the cells 
were resuspended in cold 1x PBS to obtain a single-cell suspension and added drop wise 
into ice cold ethanol while vortexing. Cells were then incubated overnight at -20˚ C. The 
following day, cells were washed with cold 1x PBS, resuspended in fluorescence-
activated cell sorting solution (PI/Triton X-100, with RNase A, 1 ml) and incubated in the 
dark for 30 mins at room temperature. Samples were then analyzed using a CyAn ADP 
flow cytometer (Beckman Coulter, Inc. Fullerton, CA). 
 
3.2.9  Statistical analysis  
Statistical significance for treatment groups were analyzed using the two-tailed Student’s 




concentration and the respective controls was considered to be statistically significant 
when P < 0.05. 
 
3.3 Results 
3.3.1 Evaluation of canonical Wnt/β-catenin signaling activity in osteosarcoma 
cells 
To investigate Wnt/β-catenin signaling status in osteosarcoma, we first evaluated the 
endogenous expression of β-catenin protein in a panel of osteosarcoma cell lines from 
various origins, given that the stabilization and nuclear accumulation of β-catenin protein 
is a hallmark of canonical Wnt/β-catenin signaling. Several of the cells lines including 
SaOS-2, U2OS, HOS, CRL11226 and CRL1423 were derived from Caucasian patients 
while OS1, OS2 and OS3 originated from the pre-chemotherapeutic tumor in either the 
femur or proximal humerus of three different Chinese patients [194]. Western blot 
analysis using an anti-β-catenin antibody revealed high expression of endogenous β-
catenin in all of the osteosarcoma cell lines tested, except CRL1423 cell line (Figure 3-1). 
Since β-catenin activation is the hallmark of Wnt signaling, we also investigated the 
protein expression of the active form of β-catenin, which is dephosphorylated on Ser37 
and Thr41. Active β-catenin expression was detected in five of the eight osteosarcoma 
cell lines, although the levels of protein expression varied considerably among these cell 
lines (Figure 3-1). Our findings are consistent with previous studies, which demonstrated 
significant accumulation of β-catenin protein in osteosarcoma patients’ specimens [73, 




Wnt/β-catenin signaling in most of the osteosarcoma cell lines tested, although the 
apparent degree of activation varied. 
 
               
                U2OS    HOS    SaOS-2   CRL      CRL      OS1      OS2      OS3 
                                                        11226      1423 
 
Figure 3-1. Evaluation of canonical Wnt signaling in osteosarcoma cell lines. 
Western blot analysis of β-catenin in eight OS cell lines using anti-β-catenin and anti-
active- β-catenin antibodies. α-Tubulin was used as a loading control. The blots shown 
were representatives of three independent experiments.  
 
3.3.2  Wnt/β-catenin inhibitors selected for our study  
Numerous studies on small molecule inhibitors of the Wnt/β-catenin pathway and their 
inhibitory mechanisms have been reported [197]. To date, no small molecule antagonists 
have been identified from large synthetic compound libraries, although several natural 
compounds ranging from plant-derived polyphenols, anti-malaria artemisinins, marine 
organisms to microorganisms as well as a number of exciting drugs such as NSAIDS and 
vitamin derivatives have scored as potent Wnt antagonists in both in vitro and in vivo 
studies (316). We have conducted a detailed literature review and selected five natural-
occurring small molecule compounds to perform initial screening for Wnt inhibitory 
activity, based on their commercial availability. These inhibitors are curcumin, quercetin, 
PKF118-310, arteminsinin and artesunate. The chemical structures of these compounds 
are shown in Figure 3-2. It is important to note that all these compounds except 
Active β-catenin  
  β-catenin  




artemisinin have been shown to disrupt the Wnt/β-catenin pathway in various cancer cell 
lines [198-201], but none has been tested in the context of osteosarcoma.   
 
Curcumin, a dietary pigment found in the spice turmeric, has been shown to be anti-
proliferative, anti-invasive and anti-angiogenic in multiple myeloma, prostate, colorectal, 
pancreatic, lung and breast cancer cell lines [202, 203] while quercetin, a major member 
of the flavonol subclass of dietary flavonoids, has been found to display both anti-oxidant 
and anti-tumor activities in colon carcinoma [204-206]. PKF118-310, on the other hand, 
is a natural compound of microbial origin and has been selected through the screening of 
libraries of natural compounds for small molecule inhibitors of the TCF/β-catenin protein 
complex [178]. Initial studies with these three compounds showed that they disrupted the 
Wnt/ß-catenin pathway by decreasing nuclear β-catenin levels, resulting in a reduced 
association of β-catenin with TCF-4, which in turn gave rise to reduced binding of the 
complexes to DNA response elements in target genes [178, 200, 201]. Curcumin was also 
reported to disrupt Wnt/ß-catenin signaling at various intersections of the pathway such 
as inducing caspase-3-mediated cleavage and degradation of ß-catenin, inhibiting the 
phosphorylation of GSK-3β and suppressing the transcriptional co-activator, p300 [96, 
193, 207, 208]. Artemisinin and its derivative, artesunate (a prodrug of artemisinin) are 
anti-malarial drugs with in vitro and in vivo anticancer activities [209, 210]. Li et al. has 
recently shown that artesunate disrupted the Wnt/β-catenin pathway via membranous 
translocation of β-catenin and down-regulation of Wnt targeted genes such as c-myc and 




included artemisinin (the active metabolite of artesunate) in our preliminary screening for 
Wnt antagonists. 
               
                              Curcumin                                                          Quercetin 
 
                    
             PKF118-310                      Artemisinin                           Artesunate 
 
Figure 3-2 Chemical structures of Wnt/β-catenin modulators used in our study 
 
3.3.3  Cytotoxicity of Wnt/β-catenin modulators on osteosarcoma cells 
It is necessary to profile the cytotoxic effect of our compounds in osteosarcoma cells to 
eliminate compounds that either promote survival or are too toxic. Since high levels of 
endogenous Wnt antagonist, DKK-1, have been reported to allow tumor cells to re-enter 
the cell cycle by inhibiting the canonical Wnt/β-catenin pathway and promote 
osteosarcoma cell survival [212], our selected compounds may act similarly. On the other 
hand, disruption of the pathway could instead have a cytostatic effect on osteosarcoma 
cell growth, given that Wnt/β-catenin affects the transcriptional regulation of genes 




compounds are toxic to osteosarcoma cells by some other non-selective and non-specific 
mechanism. The expression levels of Wnt signaling components including Wnt ligands, 
FZD and LRP5 in various human osteosarcoma cell lines have previously been reported 
[47] and using this information, we have chosen three heterogeneous representative 
osteosarcoma cell lines namely U2OS, HOS and SaOS-2 for our experiments.  
 
Accordingly, MTT cell proliferation assays were first performed on these three 
representative human osteosarcoma cell lines to profile the cytotoxicity effects of the 
compounds. All compounds inhibited growth of the osteosarcoma cells in vitro in a 
concentration-dependent manner (Figure 3-3), with the IC50 values at 72 h presented in 
Table 3-1. Comparison of the IC50 values showed that these osteosarcoma cell lines have 
relatively similar sensitivity to curcumin and artemisinin while PKF118-310 and 
quercetin had the most potent anti-proliferation effects against U2OS cells. Among the 
three cell lines, U2OS has been previously reported to be highly invasive [213] and was 
found to express the highest levels of β-catenin protein (Figure 3-1). It was thus used in 
subsequent studies to investigate various anti-cancer effects of the Wnt/β-catenin 
modulators. To determine an optimum (i.e. effective yet non-toxic) dose range for anti-
invasion and anti-migration studies, time-response cytotoxic assays were next performed. 
Figure 3-4 shows that treatment of U2OS cells with curcumin beyond 20 µM at 24 h, 48 
h and 72 h resulted in statistically significant toxicities and hence the maximum 
concentration employed in these studies was limited at 20 µM. The maximum 




respectively for similar reasons (Figure 3-4), although higher toxic concentrations were 
used to further investigate the anti-proliferation and apoptotic effects of PKF118-310.  






































































































Figure 3-3. Effect of Wnt/β-catenin modulators on osteosarcoma cell viability. MTT 
assays were used to profile the cytotoxicity effects of Wnt/β-catenin modulators in three 
osteosarcoma cell lines (U2OS (◊), SaOS-2 (▼) and HOS (■)) for 72 h at the 
concentrations indicated. Data is presented as mean IC50 ± SEM (Standard Error Mean) 













HOS 351.85 ± 41.03 55.31 ± 1.06 0.32 ± 0.02 22.72 ± 0.38 
SaOS-2 206.90 ± 26.50 105.17 ± 6.42 0.64 ± 0.03 18.51 ± 1.67 
U2OS 353.80 ± 31.71 33.84 ± 3.76 0.19 ± 0.01 19.94 ± 1.48 
 
Table 3-1. MTT proliferation assays were performed on HOS, SaOS-2 and U2OS 
cells 72 hours after the addition of test compounds. Results were obtained with six 
repeats in each of the three independent experiments. IC50 values shown are mean ± SEM 





















































































    






























Figure 3-4. Dose- and time-dependent inhibition of U2OS cell viability by curcumin, 
PKF118-310, artemisinin and artesunate. MTT assays were used to establish an 
optimum concentration range of these compounds for subsequent experiments. U2OS 
cells were treated with curcumin, PKF118-310, artemisinin or artesunate for 24, 48 and 
72 h at the concentrations indicated. The results shown were means ± SEM from three 
independent experiments repeated in triplicate. Cell viability in compound-treated cells 
was expressed as the percentage of DMSO-treated samples.  *, P<0.05, **, P<0.01 
 
 
3.3.4 Effects of selected Wnt/β-catenin inhibitors on β-catenin/TCF transcriptional 
activity in HCT116 colon cancer and U2OS cell lines 
The effects of selected Wnt/β-catenin inhibitors on intrinsic downstream β-catenin/TCF 
transcriptional activities were first evaluated using a reporter gene containing four copies 
of the TCF-binding site (TOPglow). This was done to examine the magnitude of their 
Wnt inhibitory activities in the context of osteosarcoma cells. Cells were transiently 




and pSV-β-galatosidase control vector for normalization of transfection efficiency. The 
transfectants were then treated with increasing concentrations of the compounds for 24 h 
before cell lysates were collected for luciferase assays. Human colon carcinoma HCT116 
cells were used as positive control cells as they express high levels of β-catenin due to a 
mutation that eliminates the phosphorylation site (serine 45) in β-catenin required for its 
ubiquitination and subsequent degradation [214] while U2OS cells were used as our 
model cell line.   
 
As shown in Figures 3-5 and 3-6, both curcumin and artemisinin significantly suppressed 
β-catenin/TCF transcriptional activity in a dose-dependent manner in both HCT116 and 
U2OS cells. Statistical significance was observed beyond 10 µM and 20 µM for 
curcumin in U2OS and HCT116 cell lines respectively. Compared with the control, 
curcumin at 20 μM and artemisinin at 400 μM inhibited β-catenin/TCF signaling in the 
two cell lines by 56–59 % and 46-48 %, respectively. PKF118-310, on the other hand, 
inhibited the transcriptional activity of β-catenin/TCF in U2OS cells in a concentration-
dependent manner but had no effect in HCT116 cells. As shown in Figure 3-6 , β-
catenin/TCF signaling was inhibited by PKF118-310 by approximately 59 % and 48 % at 
doses of 0.10 μM and 0.15 μM in U2OS cells respectively. Much to our surprise and 
contrary to published reports, quercetin increased β-catenin/TCF transcriptional activity 
in U2OS cells and had no dose-response relationship in HCT116 cells [200]. Artesunate 
did not show any significant effect in both HCT116 and U2OS cells. LiCl, a well known 
Wnt/β-catenin agonist, was used as a positive control here. As expected, LiCl increased 




Transcriptional activities of the FOPglow plasmid were not affected by treatment of all 
compounds. The inhibitory effects of curcumin, PKF118-310 and artemisinin on β-
catenin/TCF signaling in osteosarcoma is the first of such report although similar effect 
has been observed in colon and prostate cancer cell lines recently [178, 193, 201, 215]. 
Two of these compounds, namely curcumin and PKF118-310, showed the best profile in 
terms of suppression the β-catenin/TCF transcriptional activity in U2OS cells and were 







































































































































































































                                                                                                                      
Figure 3-5. Effects of Wnt/β-catenin modulators on the transcriptional activity of β-
catenin/TCF in HCT116 cell line. HCT116 cells were co-transfected with reporter 
genes harboring TCF-4 binding sites (TOPglow) or a mutant TCF-4 binding site 
(FOPglow) and β-galactosidase gene. 20 hours post-transfection, increasing amount of 
test compounds were added to the cells. Luciferase activity was determined 24 h post-
treatment, normalized against values for the corresponding β-galactosidase activity. 
Results were expressed as the means ± SEM of normalized ratios of luciferase and β-
galactosidase measurements of three independent experiments. Reporter activity in 
compound-treated cells is expressed as the percentage of DMSO-treated samples.             







































































































































































                                                                                                                                      
Figure 3-6. Effects of Wnt/β-catenin modulators on the transcriptional activity of β-
catenin/TCF in U2OS cell line. U2OS cells were co-transfected with reporter genes 
harboring Tcf-4 binding sites (TOPglow) or a mutant TCF-4 binding site (FOPglow) and 
β-galactosidase gene. 20 hours post-transfection, increasing amount of test compounds 
were added to the cells. Luciferase activity was determined 24 h post-treatment, 
normalized against values for the corresponding β-galactosidase activity. Results were 
expressed as the means ± SEM of normalized ratios of luciferase and β-galactosidase 
measurements of three independent experiments. Reporter activity in compound-treated 





Next, to demonstrate that extrinsic activation of the canonical Wnt/β-catenin pathway can 
be inhibited by curcumin and PKF118-310, similar reporter assays were repeated in 
U2OS cells, but with the inclusion of two specific GSK-3β inhibitors (BIO and 
SB216763), as well as plasmids for both wild-type pcDNA β-catenin and mutant S33Y β-
catenin, in separate treatments. BIO (a synthetic derivative of 6-bromoindirubin) is a 
natural product isolated from the Mediterranean mollusc Hexaplex trunculus [199], while 
SB216763 is a maleimide derivative identified from a high throughput screen against 
human GSK-3α and GSK-3β [198]. Both compounds have been shown to be potent and 
selective GSK-3β inhibitors [198, 199]. As expected, β-catenin/TCF transcriptional 
activities were increased approximately 730- and 220-fold with 5 µM BIO and 50 µM 
SB216763 treatment in our experiments respectively, most possibly due to a decrease in 
β-catenin degradation mediated by GSK-3β. Such extrinsic Wnt/β-catenin activation, 
however, could be effectively blocked by concomitant treatments with either curcumin 
(Figure 3-7a) or PKF118-310 (Figure 3-7b), in a dose-dependent manner. 
 
Similarly, β-catenin/TCF transcriptional activities were increased dramatically by 30- and 
580-fold with the forced expression of both wild-type and mutant S33Y β-catenin, 
respectively. The product of the mutant S33Y β-catenin gene is resistant to degradation 
by the Axin–APC–GSK3β complex [76] and hence gave rise to a much greater increase 
in reporter activity compared to that of the wild-type β-catenin gene. Again, treatment 
with either curcumin (Figure 3-7c) or PKF118-310 (Figure 3-7d) effectively suppressed 
β-catenin activation dose-dependently. At 20 µM, curcumin significantly reduced β-




by 32.1 % and 56.3 % respectively. Such suppression was statistically significant at all 
doses used for PKF118-310.  
 
Taken together, we have identified curcumin and PKF118-310 as the two most potent 
antagonists of Wnt signaling in the context of osteosarcoma. Our findings suggest that 
both curcumin and PKF118-310 act specifically at the level or downstream of β-catenin 
along the axis of the Wnt/β-catenin signaling pathway, independent of GSK3β, rather 
than upstream of or at the level of the β-catenin degradation machinery. Transcriptional 
activities of the negative control FOPglow plasmids were unaffected in all instances, 
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Figure 3-7. Effects of Wnt/β-catenin modulators on the extrinsic transcriptional 
activity of β-catenin/TCF in U2OS cell line. (a-b) U2OS cells were co-transfected with 
TOPglow or a mutant Tcf-4 binding site (FOPglow) and pSV-β-galactosidase control 
vector. Five hours post-transfection, various amounts of curcumin and PKF118-310 
together with GSK-3β inhibitors BIO (5 μM) or SB216763 (50 μM) were added to the 
cells. (c-d) U2OS cells were co-transfected with TOPglow or a mutant Tcf-4 binding site 
(FOPglow), pSV-β-galactosidase control vector and pcDNA β-catenin (wild type β-
catenin gene) or pcDNA S33Y (S33Y mutant β-catenin gene). The amount of DNA in 
each transfection was kept constant by the addition of an appropriate amount of empty 
expression vector, pcDNA3.1. Five hours post transfection increasing amounts of 
curcumin or PKF118-310 were added to the cells. Luciferase activities were determined 
24 h after treatment with curcumin and PKF118-310, normalized against values for the 
corresponding β-galactosidase activities. Data were represented as means ± SEM. of 
normalized ratios of luciferase and β-galactosidase measurements of three independent 
experiments. Reporter activities in compound-treated cells were expressed as the 
percentage of DMSO-treated samples. *, P<0.05, **, P<0.01, compared with the GSK-3β 





3.3.5  Effects of curcumin and PKF118-310 on the cellular accumulation of β-
catenin  
As the activation of β-catenin/TCF transcriptional activity results from the accumulation 
of nuclear β-catenin [77], we subsequently examined whether curcumin or PKF118-310 
treatments was associated with changes in the cellular contents and localization of β-
catenin protein, after having shown that these compounds significantly suppressed both 
the intrinsic and extrinsic transcriptional activities of β-catenin/TCF in U2OS cells.  
Following 24 h treatment with either curcumin or PKF118-310, both nuclear and 
cytosolic cell lysates were collected and used for western blot analysis to determine the 
amount of β-catenin in each cellular fraction. As shown in Figure 3-8a-b, we found that 
the amount of β-catenin in the cytoplasmic fraction was not altered by curcumin 
treatment, whereas that in the nuclear fraction which represent the active 
unphosphorylated form was markedly decreased by curcumin at 20 μM. Similarly, β-
catenin protein in the nuclear fraction was decreased in a dose-dependent manner by 
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Figure 3-8. Effects of curcumin and PKF118-310 treatment on the cellular and 
nuclear accumulation of β-catenin. U2OS cells were pre-treated with curcumin (a) or 
PKF118-310 (c) at the stated concentrations for 24 h, followed by collection of protein 
from the cytoplasmic and nuclear fraction. α-tubulin and lamin A/C were used for 
cytoplasmic and nuclear protein loading controls respectively. β-catenin protein 
expression in curcumin- (b) or PKF118-310-treated (d) cells were expressed as the 





3.3.6 Effects of curcumin and PKF118-310 on osteosarcoma cell migration and 
invasion 
Recent reports showed that the inhibition of the Wnt/β-catenin pathway by the dominant-
negative form of the co-receptor, DN-LRP5, and the endogenous inhibitor, DKK-3, could 
result in a reduction of motility and invasiveness of osteosarcoma cells [51, 63]. To 
investigate if curcumin, PKF118-310 and artemisinin could exert similar effects after 
having established that these compounds could effectively block Wnt/β-catenin signaling 
in preceding studies, we performed wound healing and Matrigel invasion assays using 
U2OS cells. U2OS has been reported to be highly metastatic [213], but as shown in 
Figure 3-9, curcumin, PKF118-310 and artemisinin were able to markedly inhibit U2OS 
cell migration in a dose- and time-dependent manner in wound healing assays performed 
over a period of 24 h. Of these compounds, curcumin had the greatest anti-migratory 
effects on U2OS cells. These results were also supported by Matrigel invasion assays 
whereby curcumin and artemisinin significantly reduced the ability of U2OS cells, again 
in a dose-dependent manner, to invade through the Matrigel-coated inserts over a period 
of 48 h (Figure 3-10a, c). Similar to the cell migratory studies, curcumin had the most 
anti-invasive effects on U2OS cells. Specifically, curcumin treatment significantly 
reduced the invasive capacity of U2OS cells by 29.0 ± 5.1 %, 77.3 ± 3.3 % and 85.8 
±1.2 % at 5 μM, 10 μM and 20 μM respectively (Figure 3-10a). Artemisinin, on the other 
hand, significantly suppressed U2OS cell invasion by 41.4 ± 13.7 %, 38.9 ± 15.5 % and 
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Figure 3-9. Suppression of U2OS cell migration by Wnt/β-catenin inhibitors is 
concentration- and time-dependent. Representative images from three independent 
experiments showing a dose- and time-dependent inhibition of U2OS migration by 
curcumin (a) artemisinin (b) and PKF118-310 (c) using the wound healing assays. 
Uniform scratches were created in confluent cultures which were treated with compounds 
over a period of 24 h. Images of differential wound closure rates were captured using a 
microscope at 10x objective.  
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Figure 3-10. Dose-dependent inhibition of U2OS cell invasion by curcumin, 
artemisinin and PKF118-310. U2OS cells pre-treated with curcumin (a), artemisinin 
(c), PKF118-310 (d) or DMSO (vehicle control) for 24 h were seeded into Matrigel-
coated inserts. In (b), to examine β-catenin-enhanced U2OS cell invasion by curcumin, 
U2OS cells were first transfected with pcDNA β-catenin plasmids or pcDNA3.1 control 
vector, followed by treatment with various concentrations of curcumin or DMSO (vehicle 
control) for 24 h before seeding into Matrigel-coated inserts. Cells that invaded to the 
lower surface of the insert over a period of 48 h were captured with a light microscope at 
200x magnification after staining with crystal violet dye. Ten random fields were counted 
for the number of invaded U2OS cells. Data were presented as means ± SEM of three 
independent experiments. Cell invasion in compound-treated cells and β-catenin 
transfected cells was expressed as the percentage of DMSO-treated samples (*, P<0.05, 
**, P<0.01) and that transfected with the control vector, pcDNA3.1 (* P<0.05, ** 
P<0.01, compared with the β-catenin-only group; #, P<0.01, compared with the pcDNA 
3.1-only group) respectively.  
  
Since both curcumin and artemisinin may be non-specific inhibitors of Wnt/β-catenin 
signaling and may have exerted anti-invasive effects through other signaling pathways, 
we further used PKF118-310, which is a more selective compound, in similar studies to 
ascertain the involvement of Wnt/β-catenin signaling in osteosarcoma cell migration and 
invasion. As shown in Figure 3-9c, PKF118-310 was able to significantly inhibit U2OS 
cell migration in a dose- and time-dependent manner. In parallel to its anti-migration 
effects, PKF118-310 treatment significantly reduced the invasive capacity of U2OS cells 
by 42.4 ± 16.6 % and 38.1 ± 12.0 % at 0.10 μM and 0.15 μM respectively (Figure 3-10d). 
The anti-metastatic effects of curcumin, artemisinin and PKF118-310 were observed at 
concentration ranges that are shown to inhibit downstream β-catenin/TCF transcriptional 
activities (Figure 3-6) as well as nuclear translocations of the β-catenin protein (Figure 
3-8) and were not a result of cell toxicity as U2OS cells did not exhibit significant growth 





To confirm the contribution of Wnt/β-catenin activation in affecting osteosarcoma cell 
invasion, we next transfected U2OS cells with the wild-type β-catenin plasmid followed 
by curcumin treatment and performed similar Matrigel invasion assays. The pre-treated 
U2OS cells were allowed to invade through the Matrigel-coated inserts for a period of 48 
h. As shown in Figure 3-10b, Wnt/β-catenin activation via the forced expression of wild-
type β-catenin dramatically enhanced the invasion capacity of U2OS cells, but this effect 
could be effectively reversed by curcumin treatment in a dose-dependent manner. 
Specifically, curcumin treatment significantly inhibited β-catenin-induced U2OS 
invasiveness by 50.7 ± 4.9 % at 10 μM and 74.5 ± 9.2 % at 20 μM respectively.  
 
Altogether, our results strongly suggest that the Wnt/β-catenin pathway is involved, 
possibly in part, in the regulation of the invasive behavior of U2OS cells and that 
osteosarcoma cell invasion may be delayed by disrupting the Wnt/β-catenin pathway 
using small molecule inhibitors such as curcumin, artemisinin and PKF118-310.  
 
3.3.7  Effects of curcumin and PKF118-310 on MMP-9 activity and protein 
expression in U2OS cells 
MMPs play important roles in the degradation of extracellular matrix to facilitate cancer 
cell invasion and metastasis [216]. In particular, MMP-9 is a well known Wnt target gene 
that is constitutively over-expressed in U2OS cells and its increased expression is closely 
associated with enhanced osteosarcoma tumor invasion and metastasis [217-219]. Using 
Western blotting, we selected the two most potent antagonists, namely curcumin and 




correlated with MMP-9 protein levels in U2OS cells. As shown in Figure 3-11a, we 
observed a dose-dependent reduction in MMP-9 protein expression with curcumin 
treatment. Specifically, MMP-9 protein expression was significantly down-regulated by 
27.5 ± 2.4 % at 10 µM and 48.8 ± 6.1 % at 20 µM. Parallel to the western blot results, 
gelatin zymography assays demonstrated that curcumin significantly reduced MMP-9 
activity dose-dependently over a period of 72 h. As shown in Figure 3-11b, MMP-9 
activity was significantly reduced by 32.1 ± 5.1 % at 10 µM and 59.2 ± 8.8 % at 20 µM, 
respectively. 
 
In addition, the effects of Wnt/β-catenin activation via the exogenous expression of wild-
type β-catenin on MMP-9 protein levels and activities were further investigated. As 
shown in Figure 3-11c, β-catenin protein levels were elevated, indicating successful 
transfection of the wild-type β-catenin plasmid in U2OS cells. Over-expression of β-
catenin significantly up-regulated MMP-9 protein levels but this increase could be 
suppressed with curcumin treatment in a dose-dependent manner.  Beyond 10 µM, MMP-
9 protein levels returned to basal levels with curcumin treatment. In parallel, gelatin 
zymography assays showed that MMP-9 activity was also increased with β-catenin over-
expression (Figure 3-11d). As a result of curcumin treatment, MMP-9 activity eventually 
decreased and returned to basal levels at a concentration of 20 µM. Similarly, we 
observed dose-dependent reductions in both MMP-9 protein expression and activity with 
PKF118-310 treatment (Figure 3-11e and Figure 3-11f). With PKF118-310 treatment, 




19.3 % at 20 µM while MMP-9 activity was significantly suppressed by 37.8 ± 2.5 % at 
10 µM and 54.3 ± 1.4 % at 20 µM respectively.  
 
Taken together, our findings suggest that curcumin and PKF118-310 elicited a reduction 
in the secretion of MMP-9 under conditions of either endogenous and/or exogenous 
Wnt/β-catenin activation, possibly giving rise to reduced invasiveness and migration of 
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Figure 3-11. Curcumin and PKF118-310 inhibit MMP-9 activities and protein 
expressions in osteosarcoma. (a, e) Inhibition of MMP-9 protein expressions by 
curcumin or PKF118-310. U2OS cells were treated with indicated concentrations of 
curcumin, PKF118-310 or DMSO (vehicle control) for 24 h before proteins were 
collected for western blot. (b, f) Curcumin and PKF118-310 inhibited MMP-9 activities. 
U2OS cells were treated with indicated concentrations of curcumin, PKF118-310 or 
DMSO for 72 h in serum free medium. The conditioned media were then harvested and 
concentrated. MMP-9 activity was assessed by gelatin zymography and identified by 
clear zones of digested gelatin. (c) Effect of curcumin on MMP-9 protein expression in β-
catenin-transfected U2OS cells. U2OS cells transfected with pcDNA β-catenin plasmid 
were treated with indicated concentrations of curcumin or DMSO for 24 h. Proteins were 
collected for western blot. (d) Effect of curcumin on MMP-9 activity in β-catenin-
transfected U2OS cells. U2OS cells transfected with pcDNA β-catenin plasmid were 
treated with indicated concentrations of curcumin or DMSO for 72 h in serum free 
medium. The conditioned media were then harvested and concentrated. The MMP-9 
activity was assessed by Gelatin zymography. All blots and zymograms shown in Figure 
3-11 were representative of three independent experiments. α-Tubulin was used as a 
loading control in all the western blot analysis. MMP-9 protein expressions or activities 
in compound-treated cells were expressed as the percentage of DMSO-treated samples. * 
,P<0.05, ** P<0.01. MMP-9 protein expressions or activities in compound-treated cells 
that over-expressed β-catenin were expressed as the percentage of control vector, 
pcDNA3.1. * ,P<0.05, ** P<0.01, compared with the β-catenin-only group. #, P<0.05, 






3.3.8 Effects of PKF118-310 on osteosarcoma cell proliferation, apoptosis and cell 
cycle progression in U2OS cells 
It has recently been reported that disruption of the Wnt/β-catenin signaling suppressed 
both in vitro and in vivo cell proliferation in osteosarcoma cells [51, 220]. Given that β-
catenin/TCF-dependent signaling and its gene products are known to regulate cell 
proliferation, cell cycle distribution and apoptosis, we investigated the effect of PKF118-
310 on these processes, after having demonstrated that PKF18-310 had the most potent 
anti-proliferative effect among other Wnt/β-catenin modulators against U2OS cells. 
Figure 3-3 shows that treatment with PKF118-310 inhibited U2OS cell proliferation 
dose- and time-dependently, with an IC50 of 0.19 ± 0.01 µM (Table 3-1) and PKF118-310 
beyond 0.20µM at 24 h, 48 h and 72 h resulted in statistically significant toxicities 
(Figure 3-4). Resistance against apoptosis is critical for survival and contributes to drug 
resistance in many cancers, including osteosarcoma [221]. Given the potent anti-
proliferation effects of PKF118-310, we were interested in determining whether PKF118-
310 also induces apoptosis in U2OS cells at higher toxic concentrations. PKF118-31-
induced apoptosis was evaluated by accessing the cell population using flow cytometry 
analysis after incubating PKF118-310-treated cells with annexin-V and PI. As shown in 
Figure 3-12a, treatment with PKF118-310 resulted in a dose-dependent increase in the 
number of early (stained with annexin-V only) and late (stained with both annexin-V and 
PI) apoptotic cells. Specifically, PKF118-310 treatment significantly induced the rate of 
early apoptosis by 328% and 290% at 0.20 μM and 0.30 μM respectively. The late 





In addition, cell cycle distribution of U2OS cells was examined following 24 h and 48 h 
treatment of increasing concentration of PKF11-310 using flow cytometry. As shown in 
Figure 3-12b, treatment with PKF118-310 resulted in an increase in the number of cells 
in the G2/M phase and a corresponding decrease in number of cells in the G0/G1 phase, 
indicating a PKF118-310-induced G2/M phase arrest. This trend is seen after treatment 
with PKF118-310 for 24h and 48h, although G2/M phase arrest is only statistically 
significant at 0.30 μM PKF118-310 treatment over 48 h. In parallel with the apoptotic 
assays, we also observed an increase in the number of cells in the sub-G1 phase of the 
cell cycle with PKF118-310 treatment (data not shown), confirming that PKF118-310 
promoted apoptosis in U2OS cells.  
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Figure 3-12. PKF118-310 induces apoptosis and disrupts cell cycle distribution in 
U2OS cells. (a) PKF118-310 induced apoptosis in U2OS cells. U2OS cells pre-treated 
with PKF118-310 or DMSO for 24 h were stained with annexin-V and PI and analyzed 
by flow cytometry. Data were presented as means ± SEM of three independent 
experiments. PKF118-310-treated cell which undergone early (stained with annexin-V 
only) and late (stained with both annexin-V and PI) apoptosis were expressed as the 
percentage of DMSO-treated samples. *, P<0.05. **, P<0.01. (b) PKF118-310 induced 
G2/M phase cell cycle arrest in U2OS cells. U2OS cells were treated with increasing 
concentration of PKF118-310 for 24 and 48 h before they were stained with PI. Cell 
cycle distribution of the cells was measured by flow cytometry and the results were 
plotted as the percentage of cells in each cell cycle phase. Data were presented as means 
± SEM of three independent experiments. *, P<0.05 indicated the difference in the 
various cell cycle phases compared to the control cells.  
 
3.3.9  Effects of PKF118-310 on the protein expressions of  proliferation-associated 
Wnt-responsive genes 
Given that PKF118-310 inhibited anti-proliferative effect as well as induced apoptosis 
and G2/M phase arrest in U2OS cells, we asked whether these anti-cancer effects with 
PKF118-310 treatment correlated with protein expressions of proliferation-associated β-
catenin/TCF target genes such as cyclin D1, c-Myc and survivin. Both cyclin-D1 and c-
Myc are critical for tumor growth and survival [97, 98] while survivin is both an inhibitor 
of apoptosis as well as an important regulator of the G2/M phase of the cell cycle [222-




an active Wnt/β-catenin signaling, however, treatment with PKF118-310 significantly 
suppressed the expression of these Wnt target proteins dose-dependently (Figure 3-13).  
 
Taken together, our findings strongly suggest that PKF118-310 suppressed the expression 
of several proliferation-associated Wnt-target genes such as cyclin-D1, c-Myc and 
survivin, possibly giving rise to reduced proliferation, enhanced apoptosis and G2/M 
phase arrest of U2OS cells.  
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Figure 3-13. Concentration-dependent decrease of cyclin D1, c-Myc and survivin 
protein expressions with PKF118-310 treatment. U2OS cells were treated with 
indicated concentrations of PKF118-310 or DMSO for 24 h and total cellular proteins 
were collected for western blot. α-Tubulin was used as a loading control. The blots 
shown were representative of three independent experiments 
 
3.4 Discussion  
Despite mounting evidence implicating the importance of Wnt/β-catenin in the 
development and progression of osteosarcoma, the therapeutic potential of small 
molecule inhibitors targeting this pathway in osteosarcoma remained largely unreported.  




using small molecule antagonists to prevent or reduce osteosarcoma tumorigenesis and 
metastasis, with the hope of improving the clinical outcome of the disease.  
 
In this study, we first sought to assess Wnt/β-catenin signaling in a panel of eight 
metastatic osteosarcoma cell lines from various origins and detected abundant levels of β-
catenin protein in most of these osteosarcoma cells (Figure 3-1) This suggests that 
frequent activation of canonical Wnt/β-catenin signaling is observed in osteosarcoma, 
although the apparent degree of activation varied among the cell lines. Our findings are 
consistent with previous studies, which demonstrated significant accumulation of β-
catenin protein in osteosarcoma patients’ samples [73, 74]. Together with previous 
reports on the expressions of Wnt signaling components including Wnt ligands, FZD, 
LRP5 and β-catenin protein observed in various human osteosarcoma cell lines and 
patient samples [47, 51, 63, 73, 74], our results supported the notion that canonical 
Wnt/β-catenin signaling is active in osteosarcoma. 
 
The choice of the main osteosarcoma cell lines for subsequent experiments is challenging 
given the heterogeneous nature of the cancer type. While there are numerous 
commercially available human osteosarcoma cell lines, limited information is available 
on their disease status and pathophysiological relationship with Wnt signaling. Our 
selection of the osteosarcoma cell lines was guided primarily by previous publication 
supporting a role for canonical Wnt signaling in the pathobiology and progression of 
osteosarcoma [51, 52, 63]. The highly invasive U2OS cells [213] was found to express 




be absent or markedly silenced, compared to the normal osteoblast cells (Figure 5-1). 
U2OS was thus chosen as the main cell line in subsequent studies to investigate various 
anti-cancer effects of the Wnt/β-catenin modulators. It is noteworthy that the expression 
of the Wnt co-receptor, LRP5, in osteosarcoma specimens has been previously reported 
to correlate significantly with metastatic events [47]. Given that U2OS cells highly 
express LRP5, this cell lines closely represent the clinical state of osteosarcoma 
characterized by rapid growth and aggressive metastasis. In contrast to previous reports 
supporting a significant role for canonical Wnt signaling in the pathobiology and 
progression of HOS and SaOS-2 osteosarcoma cell, very low expression of active β-
catenin was detected in these cells (Figure 3-1) [51, 52, 63]. Nevertheless, MTT assay 
was performed using HOS and SaOS-2 cell lines to compare the cytotoxicity profile of 
the test compounds in various osteosarcoma cell lines (Figure 3-3).     
 
Effective inhibitions of Wnt/β-catenin pathway by the various compounds used in our 
studies were evidenced by the suppression of intrinsic β-catenin/TCF transcriptional 
activities using luciferase reporter assays (Figures 3-5 and 3-6). Curcumin and 
artemisinin were identified as good inhibitors of the Wnt/β-catenin pathway in both 
U2OS and HCT116 colon cancer cells. PKF118-310, on the other hand, inhibited the 
transcriptional activity of β-catenin/TCF in U2OS cells but had no effect in HCT116 cells 
at the highest non-toxic concentration used (0.15 µM). Although PKF118-310 was 
reported to inhibit β-catenin/TCF transcriptional activity in HCT116 cells at an EC50 of 
0.3 ± 0.02 µM [178], Wnt inhibitory activity of PKF at concentrations beyond 0.15µM 




inhibitory effects interpretation. Artesunate did not show any significant effect in both 
HCT116 and U2OS cells. These results did not agree with previous reports possibly 
because of the lower concentrations used in our study [211]. Contrary to expected, we 
found that quercetin increased β-catenin/TCF transcriptional activity in U2OS cells and 
had no dose-response relationship in HCT116 cells. A similar induction of transcriptional 
activity was reported in HEK293 human embryonal kidney cells [226]. This conflicting 
observation whereby known inhibitors enhanced the β-catenin/TCF transcriptional 
activity also occurred in the case of indomethacin and rofecoxib in SW480 cells [227]. 
Intrinsic resistance of cells against such inhibitors may have resulted in this anomaly. 
Other reasons to the discordant results may include the variation in levels of intrinsic Wnt 
signaling in different tissues, biphasic responses to increasing concentrations of 
compounds and difference in potency of the compounds in different cell lines. Given that 
compounds derived from natural sources are known to be multi-targeted, we also cannot 
rule out multiple inhibitory effects of these compounds on different targets. Further 
studies are needed to characterize their specificity on Wnt inhibition.  
 
Given that curcumin and PKF118-310 showed the best profiles in terms of suppression 
the β-catenin/TCF transcriptional activity in U2OS cells, we further investigated their 
mechanisms of Wnt inhibitions and anti-metastatic effects. In agreement with previous 
findings [178, 201, 228], the inhibitory effects of both compounds were not related to the 
β-catenin degradation machinery, but rather to downstream components. This was 
supported by the following observations: Firstly, both curcumin (Figure 3-7a) and 




presence of specific GSK-3β inhibitors, BIO and SB216763; secondly, the inhibitory 
effect of curcumin (Figure 3-7c) and PKF118-310 (Figure 3-7d) were unaffected when 
the Wnt/β-catenin pathway was activated with over-expression of constitutively active 
mutant S33Y β-catenin gene, whose product is resistant to degradation by the Axin–
APC–GSK3β complex; and lastly both compounds were capable of disrupting  nuclear β-
catenin translocation without changing the total cellular levels (Figure 3-8). Similar to the 
phenomenon previously reported by Park et al., we observed a more pronounced 
inhibitory effect on the extrinsic transcriptional activity by curcumin with either forced 
expression of mutant S33Y β-catenin gene or treatment with GSK-3β inhibitors 
compared to the over-expression of wild-type β-catenin, although the transcriptional 
activity of the latter was increased much less than other treatments [201]. These 
observations may be explained by the fact that both treatments with the mutant S33Y β-
catenin and GSK-3β inhibitors negatively affected β-catenin degradation [76, 198, 199], 
which in turn may have resulted in the stabilization of β-catenin protein and consequently 
a much greater increase in its nuclear translocation compared to treatment with the wild-
type β-catenin gene. Curcumin could have acted effectively in disrupting the nuclear 
translocation of β-catenin protein in these treatments giving rise to a more pronounced 
decrease in transcriptional activity, but further experiments are required to confirm this. 
On the other hand, these differences were not observed for PKF118-310 since it is 
capable of antagonizing Wnt/β-catenin signaling at various juncture of Wnt signaling 
such as preventing the translocation of nuclear β-catenin, as well as inhibiting the 
complexation of β-catenin/TCF [178]. Synergistic antagonism at various critical points of 




inhibitory effects. As several Wnt components including cell-surface receptor (LRP5), 
Wnt ligands (Wnt 10b) as well as natural antagonist (DKK-3) have recently been shown 
to regulate cellular invasion in osteosarcoma [47, 48, 51, 52, 63, 73, 193], we next asked 
if curcumin, artemisinin and PKF118-310 could act as anti-invasive agents in U2OS cells 
after having established their inhibitory effects on Wnt/β-catenin signaling (Figures 3-5, 
3-6 and 3-7). Indeed, we showed that U2OS cell migration and invasiveness were 
significantly reduced using non-toxic concentrations of curcumin and artemisinin 
(Figures 3-9 and 3-10). The demonstration that PKF118-310, a selective antagonist of 
Wnt/β-catenin signaling, inhibited osteosarcoma cell migration and invasiveness further 
supported the involvement of the pathway in osteosarcoma cell metastasis (Figure 3-9c 
and 3-10d). As an alternative confirmatory approach to correlate osteosarcoma 
invasiveness with the Wnt/β-catenin pathway, we transfected U2OS cells with wild-type 
β-catenin plasmid and demonstrated that the activation of the Wnt/β-catenin pathway 
with the over-expression of the wild-type β-catenin gene resulted in enhanced invasion 
capacity of osteosarcoma cells, promoting their ability for transmigration through the 
extracellular matrix. Again, curcumin effectively reversed this phenomenon (Figure 
3-10b).  
 
Although we do not fully understand the specific mechanisms of their anti-invasive 
effects, curcumin and PKF118-310 may suppress osteosarcoma cell invasion through 
Wnt-targeted genes such as MMPs [100, 101, 229]. Given the myriad of MMPs that may 
be affected, we focused on MMP-9 since several groups have shown that MMP-9 is the 




and that its increased expression is associated with osteosarcoma tumor aggressiveness, 
metastasis and poor prognosis [217-219]. Indeed, the suppression of U2OS cell invasion 
by curcumin and PKF118-310 was found to correlate with the inhibition of MMP-9 
activity and protein levels (Figure 3-11e-f). This observation may be explained by the 
fact that the MMP-9 gene contains consensus TCF/LEF-binding elements in the promoter 
region and has been shown to be highly regulated by Wnt/β-catenin signaling [230]. 
Hence, PKF118-310, a selective Wnt/β-catenin antagonist, was able to inhibit MMP-9 
protein expression and activity (Figure 3-11e-f). In addition, curcumin was shown to 
suppress MMP-9 protein levels and activities under both conditions of intrinsic (Figure 
3-11a-b) and extrinsic (Figure 3-11c-d) Wnt/β-catenin activation. It is noteworthy that the 
inhibitory effect by curcumin was more pronounced under Wnt-stimulated conditions, 
further supporting the notion that MMP-9 is regulated by Wnt/β-catenin signaling. Taken 
together, our findings suggest that curcumin and PKF118-310 down-regulated MMP-9 
under conditions of either endogenous and/or exogenous Wnt/β-catenin activation, 
possibly giving rise to reduced invasiveness and migration of U2OS cells.  
 
Besides MMP-9, other Wnt-targeted oncogenes may possibly be involved in regulating 
the invasive behavior of osteosarcoma. For instance, attenuating Wnt/β-catenin signaling 
using DN-LRP5 inhibited both in vitro and in vivo metastasis in several osteosarcoma 
cells by suppressing MMP-2, MMP-14, Twist, Slug and Snail [51, 52]. Several other 
metastatic-associated Wnt responsive genes including MMP-2, MMP-7, membrane-type 
matrix metalloproteinase 1 (MT1-MMP) and uPAR were previously reported to regulate 




studies are required to investigate the effects of curcumin and PKF118-310 on the levels 
of MMPs and metastatic-associated Wnt target genes, as well as fully elucidate their roles 
in regulating osteosarcoma cell metastasis.  
 
Given that curcumin is a multi-targeted compound, we cannot exclude the possibility that 
curcumin reduced osteosarcoma cell invasiveness through a combination of Wnt-
dependent and Wnt-independent effects. A recent report showed that curcumin was able 
to transcriptionally activate the tumor suppressor HLJ1 through the JNK/JunD pathway, 
resulting in the up-regulation of E-cadherin which in turn leads to the inhibition of cancer 
cell invasion and metastasis in human lung adenocarcinoma [233]. Further experiments 
are needed to examine the effect of curcumin on the relative expression of epithelial and 
mesenchymal markers in osteosarcoma. Nevertheless, our studies provide first evidence 
that curcumin and PKF118-310 effectively reduced the metastatic capacity of 
osteosarcoma by mediating, at least in part, the Wnt/β-catenin signaling pathway through 
inhibiting MMP-9 protein and activity.  
 
Apart from its potent anti-invasive effects at lower non-toxic concentrations, PKF118-
310 was also found to demonstrate anti-proliferative effect in U2OS cells, attributed to 
PKF118-310 induced apoptosis and G2/M phase arrest, at higher toxic concentrations 
(Figure 3-12). Previous reports on prostate and colon cancer cell lines supported the 
potent anti-proliferative effect of PKF118-310 [178, 215]. Given that several survival-
associated Wnt target genes such as cyclin D1, c-Myc and survivin have been reported to 




significantly with reduced survival time and prognosis [234-241], we further examined 
the expression of these genes with PKF118-310 treatment. Cyclin D1 and c-Myc regulate 
cell proliferation and cell cycle progression [97, 98] while survivin is both an inhibitor of 
apoptosis and a regulator of mitosis in the G2/M checkpoints of the cell cycle [222-225]. 
Indeed, we found that the suppression of cell proliferation through induction of apoptosis 
and G2/M phase cell cycle arrest in U2OS cells by PKF118-310 correlated with the 
down-regulation of cyclin D1, c-Myc and survivin protein expressions (Figure 3-13).  
 
Downregulation of genes that regulate apoptosis such as c-Myc and survivin represent an 
advantage in controlling metastatic behavior in osteosarcoma [240, 242].  For instance, c-
myc was previously reported to induce a more aggressive phenotype and metastatic 
features in osteosarcoma while a synchronous over-expressions of c-Myc and c-fos were 
strongly correlated to the development of metastases [240]. In another study, survivin 
expression was found to be significantly down-regulated in a U2OS cell model with 
markedly reduced invasiveness and metastatic potential as a result of the forced 
expression of L/B/K ALP (Liver-bone-kidney alkaline phosphatase) or CD99 [242]. 
Altogether, our results suggested that the suppression of c-Myc, cyclin D1, survivin and 
MMP-9 by PKF118-310 treatment may collectively delayed tumorigenesis and 








In the previous chapter, we have reported the therapeutic potential of curcumin as an anti-
invasion agent in osteosarcoma and found that its anti-invasive activity was associated 
with the suppression of intrinsic and extrinsic Wnt/β-catenin signaling, as well as the 
down-regulation of metastatic-related Wnt target gene, MMP-9 [195]. Our findings were 
supported by others which showed that curcumin exert its anti-cancer properties through 
disrupting Wnt signaling in other malignancies such as colon, gastric and stomach cancer 
[193, 201, 207, 208, 228]. However, the clinical application of curcumin as an effective 
Wnt antagonist is limited by its low bioavailability due to poor absorption and rapid 
metabolism [243-245]. As such, the effective but high concentrations used in previous 
studies may not be feasible for human clinical intervention studies. Therefore, a 
requirement obviously exists for access to compounds that combine improved Wnt 
inhibitory potency (lower EC50) and selectivity with a suitable drug-like character that 
would circumvent the limitations encountered with curcumin. Furthermore, identification 
of critical targets for Wnt inhibition as well as elucidation of structure-activity-
relationships (SAR) that critically influence Wnt inhibitory activity would provide useful 
direction for designing novel derivatives with desirable drug-like profiles. The objectives 
of this chapter  are thus to (1) synthesize, evaluate and identify curcumin analogues with 
enhanced potency and good selectivity as Wnt antagonists to prevent or delay 




identify crucial structural motifs leading to improved potency and selectivity as Wnt 
inhibitors and (3) examine the underlying mechanism of Wnt inhibition of selected 
curcumin analogue by evaluating the perturbations in gene expression of various Wnt 
signaling components using the Human Wnt Signaling Pathway RT2 ProfilerTM PCR 
array.  
 
To study the effect of structural modification on Wnt inhibition, we modified the lead 
compound, curcumin (1-1) to produce five series of curcumin analogues with diverse 
linkers joining the terminal phenyl rings as well as different substituent at the phenyl 
rings. These compounds were synthesized by base-catalyzed Clasien-Schmidt 
condensation reactions of substituted aromatic aldehydes with the appropriate 
acetophenones (see Material and methods). The structures of curcumin analogues are 
presented in Table 4-1. Series 1 consists curcumin-type compounds that retain the 7-
carbon spacer between the terminal phenyl rings known as the diarylheptanoids while 
Series 2 represents diarylpentanoid analogues with a 5-carbon spacer between the 
terminal phenyl rings. Series 3 (dibenzylidene-cyclohexanones) and 4 (dibenzylidene-
cyclopentanones) consist of diarylpentanoid-type compounds in which flexibility of the 
5-carbon chain is constrained by incorporating it as part of a cyclohexanone and 
cyclopentanone ring respectively. Lastly, Series 5 compounds, known as chalcones, were 
considered as structures equivalent to “half a curcuminoid” with loss of symmetry and a 





The choice of these templates and the associated substitutions at the terminal phenyl rings 
were prompted by the following observations: Firstly, natural derivatives of curcumin 
with different substitutions on the end rings were reported to suppress β-catenin/TCF 
transcription. Hence, regioisomers of diarylheptanoids (Series 1) were included to 
determine how changes in substitution pattern would impact inhibitory activity [96]. 
Second, the deletion of the β-ketone moiety in curcumin to give diarylpentanoids (Series 
2), dibenzylidene-cyclohexanones (Series 3) and dibenzylidene-cyclopentanones (Series 
4) is known to give rise to analogues with improved pharmacological and metabolic 
profiles [243, 244, 246]. These compounds may also be more potent inhibitors of the 
Wnt/β-catenin signaling pathway. Finally, the substitution pattern on the terminal phenyl 
rings were kept symmetrical (i.e. both rings share the same substitution pattern) and 
largely restricted to groups present on curcumin. Thus the 3’OCH3-4’OH substitution 
pattern of curcumin was modified by (i) excluding either one substituent to give 3’OCH3 
or 4’OH analogs; (ii) removing both substituent; (iii) switching their positions to give 
3’OH-4’OCH3 substituted rings; and (iv) introducing an additional OCH3 in place of OH.  
An exception was the introduction of fluorine which was made in view of the bioisosteric 
relationship between F and H, as well as the anomalous properties of fluorine which have 
led to improved activities in many instances [247-249]. It is noteworthy that except for 
some fluorinated analogues, other compounds have physicochemical properties that 
comply with the Lipinski’s Rule of Five [250] which provide guidelines for drug-like 
profiles related to good oral bioavailability. In fact, 38 of the 43 synthesized analogues 
have enhanced lipohilicity compared to parental curcumin (Appendix 1). For example, 





Table 4-1. Structures of curcumin analogues (Series 1-5). 
 











1-1 (curcumin) OCH3 OH 
1-2 OCH3 OCH3 
1-3 OH OCH3 
1-4 H H 
1-5 OCH3 H 
1-6 H OH 










2-1 OCH3 OH 
2-2 OCH3 OCH3 
2-3 OH OCH3 
2-4 H H 
2-5 OCH3 H 
2-6 H OH 










3-1 OCH3 OH 
3-2 OCH3 OCH3 
3-3 OH OCH3 
3-4 H H 




3-6 H OH 
3-7 F F 
3-8 2’F  
3-9 F H 











4-1 OCH3 OH 
4-2 OCH3 OCH3 
4-3 OH OCH3 
4-4 H H 
4-5 OCH3 H 
4-6 H OH 
4-7 F F 
4-8 2’F  
4-9 F H 











5-1 OCH3 OH 
5-2 OCH3 OCH3 
5-3 OH OCH3 
5-4 H H 
5-5 OCH3 H 
5-6 H OH 
5-7 F F 
5-1 OCH3 OH 
5-2 OCH3 OCH3 
5-3 OH OCH3 
5-4 H H 
5-5 OCH3 H 
5-6 H OH 





In total, we evaluated the effects of 43 curcumin analogues on the Wnt/β-catenin pathway 
and identified 6 promising analogues that were effective in suppressing β-catenin/TCF 
transcriptional activities in osteosarcoma with a lower EC50 compared to parental 
curcumin. Results from invasion assays further demonstrated that these analogues were 
more potent than curcumin in osteosarcoma, possibly through suppressing MMP-9. 
Perturbations of genes related to Wnt signaling components and other Wnt-targeted genes 
following treatment with the most potent analogue (3-3) indicated that 3-3 may be 
capable of disrupting Wnt signaling in U2OS cells at multiple intersections of the Wnt 
cascade including interrupting cell surface FZD receptor-Wnt ligand interactions, 
inducing proteasomal degradation of cytoplasmic β-catenin, preventing β-catenin/TCF 
complexation and transcription and down-regulating Wnt target oncogenes. In addition, 
Wnt inhibitory effects were observed to be markedly enhanced by shortening and 
restraining the flexibility of the 7-carbon linker moiety connecting the terminal aromatic 
rings of curcumin. Our results strongly suggest that curcumin analogues especially those 
with the dibenzylidene-cyclohexanone and dibenzylidene-cyclopentanone scaffolds are 
promising templates for lead optimization and may yield clinically useful candidate drugs 
for the treatment and prevention of osteosarcoma.  
 
4.2 Experimental Methods 
4.2.1 General experimental details for synthesis 
Reagents (synthetic grade or better) were obtained from Sigma-Aldrich Chemical 
Company Inc (Singapore) and used without further purification. Melting points were 




uncorrected. Mass spectra were captured on an LCQ Finnigan MAT equipped with an 
Atmospheric Chemical Ionization probe and m/z ratios for the molecular ions (M+1)+ 
were reported.  Chemical shifts of 1H-NMR and 13C-NMR spectra, obtained on a Bruker 
Spectrospin 300 Ultrashield spectrometer at 300 MHz and 75 MHz respectively, were 
analyzed using MestRec-C 4.9.9.6 (Mestrelab Research SL, Spain) and reported in δ 
(ppm) relative to tetramethylsilane (TMS) as an internal standard.  Silica 60 F254 sheets 
(Merck, Darmstadt, Germany) and silica gel 60 (0.040-0.063) (Merck, Darmstadt, 
Germany) were used for Thin Layer Chromatography (TLC) and flash chromatography 
respectively. Purity of the final compounds were verified either by elemental analysis on 
a Perkin Elmer PRE-2400 Elemental Analyzer or by High Pressure Liquid 
Chromatography (HPLC) using two different solvent systems. Spectroscopic data, 
melting points, yields and purities of individual compounds were listed in Appendix 2. 
 
4.2.2 Mechanism of reaction for Series 1 curcumin analogues 
 
Various methods to prepare Series 1 curcumin analogues were previously reported [251-
253].  Their basic principles remained the same, but differed in technique, reaction time 
and temperature. Generally, the first step is the protection of the active methylene group 
by reacting acetylacetone with boron anhydride to yield the acetylacetone-boric 
anhydride complex in order to avoid Knoevenagel condensation reaction of the active 
methylene group (Scheme 4-1). Subsequently, the less reactive methyl terminals of this 
complex will react with aromatic aldehyde to give Series 1 curcumin analogues in the 





























Scheme 4-1. General method for the synthesis of Series 1 curcumin analogues 
 
4.2.2.1 General procedure for the synthesis of Series 1 curcumin analogues 
Specifically, our curcumin analogues from Series 1 were prepared according to Pedersen 
method with slight modifications [251]. A mixture of boric anhydride (0.35 g, 5 mmol), 




for 3 h at 70 ºC. After removing the solvent, the resultant white residue was washed with 
hexane. Following this, substituted aldehyde (20 mmol), tributyl borate (4.60 g, 20 mmol) 
and 20 ml EtOAc were added and stirred at room temperature for a further 30 mins. 
Butylamine (73 mg, 1 mmol) dissolved in EtOAc (5 ml) was then added drop wise over 
15 mins and the mixture was stirred at 70 ºC for another 24 h. Next, the reaction mixture 
was heated for 30 mins at 60 ºC after adjusting to pH5 by adding 1 N HCl. EtOAc (3 x 50 
ml) was then used to extract the crude product from the water layer. The organic layer 
was washed with brine, dried with anhydrous NaSO4 and evaporated in vacuo to give 
either a solid or liquid residue and purified by column chromatography on silica gel using 
hexane: ethyl acetate as eluting solvents. Further purification by re-crystallization from 
ethyl acetate yielded yellow crystals.   
 
4.2.3   Mechanism of reaction for Series 2, 3, 4 and 5 curcumin analogues 
The alkoxylated Series 2, 3, 4 and 5 curcumin analogues were synthesized using a base-
catalyzed Clasien-Schmidt condensation of a substituted aromatic aldehyde with the 
appropriate acetophenone in the ratio of 2:1 (Series 2-4) and 1:1 (Series 5) (Scheme 4-2) 



























Scheme 4-2.  Curcumin analogues from Series 2, 3, 4 and 5 
 
 
Briefly, sodium hydroxide (20% w/v) acted as a base catalyst to protonate the methyl 
group of the acetophenone, forming a carbanion. The resultant carbanion attacks the 
carbonyl carbon of the substituted benzaldehyde via a nucleophilic addition reaction to 




















Scheme 4-3. General method for the synthesis of Series 2, 3 and 4 curcumin 
analogues. Reagents and conditions: (i) 20% NaOH, RT, 3h. (ii) carbanion attacks 
aldehyde by nucleophilic addition. (iii) Dehydration.  
 
For the synthesis of the hydroxylated analogues from Series 2-4, protection of the 
phenolic groups on the aromatic aldehyde with 2H-3, 4-dihydropyran is necessary to 
minimize reaction between these OH groups and the carbonyl group of the benzaldehyde 
for improved yields (Scheme 4-4). In the case of Series 5 analogues, phenolic groups 
from both the aromatic aldehyde and ketone were needed. Protection converts the OH 
groups to tetrahydropyranyl ethers which can easily be removed by acid hydrolysis to 
give the desire curcumin analogues.  
 
The dihydropyran is an enol ether which is susceptible to electrophilic attack by an acid 
provided by the pyridinium cation of pyridinium p-toluenesulphonate. The phenolic OH, 
to be protected, act as a nucleophile and attacks the α-carbon on the pyran ring, resulting 
in the removal of a proton form the intermediate by pyridine (which is a stronger base 




aldehyde with its hydroxyl groups protected is then subjected to based-catalyzed Claisen-
















Scheme 4-4. Protection and deprotection of phenolic hydroxyl groups for the 
synthesis of compound 2-6. Reagents and conditions: (i) pyridinium p-
toluenesulphonate, RT, 4 h. (ii) 20% NaOH, RT, 3h. (iii) 4M HCl, RT, 4 h. 
 
4.2.3.1 General procedure for the synthesis of Series 2, 3, 4 and 5 alkoxylated 
curcumin analogues 
The method by Liang et al. was followed [246]. To a solution of substituted 
benzalaldehyde (30 mmol) in methanol (20 ml) was added appropriately substituted 
ketone (15 mmol) such as acetone (Series 2), cyclohexanone (Series 3) and 




substituted benzalaldehyde and 15 mmol of substituted ketone were used instead. The 
resultant mixture was stirred at room temperature for 20 mins before 20 % (w/v) NaOH 
(3.0 ml, 15 mmol) was added drop wise. After the reaction has completed, the residue 
was poured into saturated NH4Cl solution and filtered. The precipitate was washed with 
brine and cold ethanol, dried with anhydrous NaSO4, evaporated in vacuo to give either a 
solid or liquid residue and purified by column chromatography on silica gel using hexane: 
ethyl acetate as eluting solvents. Further purification by re-crystallization from ethyl 
acetate or ethanol yielded yellow crystals.   
 
4.2.3.2 General procedure for the synthesis of Series 2, 3 and 4 hydroxylated  
curcumin analogues 
For compounds with phenolic hydroxyl substituent, additional protection and de-
protection of the phenolic hydroxyl groups on the benzalaldehyde were required and the 
method by Liang et al. was followed [246]. A solution of 3, 4-dihydro-α-pyran (44 mmol) 
in dichloromethane (40 ml) was added drop wise to a well stirred suspension of hydroxyl 
benzalaldehyde (28.8 mmol) and pyridium p-tolenesulfonate (0.32 mmol) in 
dichloromethane (80 ml) and stirred at room temperature for 4 h. The reaction mixture 
was then washed with 1 M NaCO3 solution (60 ml x 3) and brine (60 ml x 3), dried with 
anhydrous Na2SO4, evaporated in vacuo and purified by column chromatography on 
silica gel using hexane: ethyl acetate as eluting solvents to yield 4-(tetrahydropyran-2-
yloxy) as a pale yellow oil. This purified protected derivative was condensed with 
substituted ketone at a ratio of 2:1 using similar procedures as described earlier for 




protecting groups were removed by acidifying with 4 M HCl, followed by stirring the 
mixture for 4 h at room temperature. The reaction mixture was then diluted with water, 
followed by extracting with ethyl acetate (50 ml x 3) and the combined organic phase 
was washed with brine (50 ml x 3), dried over anhydrous NaSO4, evaporated in vacuo 
and purified by column chromatography and/or re-crystallization as described earlier in 
Section 4.2.3.1.  
 
4.2.3.3 General procedure for the synthesis of Series 5 hydroxylated chalcones 
For chalcones with phenolic hydroxyl substituent, additional protection and de-protection 
of the phenolic hydroxyl groups on both the acetophenone and substituted aromatic 
aldehyde were required. The benzaldehyde (15 mmol) and aromatic ketone (15 mmol), 
were reacted separately each with pyridinium p-toluenesulphonate (1 mmol) and 3,4-
dihydro-2H-pyran (40 mmol) in dichloromethane (40ml) and stirred  at room temperature 
for 4 h. The reaction mixture was then washed with 1 M NaHCO3 solution (60 ml x 3) 
and brine (60 ml x 3), dried with anhydrous Na2SO4, evaporated in vacuo to yield the 
crude tetrahydropyranyl ether as a pale yellow oil and used without purification. This 
crude protected aromatic aldehyde and ketones were then reacted at a ratio of 1:1 using 
similar procedures as described earlier for alkoxylated Series 5 analogues (Section 
4.2.3.1). At the end of the reaction, the protecting groups were removed by acidifying 
with 4 M HCl, followed by stirring the mixture for 4 h at room temperature. The reaction 
mixture was then diluted with water, followed by extracting with ethyl acetate (50 ml x 3) 




NaSO4, evaporated in vacuo and purified by column chromatography and/or re-
crystallization  as described earlier (Section 4.2.3.1).  
 
4.2.4  High Pressure Liquid Chromatography (HPLC) analysis of compounds 
The purity of most analogues was verified by HPLC using Waters Delta 600-2487 
systems. Briefly, the compounds were dissolved in methanol and injected through a 50 µl 
loop at a flow rate of 1 ml/min in a Nova Pak C18 column (2.0 x 150 mm, 10 μm particle 
size, (Waters Corp., Milford, USA) with UV detection at λmax 254 nm. Elution was done 
using two different mobile phases namely methanol: water (80:20) and acetonitrile: water 
(80:20). The retention times and peak Area Under Curve (AUC) were recorded from at 
least two independent determinations for each compound. Peaks were found to 
have >95% AUC for all compounds.  
 
4.2.5  Cell culture, transfection and plasmids 
All cell culture reagents were purchased from Sigma Chemical Co. (St Louis, MO) unless 
otherwise stated. The U2OS human osteosarcoma cell line was purchased from American 
Tissue Culture Collection (Rockville, MD) and cultured in McCoy’s 5A medium. The 
human embryonic kidney cells HEK293T was a gift from Dr Yang Yi Yan (Institute of 
Biotechnology and Nanotechnology, (IBN), Singapore). These cells were grown in 
DMEM. Both control L cells and L cells stably transfected with a Wnt-3A expression 
factor (L Wnt-3A cells) were kindly provided by Professor Victor Nurcombe (Institute of 
Medical Biology, A*STAR, Singapore) and were maintained in DMEM supplemented 




(Invitrogen, Carlsbad, CA), 10U/ml penicillin G and 100μg/ml streptomycin. The cells 
were cultured in a humidified atmosphere at 37 ºC containing 5 % CO2. For the 
preparation of Wnt-3A conditioned medium (Wnt-3A CM), Wnt-3A secreting L Wnt-3A 
cells were cultured in DMEM supplemented with 10 % FBS for four days before this first 
batch of CM was harvested. Fresh medium was added and the cells were cultured for 
another three days. Following this, the medium was collected, combined with the 
previous batch and filtered using a 0.22 µM filter. TOPglow and FOPglow reporters used 
in the dual luciferase reporter gene assays were purchased from Upstate Biotechnology 
(Lake Placid, NY). The pCMV-RL renilla control vector was purchased from Promega 
(Madison, WI). The synthesized curcumin analogues were dissolved in DMSO before use. 
The final concentration of DMSO did not exceed 0.1 % in all instances. 
 
4.2.6  Luciferase reporter gene assay 
HEK cells (1.4x 106) grown to 40% confluency in 60 mm culture dish were transiently 
co-transfected with either 3ug TOPGlow, or 3ug FOPGlow, a negative control plasmid, 
and 0.012ug pCMV-RL Renilla control plasmids for normalization of transfection 
efficiency using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the 
manufacturer’s instructions. On the other hand, U2OS cells (1.0 x 105/well) grown to 90–
95% confluency in 24-well plates were transiently co-transfected with either 0.3µg 
TOPGlow or 0.3 µg FOPglow, and 1.2 ng pCMV-RL renilla plasmids. Twenty hours post 
transfection, both type of cells were treated with curcumin analogues at various 
concentrations (0.01 - 20µM) for 24 h before cell lysis and harvesting. For HEK293T 




treatment. To activate the Wnt/β-catenin signaling pathway, HEK cells were co-incubated 
with Wnt-3A CM and the curcumin analogues for 24 h. Luciferase assays were 
performed with the Dual Luciferase assay kit (Promega, Madison, WI) according to the 
manufacturer’s instructions. For firefly luciferase activity, 20 µl cell lysate was mixed 
with Dual-Glo® Luciferase Reagent (100 µl) and the light output was determined in a 
luminometer (Tecan, MTX Lab Systems Inc., Vienna, VA). An equal volume of Dual-
Glo® Stop & Glo® Reagent (100 µl) was subsequently added to the same samples and a 
second luminescence measurement was taken for the Renilla luciferase activity. Results 
were expressed as mean ± SEM of normalized ratios of Firefly luciferase and Renilla 
luciferase activities for each triplicate sets. Reporter activities in curcumin analogue-
treated cells were expressed as the percentage of DMSO-treated samples. For HEK293T 
cells, the EC50 values were obtained from the sigmoidal curve by plotting the percentage 
normalized luciferase activity against the concentration of curcumin analogues using 
GraphPad Prism version 4.00 for Windows, GraphPad Software (San Diego, CA). 
 
4.2.7  MTS cell cytotoxicity assay 
MTS cell cytotoxicity assay was used to evaluate the cytotoxic profile of the curcumin 
analogues. Briefly, HEK293T and U2OS cells were seeded into 96-well plates at a 
density of 18 x 103 cells/well and 10 x 103 cells/well respectively and cultured for 24 h. 
HEK293T cells were then treated with curcumin analogues at their respective 
concentrations for 24 h while U2OS cells were treated with selected curcumin analogues 
at 1 and 5 µM. After treatment, cell viability was analyzed by adding 20 μl of CellTiter 




period of 4 h, the absorbance of the formazan product was determined at λmax of 490 nm 
using a Tecan Spectra Fluor spectrophotometer (MTX Lab Systems Inc Vienna, VA). 
The percent cell viability after treatment with curcumin analogues was calculated using 
the following formula:  % viability = (AAnalogues  –  ABlank)/ (AControl (DMSO)  – ABlank)  X 
100%, where AAnalogue = absorbance of wells with cells treated with curcumin analogues, 
ABlank = absorbance of wells with media and AControl (DMSO) = absorbance of wells with 
cells treated with DMSO (vehicle control). Each concentration of curcumin analogue was 
performed in triplicate on three separate occasions.  
 
4.2.8  Western blot analysis 
Western blotting was used to examine the protein expression levels of β-catenin, MMP-9, 
and cyclin D1 before and after 24 h treatment of curcumin analogues using similar 
methods detailed in section 3.2.5. Primary and secondary antibodies used were similar to 
those mentioned earlier (section 3.2.5). For the collection of proteins from the cytosolic 
and nuclear fractions, the NE-PER cytoplasmic and nuclear protein extraction kit (Pierce, 
Rockford, IL) was used according to the manufacturers’ protocol. Bands were quantified 
using Quantity One software (BioRad, Hercules, CA), normalized to either α-tubulin or 
lamin A/C loading controls, before bands in treatment group are expressed relative to 
DMSO control (set as 100%). 
 
4.2.9  Cell invasion assay 
U2OS cell invasion were determined using the Matrigel invasion assays as previously 




concentrations for 24 h and allowed to invade through the precoated inserts for a period 
of 48 h. Cells that have invaded to the lower surface of the membrane were then fixed 
with 70% ethanol and stained with 0.2% w/v crystal violet before they were counted 
using the Nikon Eclipse TE2000U microscope (Melville, NY). Invaded cells from ten 
random microscopic fields (200 x magnifications) were enumerated and all experiments 
were performed in triplicates at least.   
 
4.2.10 Gene expression profiling using real-time PCR array 
The Human Wnt Signaling Pathway RT2 ProfillerTM PCR Array (SA Bioscience, MD) 
was used to identify changes in expression of 84 key genes related to Wnt-mediated 
signaling transduction with curcumin analogue treatment. The 84 genes comprises 
representative upstream and downstream components of the Wnt pathway including 
glycosylated extracellular signaling molecule and ligands belonging to Frizzled family, 
cell surface receptors serving as ligands of the Wnt genes, competitive Wnt binding 
antagonists, intracellular signaling molecules, targets genes implicated in cancer 
tumorigenesis and metastasis, as well as those involved in protein modifications 
downstream of Wnt signaling. These genes are shown in Appendix 3. Total RNA from 
the osteosarcoma cell lines, treated with compounds or DMSO for 24 h, were extracted 
using Qiagen’s RNeasy mini kit (Qiagen, Valencia, CA), followed by on-column DNase 
treatment to remove genomic contaminants, according to the manufacturer’s instructions. 
RNA samples were reverse-transcribed to cDNA using RT2 first strand kit provided 
according to the manufacturer’s instructions (SA Bioscience, MD). Thermal cycling was 
performed using iQ5 machine (BioRad, Hercules, CA) and the cycling conditions are as 




extension at 60 ºC for 1 min, followed by melt curve analysis (95°C, 1 min; 65 °C, 2 min 
(OPTICS OFF); 65 °C to 95 °C at 2 °C / min (OPTICS ON)). Gene expression was 
normalized to internal control housekeeping gene (GAPDH) to determine fold changes in 
gene expression between control (DMSO) and test (treated with analogue) samples. 
Average ∆Ct value for each gene across triplicate arrays for each treatment group was 
calculated. ∆∆Ct for each gene across control and experimental group were determined. 
Finally the fold difference was computed for each gene from control and other group as 
2^ (- ∆∆Ct).  
 
4.2.11 Statistical analysis 
Statistical significance for treatment groups were analyzed using the two-tailed Student’s 
t-test (SPSS, Chicago, IL). The difference between values for each treatment 
concentration and the respective controls was considered to be statistically significant 
when P < 0.05. 
 
4.3 Results 
4.3.1  Purity of curcumin analogues synthesized 
The purity of all final compounds were at least ± 0.4 % or 95% AUC based on elemental 
analysis and HPLC respectively (Appendix 2).   
 
4.3.2 Preliminary evaluation of curcumin analogues on the inhibition of Wnt-3A-




Preliminary screening of curcumin analogues for potent inhibition of the Wnt/β-catenin 
signaling pathway was first performed with a cell-based screening system using 
HEK293T cells. Cells were stimulated with Wnt-3A CM following co-transfection with 
TOPGlow and CMV-RL renilla control vector for normalization of transfection 
efficiency. The transfectants were treated with increasing concentrations of curcumin 
analogues (1-20 µM) for 24 h. HEK293T cells have low β-catenin/TCF transcriptional 
activity because of low endogenous levels of β-catenin protein [254] and are thus suitable 
cell model for screening Wnt inhibitory activities [255, 256]. Wnt/β-catenin signaling in 
HEK293T cells is stimulated by incubation with Wnt-3A CM, which causes the 
accumulation of and stabilization of unphosphorylated β-catenin [257]. As expected, β-
catenin/TCF transcriptional activities were increased approximately 30-fold with Wnt-3A 
CM treatment in our experiments. Table 4-2 shows the normalized luciferase activity in 
the presence of curcumin analogues (1-20 µM), expressed as % of DMSO with Wnt-3A 
activation. Compared with control, Wnt-3A CM-induced β-catenin response transcription 
(CRT) was inhibited by approximately 18.5 % and 38.2 % with  1 0 μM an d  2 0 μM 
curcumin treatment respectively (Table 4-2). Given that our lead compound, curcumin 
(compound 1-1) was found to have an EC50 value of 20.67 ± 0.82 μM, a total of 16 other 
analogues (Table 4-2, bold and indicated with *) that were capable of suppressing the 
Wnt-3A-induced CRT by more than 50 % at 20 µM or lower concentrations (i.e. more 








Table 4-2. Screening of Series 1-5 for Wnt-3A-induced Wnt inhibitory activity in 





Normalized luciferase activity (Firefly/Renilla)a  
Concentration of curcumin analogues  
1µM 5µM 10µM 20µM 
Series 1 Analogues 
1-1 (curcumin) 99.36 ± 3.64 98.20 ± 3.25 82.50 ± 7.86 62.82 ± 12.43 
   1-2 * 101.58 ± 3.85 69.97 ± 1.73 46.51 ± 7.23 N.D b 
1-3 99.74 ± 3.11 110.28 ± 3.12 104.61 ± 10.28 112.77 ± 1.05 
1-4 108.92 ± 4.38 104.09 ± 3.44 107.10 ± 0.78 97.18 ± 7.52 
1-5 97.69 ± 0.93 107.44 ± 4.01 107.46 ± 4.23 101.41 ± 6.09 
1-6 100.33 ± 8.28 77.73 ± 1.80 72.47 ± 0.56 69.08 ± 1.90 
1-7 83.32 ± 9.01 92.19 ± 0.54 89.20 ± 19.22 93.10 ± 20.00 
 
Series 2 Analogues 
2-1 118.41 ± 4.13 110.87 ± 10.53 110.36 ± 23.04 90.35 ± 12.99 
2-2 107.13 ± 1.15 107.55 ± 0.12 108.61 ± 0.18 103.39 ± 1.05 
   2-3 * 82.49 ± 4.05 38.79 ± 4.05 34.36 ± 7.72 N.D b 
2-4 92.95 ± 2.42 82.68 ± 9.03 79.70 ± 14.16 77.94 ± 17.69 
2-5 100.43 ± 5.73 113.88 ± 3.38 102.71 ± 2.53 102.89 ± 4.83 
   2-6 * 62.29 ± 2.35 51.30 ± 6.61 51.97 ± 4.99 37.82 ± 3.55 
2-7 102.95 ± 12.98 100.02 ± 12.46 110.08 ± 6.17 110.85 ± 9.73 
2-8 83.32 ± 4.79 91.17 ± 10.68 70.43 ± 9.61 57.04 ± 5.33 
2-9 82.26 ± 1.03 85.89 ± 9.32 69.38 ± 2.90 64.60 ± 3.38 
 
Series 3 Analogues 
  3-1 * 86.13 ± 0.83 28.92 ± 5.58 21.33 ± 3.76 N.D b 
  3-2 * 97.67 ± 3.10 64.33 ± 7.73 62.77 ± 3.54 40.82 ± 7.13 
  3-3 * 37.30 ± 1.89 27.70 ± 1.52 24.73 ± 3.69 21.36 ± 1.86 
  3-4 * 85.77 ± 5.65 49.57± 6.14  40.60 ± 9.16 39.01 ± 11.22 
3-5 93.28 ± 11.15 60.65 ± 17.70 72.65 ± 5.78 81.51 ± 21.17 
   3-6 * 51.88 ± 5.86 26.87 ± 3.49 26.33 ± 4.33 16.65 ± 2.85 
3-7 94.54 ± 3.15 125.86 ± 14.37 117.90 ± 7.36 113.71 ± 7.28 
   3-8 * 52.20 ± 1.78 21.86 ± 1.50 14.46 ± 0.63 20.85 ± 3.64 
3-9 96.07 ± 9.85 119.07 ± 22.15 105.06 ± 22.08 103.61 ± 12.14 
3-10 70.25 ± 5.39 65.23 ± 6.27 61.58 ± 8.81 60.18 ± 2.29 
 
Series 4 Analogues 
  4-1 * 91.57 ± 5.80 54.09 ± 3.98 37.50 ± 2.31 13.29 ± 2.71 
  4-2 * 88.86 ± 2.67 65.91 ± 6.72 55.48 ± 6.18 39.14 ± 7.24 
  4-3 * 52.57 ± 6.70 45.04 ± 4.96 39.48 ± 4.14 39.19 ± 4.99 




4-5 92.30 ± 3.09 72.74 ± 2.69 72.02 ± 5.56 61.33 ± 9.42 
  4-6 * 34.34 ± 1.49 28.25 ± 3.16 19.63 ± 3.31 7.99 ± 2.35 
4-7 71.04 ± 7.59 73.11 ± 6.01 60.20 ± 2.41 59.50 ± 6.74 
4-8 79.97 ± 12.11 75.70 ± 12.09 85.27 ± 5.60 72.80 ± 4.70 
4-9 123.83 ± 16.40 119.20 ± 5.37  109.00 ± 10.25 102.60 ± 7.07 
4-10 119.50 ± 10.83 112.53 ± 15.60 105.43 ± 6.10 107.71 ± 5.35 
 
Series 5 Analogues 
5-1 111.96 ± 8.25 115.28 ± 13.91 86.91 ± 9.69 69.64 ± 6.69 
5-2 94.95 ± 6.48 86.63 ± 7.68 60.30 ± 4.34 41.58 ± 5.45 
  5-3 * 95.72 ± 3.92 53.85 ± 6.94 41.95 ± 4.71 25.72 ± 2.79 
  5-4 * 101.46 ± 5.68 90.57 ± 14.07 69.03 ± 8.78 18.91 ± 5.43 
5-5 106.81 ± 4.31 107.79 ± 6.37 111.19 ± 10.51 72.94 ± 7.04 
5-6 92.72 ± 1.70 89.57 ± 8.74 70.85 ± 0.41 68.31 ± 6.96 
5-7 117.13 ± 14.80 111.53 ± 13.34 90.21 ± 15.68 59.08 ± 6.77 
 
a  Results are presented as the mean ± S.E.M of normalized luciferase activity (Firefly/Renilla) 
from three  independent experiments, expressed as % of DMSO under Wnt-3A induced 
condition.  (*) indicates analogues designated as ‘actives’ and shortlisted for EC50 determinations 
(With an estimated EC50 value of less than 20 µM compared to curcumin (EC50 20.67 ± 0.82). b 
Not determined (N.D). Tested at 1, 5 and 10 µM because of toxicity at higher concentrations. 
 
 
4.3.3 Determination of EC50 values for Wnt-3A-induced Wnt inhibitory activity of 
‘active’ curcumin analogues in HEK293T cells 
EC50 values were used for the qualitative comparison of Wnt inhibitory activity for the 16 
selected active curcumin analogues (Table 4-2, bolded and indicated with *) and found to 
be more potent than curcumin (1-1). As shown in Table 4-3, Series 3 and Series 4 
analogues were the most promising, with several members such as 3-3, 3-6, 3-8, 4-3 and 
4-6 having EC50 values in the submicromolar ranges. Specifically, the most potent 
analogue from these series, 3-3 (EC50 0.35 ± 0.03 µM) and 4-6 (EC50 0.41 ± 0.02 µM) 
were approximately 60 and 51 times more potent than curcumin (EC50 20.67 ± 0.82 µM) 
in inhibiting CRT respectively. The other analogues were between 1.2- and 40.4-fold 




plasmids were unaffected with treatment of all analogues at the EC50 values (Table 4-3), 
indicating that these analogues specifically inhibited β-catenin/TCF transcription. Except 
for 1-2, 3-1, 3-2, 4-1, and 4-2, all the other analogues have limited cytotoxicity at their 
EC50 for inhibition of TOPGlow β-catenin/TCF transcriptional activity (Table 4-3). 
Taken together, we have identified several novel curcumin analogues (3-3, 3-6, 3-8, 4-3 
and 4-6) with novel effects of inhibiting the Wnt/β-catenin pathway, yet with limited cell 
cytotoxicity at submicromolar concentrations.  
 
Table 4-3. EC50 values of selected curcumin analogues in HEK293T cells. 
 









Series 1 1-1 OCH3 OH 20.67 ± 0.82 1.0 42.43 ± 2.34 89.3 ± 3.64 
1-2 OCH3 OCH3 8.34 ± 0.19 2.5 41.58 ± 0.09 117.6 ± 17.36 
Series 2 2-3 OH OCH3 1.84 ± 0.34 11.2 86.57 ± 1.52 105.1 ± 16.0 
2-6 H OH 3.16 ± 0.24 6.5 99.2 ± 6.90 100.4 ± 11.1 
Series 3 3-1 OCH3 OH 2.63 ± 0.21 7.9 57.64 ± 12.42 87.6 ± 7.09 
3-2 OCH3 OCH3 15.86 ± 0.38 1.3 62.13 ± 8.65 103.6 ± 6.40 
3-3 OH OCH3 0.34 ± 0.01 59.7 91.64 ± 7.59 93.8 ± 8.27 
3-4 H H 2.04 ± 0.26 10.1 99.99 ± 11.85 90.7 ± 7.08 
3-6 H OH 0.80 ± 0.03 25.8 105.85  ± 10.14 85.1 ± 9.24 
 3-8 # 2’F H 0.90 ± 0.10 22.8 87.01 ± 1.84  93.0 ± 4.49 
Series 4 4-1 OCH3 OH 5.91 ± 0.46 3.5 38.40 ± 7.81 90.8 ± 4.77 
4-2 OCH3 OCH3 17.07 ± 1.80 1.2 40.02 ± 9.45 85.2 ± 5.97 
4-3 OH OCH3 0.51 ± 0.04 40.4 86.94 ± 4.52 110.2 ± 12.33 
4-4 H H 3.08 ± 0.39 6.7 83.53 ± 3.34 82.9 ± 7.15 
4-6 H OH 0.40 ± 0.01 50.5 81.43 ± 1.77 101.3 ± 11.3 
Series 5 5-3 OH OCH3 3.89 ± 0.46 5.3 87.15 ± 6.87 130.7 ± 11.7 
 5-4 H H 10.95 ± 0.99 1.9 73.09 ± 12.37 111.9 ± 6.49 
a The concentration of curcumin analogues that inhibits 50 % of TOPGlow β-catenin/TCF 
transcriptional activity. EC50 values are presented as the mean ± S.E.M from three independent 
experiments repeated in triplicate at least. 
b  Potency fold: EC50 values of curcumin/ EC50 values of other analogues.  
c Normalized FOPglow transcriptional activities and cell viability of the cells on treatment with 
analogues at the concentrations of  EC50 a. 





4.3.4 Inhibition of the intrinsic downstream β-catenin/TCF transcriptional activity 
by active curcumin analogues in U2OS cells 
The effects of several potent and specific curcumin analogues 2-3, 3-3, 4-3, 2-6, 3-6 and 
4-6 on the intrinsic downstream β-catenin/TCF transcriptional activity were further 
evaluated in U2OS osteosarcoma cells. These cells present with activated Wnt/β-catenin 
signaling which culminates in the abnormal accumulation of β-catenin in the nucleus [73, 
74]. These six analogues were selected based on the observations that analogues with 3’-
OH-4’OCH3 and 4’OH ring substituent have the most promising Wnt inhibitory effects 
(Table 4-3). Cells were transiently transfected with either TOPglow or the inactive 
mutant FOPglow luciferase reporter plasmids, together with the pCMV-RL renilla 
control vector for normalization of transfection efficiency followed by incubation with 
increasing concentrations of curcumin analogues for 24 h. We have previously shown 
that curcumin significantly inhibited β-catenin/TCF transcriptional activity in U2OS cells 
by approximately 27.1 % and 59.3 % at 10 μM and 20 μM respectively (Figure 4-1). As 
shown in Figure 4-1, curcumin analogues 2-3, 3-3, 4-3, 2-6, 3-6 and 4-6 were more 
potent than curcumin in suppressing β-catenin/TCF transcriptional activity in U2OS. Our 
findings were in parallel to our previous results using HEK293T cells which showed that 
these analogues were 7- to 60-fold more potent than curcumin (Table 4-3). Specifically, 
at as low as 0.5 μM, analogue 3-3, 4-3 and 3-6 significantly reduced β-catenin/TCF 
transcriptional activity in U2OS cells by approximately 27.5 %, 35.1 % and 29.2 % 
respectively (Figure 4-1). Compared with control, β-catenin/TCF transcriptional activities 
were reduced by 25.7 % and 37.0 % with analogue 2-6 and 4-6 treatments at 1 μM. The 




49.4 % of β-catenin/TCF transcriptional activity in U2OS cells at 5 μM. Transcriptional 
activities of the negative control FOPglow plasmids were again unaffected in all 
instances, indicating that the curcumin analogues specifically inhibited β-catenin/TCF 
transcription in U2OS osteosarcoma cells. Taken together, our results demonstrated that 
curcumin analogue 2-3, 3-3, 4-3, 2-6, 3-6 and 4-6 were more potent than curcumin in 
suppressing β-catenin/TCF transcription in U2OS osteosarcoma cells and are promising 
candidates for treatment of osteosarcoma. 

























































Figure 4-1. Effects of curcumin analogues on the transcriptional activity of β-
catenin/TCF in U2OS cell line. U2OS cells were co-transfected with reporter genes 
harboring Tcf-4 binding sites (TOPglow) or a mutant TCF-4 binding site (FOPglow) and 
CMV Renilla gene. 20 hours post-transfection, increasing amount of test compounds 
were added to the cells. Firefly luciferase activity was determined 24h post-treatment, 
normalized against values for the corresponding Renilla luciferase activity. Results were 
expressed as the means ± SEM of normalized ratios of firefly luciferase and renilla 
luciferase measurements of three independent experiments. Reporter activity in 
compound-treated cells is expressed as the percentage of DMSO-treated samples.             





4.3.5 Effects of selected curcumin analogues on the nuclear translocation of β-
catenin in U2OS cells 
The activation of β-catenin/TCF transcriptional activity results from the accumulation of 
nuclear β- catenin [77]. As we have previously shown that curcumin was capable of 
disrupting the translocation of β-catenin into the nucleus without changing the total 
cellular levels [195], we asked the question if the analogues were also able to effect 
changes in the cellular contents and localization of β-catenin protein. Both nuclear and 
cytosolic U2OS cell lysates were collected and used for western blot analysis to 
determine the amount of β-catenin in each cellular fraction following treatment with 1 
μM and 5 μM curcumin analogues for 24 h. As shown in Figure 4-2c, we found that the 
amount of β-catenin in the cytoplasm was not altered by treatments with 3-3, 2-6 and 4-6, 
whereas those in the nuclear fractions were decreased by 3-3, 2-6 and 4-6 at 5 μM, 
suggesting that these analogues disrupted the translocation of nuclear β-catenin. 
Specifically, treatment with analogues 3-3, 2-6 and 4-6 resulted in an approximately 
41.8 %, 52.9 % and 41.9 % reduction in nuclear β-catenin protein expression respectively 
(Figure 4-2d). β-catenin protein levels of both the nuclear and cytoplasmic fractions were, 
however, not altered with treatment of these analogues at 1 μM (Figure 4-2a-b). In 
contrast to analogues 3-3, 2-6, 4-6, and curcumin, treatment with the other analogues (2-3, 
4-3 and 3-6) had no effects on either the nuclear or cytoplasmic β-catenin protein levels 
at any of the concentrations tested (Figure 4-2), suggesting that the substitution groups on 
the benzene rings may affect the components of the Wnt/ß-catenin cascade differentially 




mechanisms may be involved. Further experiments are needed to investigate the specific 
mechanisms of Wnt inhibition by the curcumin analogues. 
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Figure 4-2 Effects of curcumin analogues treatment on the cellular and nuclear 
accumulation of β-catenin. (a, c) U2OS cells were pre-treated with curcumin analogues 
at the stated concentrations for 24 h, followed by collection of protein from the 
cytoplasmic and nuclear fraction. α-tubulin and lamin A/C were used for cytoplasmic and 
nuclear protein loading controls respectively. (b,d) β-catenin protein expression in 
analogue-treated cells were expressed as the percentage of DMSO-treated samples. 
* ,P<0.05, ** P<0.01.                                           
 
4.3.6 Effects of selected curcumin analogues in inhibiting U2OS cell invasion 
We have recently reported that activation of the Wnt/β-catenin pathway via forced 
expression of wild-type β-catenin plasmid drastically enhanced the invasive capacity of 
U2OS cells, but this effect was significantly reversed by curcumin in a dose-dependent 
manner [195]. To determine if curcumin analogues could exert similar, but more potent 
anti-invasive effects, we next performed Matrigel invasion assays using U2OS cells. 
U2OS has been reported to be highly metastatic [213], but as shown in Figure 4-3a the 
curcumin analogues significantly reduced the ability of U2OS cells to invade through the 
Matrigel-coated inserts over a period of 48 h dose-dependently. While curcumin 




μM, treatment with analogue 2-3, 3-3, 4-3, 2-6, 3-6 and 4-6 drastically suppressed U2OS 
cell invasiveness by 63.0 ± 2.4 %, 76.2 ± 1.4 %, 69.3 ± 4.9 %, 81.6 ± 2.6 %, 74.5 ± 5.4 %, 
72.8 ± 0.96 % at the same respectively concentration (Figure 4-3b). We found that these 
analogues were also effective in suppressing U2OS cell invasion by between 34.8 ± 
2.2 % to 71.0 ± 5.9 % at a lower treatment concentration of 1 μM. The anti-invasive 
effects of these analogues were observed at concentration ranges (1-5 μM) that are shown 
to inhibit downstream β-catenin/TCF transcriptional activities (Figure 4-1) and were not a 
result of cell toxicity given that U2OS cells did not exhibit significant growth inhibition 
at these concentrations (Figure 4-3c). Altogether, our results suggest that analogues 2-3, 
3-3, 4-3, 2-6, 3-6 and 4-6 were more potent than the parental curcumin in inhibiting 
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Figure 4-3. Dose-dependent inhibition of U2OS cell invasion by curcumin analogues. 
(a) Representative images from three independent experiments showing a dose- and time-




pre-treated with curcumin analogues or DMSO for 24 h were seeded into Matrigel-coated 
inserts. Cells that invaded to the lower surface of the insert over a period of 48 h were 
captured with a light microscope at 200x magnification after staining with crystal violet 
dye. Ten random fields were counted for the number of invaded U2OS cells. Data were 
presented as means ± SEM of three independent experiments. Cell invasion in 
compound-treated cells was expressed as the percentage of DMSO-treated samples, *, 
P<0.05, **, P<0.01. (c) Effect of curcumin analogues on osteosarcoma cell proliferation. 
MTS cell cytotoxicity assay was used to evaluate the cytotoxic profile of the curcumin 
analogues. U2OS cells were treated with curcumin analogues for 24 h at the 
concentrations indicated. The results shown were means ± SEM from three independent 
experiments repeated in triplicate. Cell viability in compound-treated cells was expressed 
as the percentage of DMSO-treated samples. 
 
4.3.7 Effects of selected curcumin analogues on protein expression of Wnt 
responsive genes (MMP-9 and cyclin D1) in U2OS cells. 
MMPs play important roles in the degradation of extracellular matrix to facilitate 
osteosarcoma cancer cell invasion and metastasis [216]. In particular, MMP-9 is a well 
known Wnt target gene that is associated with enhanced osteosarcoma tumor invasion 
and metastasis [217-219]. Indeed, in our earlier study, we showed that curcumin elicited a 
reduction in the secretion of MMP-9 under conditions of either endogenous and/or 
exogenous Wnt/β-catenin activation, possibly giving rise to reduced invasiveness of 
U2OS cells (Figure 3-9). Thus using Western blotting, we further examined whether 
reduced invasion with curcumin analogues treatment correlated with MMP-9 protein 
levels in U2OS cells. As shown in Figure 4-4, we observed reductions in MMP-9 protein 
expression with analogue treatments at 1 μM and 5 μM. These effects correlated to the 
reduced anti-invasive effects of these analogues at similar concentrations used in the 
Matrigel invasion assays (Figure 4-3). Taken together, our findings suggest that curcumin 




concentrations compared to curcumin, possibly explaining the reduced invasiveness of 
U2OS cells as seen in Figure 4-3. 
 
Besides MMP-9 levels, we also tested the effects of curcumin analogue treatments on 
other Wnt downstream markers such as cyclin D1. As shown in Figure 4-4 , we observed 
a dose-dependent suppression of cyclin D1 with treatment of the analogues. 
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Figure 4-4. Curcumin analogues inhibit MMP-9 and cyclin D1 protein expression in 
osteosarcoma. U2OS cells were treated with indicated concentrations of curcumin 
analogues or DMSO for 24 h before proteins were collected for western blot.  These blots 






4.3.8 Structure-Activity-Relationship (SAR) Analysis of  the Wnt-inhibitory 
activity of curcumin analogues 
To have a better understanding of the structural features important for Wnt inhibitory 
effects, we examined the SAR among the curcumin analogues. As shown in Tables 4-2 
and  4-3, out of 16 compounds identified to be more potent than curcumin (1-1, EC50 
20.67 ± 0.82 μM), 11 were from Series 3 and 4, in which the terminal phenyl rings were 
linked by conformationally restricted dibenzylidene-cyclopentanone and dibenzylidene-
cyclohexanone ring structures. All non-fluorinated cyclic analogues from both series, 
except those with 3’-methoxy ring substituent (3-5 and 4-5) were found to be more potent 
than curcumin. These active cyclic analogues significantly reduced luciferase activity in 
HEK293T cells by approximately 78.1 % to 34.1 % at as low as 5μM. A few others such 
as 3-3, 3-6, 3-8, 4-3 and 4-6 significantly suppressed Wnt activity at even lower 
concentrations of 1 μM. Interestingly, compound 3-8, which was mono-fluorinated at the 
2’ position, was found to be active, with luciferase activity reduced to only approximately 
45.7 % and 15.0 % at 5 µM and 10 µM concentrations respectively. This trend was 
however not seen for compound 4-8 in Series 4. Nor was it observed among other 
fluorinated analogs (4’-F or 3’, 4’-diF) represented across the different series.  We also 
observed that analogues that were substituted with a methoxy group at the 3’ position 
showed consistently poor activity in all series. On the other hand, the inclusion of another 
methoxy group to give 3’4’-dimethoxy improved activity in Series 1, 3 and 4. Next, 
comparison of the EC50 values among analogues from Series 2-5 with various aromatic 
ring substitutions showed that Wnt inhibitory effects were influenced by the nature of the 




OH (most active)  >>  3’-H-4’-H  > 3’-OCH3 4’-OH  > 3’-OCH3 -4’-OCH3  >> 3’-OCH3  
≈  4 ’-F  ≈  3’ -4’-F (least active). For Series 1 analogues, the only compound that 
exhibited significantly greater Wnt activity than curcumin was compound 1-2, which has 
a 3’-4’-di-methoxyl substituent. A couple of chalcones, which lacks structural symmetry 
is capable of suppressing Wnt activity with an EC50 values that were at least 2-fold higher 
than curcumin.   
 
4.3.9 Real time PCR array analysis of related Wnt components and target genes 
with  curcumin analogue 3-3 treatment in U2OS cells 
The global changes in gene expression of related Wnt components with analogue 3-3 
treatment (most potent) was tested using the Human Signaling Pathway RT2 ProfilerTM 
PCR array. As mentioned in Section 4.2.10 (Material and Methods), these 84 genes 
comprises representative upstream and downstream components of the canonical Wnt/β-
catenin pathway. Expressions of selected genes that were significantly up- or down-
regulated (p-value < 0.05) were presented in Table 4-4 while the others were reported in 
Appendix 3. As shown in Table 4-4, the expressions of β-TrCP and Transducin-like 
Enhancer of Split 2 (TLE2) were significantly up-regulated 1.54- and 2.40-fold following 
analogue 3-3 treatment at 1 µM for 24 h respectively. On the other hand, the gene 
expressions of Wnt ligands including WNT 5a, 5b, 6, 7a, 7b, 8a, 10a and 11 were 
significantly suppressed, while all 16 Wnt ligands tested, except WNT 2b, were down-
regulated with curcumin analogue 3-3 treatment (Appendix 3). Similarly, the gene 
expression of all FZD (FZD1-8) were decreased following 1 µM curcumin analogue 3-3 




3.77-, 1.34- and 2.60-fold reduction respectively. Furthermore, expressions of several 
Wnt target genes that are critical for cancer tumorigenesis and metastasis such as FOS-
like antigen 1 (FOSL1), PITX2, WISP1 and cyclin D1 were markedly suppressed in 
U2OS cells after treatment with curcumin analogue 3-3. T-cell specific transcription 
factor 7-like 1 (TCF7L1), a member of TCF/LEF transcription factors that function as a 
mediator of the Wnt/β-catenin transcription, was also inhibited. Much to our surprise, we 
found a reduction in the gene expressions of two negative regulators of the Wnt/β-beta-
catenin/TCF signaling pathway. These two genes were SFRP1 belonging to a family of 
five glycoprotein (SFRP1-5) that competes with FZD for binding of Wnt ligands and 
Naked Cuticle Homolog 1 (NKD1), a dishevelled-binding protein (Table 4-4). Taken 
together, this global analysis has provided some preliminary observations that may 
explain the mechanism of Wnt inhibition by curcumin analogue 3-3 in U2OS cells. Our 
results suggest that down-regulation of target oncogenes critical for cancer tumorigenesis 
and metastatic transformation including FOSL1, PITX2, WISP1 and cyclin D1, may 
possibly contribute synergistically to the reduction of invasiveness of U2OS cells 





Table 4-4. Effects of curcumin analogue 3-3 on related Wnt components and target genes in U2OS cells using Human Wnt 
signaling real time PCR array analysis. 
Gene Gene 
symbol  
Function  Fold  
change  





β-TrCP A component of an E3 ubiquitin ligase complex, which 
functions in phosphorylation-dependent ubiquitination of 
cytoplasmic β-catenin, thus destabilizes it. 
1.54 0.047 ↑ 
Transducin-like 
enhancer of split 2 
TLE2 Mammalian homologue of the Drosophila groucho which serves 
as a nuclear transcriptional co-repressor by interacting with TCF 
family of proteins to block TCF/β-catenin transcription and thus 
repress Wnt target oncogenes 
2.41 0.00052 ↑ 
Cyclin D1 CCND1 Wnt target oncogene that stimulates tumor cell proliferation and 
cell cycle progression in the G1/S phase.  
1.46 0.042 ↓ 
FOS-like antigen 1 FOSL1 Member of FOS protein family that is implicated as regulator of 
tumor cell proliferation, invasion, motility, differentiation and 
transformation.  
4.57 0.044 ↓ 
Frizzled receptor 2 FZD2 Member of the 'frizzled' gene family encode 7-transmembrane 
domain proteins receptors that interacts with Wnt signaling 
proteins to initiate Wnt signaling. 
3.77 0.030 ↓ 
Frizzled receptor 3 FZD3 1.34 0.015 ↓ 
Frizzled receptor 4 FZD4 2.60 0.029 ↓ 




homolog 1 regulator of the Wnt/β-beta-catenin/TCF signaling pathway 
paired-like 
homeodomain 2 
PITX2 A transcriptional factor of the Wnt/β-catenin signaling that 
promotes tumorigenesis by directly activating cyclin D1, cyclin 
D2 and c-Myc expressions. 
3.85 0.030 ↓ 
secreted frizzled-
related protein 1 
SFRP1 Belongs to a family of five glycoprotein (SFRP1-5) that 
competes with Frizzled receptors for bind Wnt ligands, but  has 
been shown to be capable of increasing Wnt signaling rather 
than antagonizing it in some conditions  
1.56 0.00062 ↓ 
T-cell specific 
transcription factor 
7-like 1  
TCF7L1 Member of TCF/LEF transcription factors that function as 
mediator of the Wnt/β-catenin transcription  




WISP1 A member of the connective tissue growth factor that is 
frequently over-expressed in various tumors, and is involve in 
the regulation of various processes leading to tumorigenesis and 
malignant transformation including cell proliferation, migration, 
adhesion, angiogenesis and extracellular matrix formation. 





WNT 5a Secreted signaling protein that are implicated in oncogenesis and 
in several developmental processes 











































Selected genes that are involved in the Wnt/β-catenin signaling in U2OS cells treated with curcumin analogue 3-3 were listed. The 
gene symbol, gene function, fold-change, p-value, status of transcription has been described for each gene. The fold-changes in gene 






4.4 Discussion  
We have established in Chapter 3 that Wnt inhibition mediated by curcumin could result 
in reduced osteosarcoma proliferation and invasion. However, the clinical application of 
curcumin as a Wnt inhibitor is likely to be curtailed given its poor bioavailability due to 
poor absorption and rapid metabolism, and high concentrations needed for effective Wnt 
inhibition for good in vivo pharmacological bioavailability [243, 244, 246]. We thus 
aimed in this chapter to identify more potent curcumin analogues, elucidate important 
chemical features for improved Wnt inhibitory potency and provide preliminary 
observations on their mechanism of action.  
 
Based on the rationale of drug design as described in (Sections 4.2.2 and 4.2.3), we have 
synthesized and evaluated five series of curcumin analogues for improved potency as 
Wnt inhibitors in osteosarcoma. Our preliminary screening yielded 16 compounds that 
were 1.2- to 40.4-fold more potent than curcumin in suppressing CRT (Table 4-3). A 
study of SAR revealed that Series 3 (dibenzylidene-cyclohexanones) and Series 4 
(dibenzylidene-cyclopentanones) analogues, both with conformationally restricted and 
bulkier tethers between the terminal phenyl rings, exhibited much higher Wnt inhibitory 
potency than the other analogues in which the terminal rings were linked by longer and 
more flexible carbon spacers such as the diarylheptanoids (Series 1), diarylpentanoids, 
(Series 2) and chalcones (Series 5). Specifically, 11 of the 16 analogues that were 
identified to be more potent than our lead compound (curcumin, 1-1) in suppressing the 
Wnt-3A-mediated transcriptional activity were from Series 3 and 4. In addition, all 




activated Wnt activity in HEK293T cells. Besides having the largest number of potent 
analogues, cyclic analogues (Series 3 and 4) also gave rise to the most potent analogues 
such as compound 3-3 (EC50 0.34 ± 0.01 μM) and 4-6 (EC50 0.40 ± 0.01 μM) which were 
51- to 60-fold more potent than curcumin (1-1, EC50 20.67 ± 0.82 μM), strongly 
suggesting the importance of restricting the flexibility of the central linker for Wnt 
inhibitory potency. In fact, in terms of number of rotatable bonds, the Series 3 and 4 
compounds (two rotatable bonds) have the most restricted carbon tethers. This is 
followed by the chalcones (three rotatable bonds), series 2 (four rotatable bonds) and 
series 1 (five rotatable bonds). There is also a change in lipophilicity across the five series. 
Based on analogs with unsubstituted phenyl rings (1-4,2-4, 3-4, 4-4, 5-4), lipophilicities 
estimated by ClogP decreased in the order 3-4 (ClogP 5.33) > 4-4 (ClogP 4.77) > 1-4 
(ClogP 4.57) > 2-4 (ClogP 4.20) > 5-4 (ClogP 3.62).  It is notable that besides restricting 
flexibility, embedded ring structures within the linker as in Series 3 and 4, led to 
increases in lipophilicity. However, no significant correlation could be established 
between EC50 for Wnt inhibition and ClogP values. 
 
In curcumin, the terminal phenyl rings were substituted with 3’-OCH3-4’-OH substituent. 
A recent study by Ryu et al. showed that natural derivatives of curcumin, such as 
demethoxycurcumin and bisdemethoxycurcumin, which lack one or more methoxy 
groups on both rings, suppressed the transcriptional co-activator, CBP/p300, but had no 
effects on the protein expression of both cytoplasmic and nuclear ß-catenin and nuclear 
TCF-4 whereas removal of the double bond in tetrahudrocurcumin abolished Wnt 




substituents at the terminal rings of Series 1-5 compounds was investigated by various 
permutations centered on the OH/OCH3 groups. Thus, the positions of these groups were 
reversed (3’-OH-4’-OCH3) or replaced with 3’4’-di-OCH3 or one group was omitted or 
both were removed to give the unsubstituted ring. One or more fluorine atoms were also 
introduced to the rings to test the bioisosteric relationship of F and H. Compounds in 
Series 1 bear the same scaffold as curcumin. It is seen that the Wnt inhibitory activity of 
this Series was significantly affected by the type of substituent on the terminal phenyl 
rings. Except for the dimethoxy analog 1-2 which was more potent than curcumin, the 
other analogs in this Series fared poorly in terms of Wnt inhibitory activity. Thus, it 
would seem that there is limited tolerance for the type of groups that can be introduced 
into phenyl rings of the Series 1 template.  A similar trend was observed in Series 2 and 5 
where no more than 2 different substitution patterns were permissible. As mentioned 
earlier, the central linker in these Series are of intermediate flexibility.  It is observed that 
for both Series 2 and 5, the preferred substituent were 3’-OH-4’-OCH3 and not 
dimethoxy as noted for Series 1.  It is evident that optimal ring substitution pattern is 
influenced in part by the type of linker present and would be expected to vary from one 
series to another. 
 
In contrast to the earlier series, Series 3 and 4 have restricted and lipophilic linkers and 
interestingly, their Wnt inhibitory activities were less influenced by the type of 
substituent on the terminal phenyl rings. Thus, the shortlisted compounds in Series 3 
represent six out of the 10 different substitution patterns investigated, while in Series 4, 




greater tolerance for different substituent on the phenyl rings, there were some groups 
that fared better than others,  notably the 3’OH-4’OCH3 identified for Series 2 and 5, as 
well as 4-OH emerged as top contenders. The good activity associated with the 4’-OH 
group (3-6, 4-6) is notable as 4’-OH groups are also present on the phenyl rings of 
curcumin.  On the other hand, a 3’-OCH3 group is also present in curcumin but no analog 
with 3’-OCH3 (Series 1-5) was shortlisted for EC50 determination.     
 
The poor activity of the 3’OCH3 analogs may suggest the need to restrain the steric 
dimensions of groups at this position. It may also reflect a preference for groups that are 
not electron withdrawing at this position. It is notable that 3’OCH3 is electron 
withdrawing unlike 4’OCH3 which is electron donating, as seen from their Hammett 
sigma values (σp OCH3 -0.27 ; σm OCH3 = 0.12). Inhibitory activity may be determined 
by an interplay of the size and electrostatic nature of groups at this position. Thus, the 
poor activity of 3’F analogs would suggest that the strong electron withdrawing effect of 
F has more than offset its small steric dimensions while the moderate activities of analogs 
with unsubstituted phenyl rings (3-4, 4-4) may be attributed to their limited size 
requirements. Taken together, it is tempting to suggest that Wnt inhibitory activity is 
favored by the absence of electron withdrawing groups on the terminal phenyl rings of 
Series 3 and 4.  Support for this view is seen from the exceptionally good activities of the 
4’OH analogs (3-6, 4-6) and the 3’OH-4’OCH3 analogs (3-3, 4-3). As to why switching 
3’OH-4’OCH3 to 3’OCH3-4’OH resulted in analogs (3-1, 4-1) with a modest decline in 




larger lost in inhibitory activity was observed when both 3’ and 4’ positions were 
occupied by OCH3 groups.    
 
Taken together, some general structure activity trends may be deduced from the present 
results (Figure 4-5). First, reducing the flexibility of the intermediate linker joining the 
terminal phenyl rings improved inhibitory activity. Notably, incorporating the linker as 
part of a ring structure like those represented in Series 3 and 4 resulted in several 
compounds with outstanding activities. Second, the flexibility of the intermediate side 
chain influenced the substitution on the terminal phenyl rings that were required for good 
activity. In those compound series (Series 1, 2, 5) that had more flexible linkers, only 
limited substitution patterns were tolerated at the phenyl rings. In contrast, a wider range 
of substitution patterns were permitted in compound series that had less flexible linkers 
(Series 3, 4). In Series 3 and 4, the preferred substituent were deduced to be electron 
donating and/or of limited size requirements if sited at the 3’ position. These 
requirements may reflect the involvement of these groups in key interactions with target 
proteins and would require further confirmation with additional analogs. These SAR 
trends observed would be highly valuable and may served as leads for future rational 
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Figure 4-5. Structural features of curcumin analogues important for enhanced Wnt 
inhibitory activity. (a) Reducing the flexibility of the intermediate linker joining the 
terminal phenyl rings improved Wnt inhibitory activity. Incorporating the linker as part 
of a ring structure such as dibenzylidene-cyclohexanone (Series 3) and dibenzylidene-
cyclopentanone (Series 4) spacers are favored. (b) Flexibility of the intermediate side 
chain influenced the substitution on the terminal phenyl rings. Only limited ring 
substitution patterns were tolerated in analogues with flexible linkers (Series 1, 2, 5), but 
a wider range of substitution patterns were permitted in analogues that had less flexible 
linkers (Series 3, 4). (c) Electron donating ring substitutions are more favorable. (d) Ring 
substitutions with limited size requirements are preferred at the 3’ position.  
 
To provide preliminary understanding of the interactions of curcumin analogues with 
various critical Wnt players, perturbations in gene levels of 84 Wnt signaling components 
and target genes by curcumin analogue 3-3 (the most potent analogue) were evaluated 
using the Human Wnt Signaling Pathway RT2 ProfilerTM PCR Array. Our preliminary 
findings support a model in which analogue 3-3 is likely to attenuate the Wnt/β-catenin 
signaling pathway at various points of the pathway including interruption of receptor-




cytoplasmic β-catenin, disruption of β-catenin/TCF complexation and transcription and 
inactivation of Wnt target oncogenes within the nucleus. This is supported by these 
observations: Firstly, suppression of mRNA expressions of several frizzled receptors 
(FZD2, FZD 3, FZD4) and Wnt ligands (WNT 10a, 11, 5a, 5b, 6, 7a, 7b, 8a) suggest that 
analogue 3-3 may attenuate receptor-ligand interactions and thus block signal initiation at 
the membranous level. However, it is practically challenging to determine precise 
binding affinities and specificities of the native WNT-FZD complexes due to the lack of 
purified Wnt ligands and the sheer number of members identified to date [37, 38]. 
Secondly, the significant up-regulation of β-TrCP protein, a component of an E3 
ubiquitin ligase complex, indicated that analogue 3-3 could have increased the 
phosphorylation-dependent ubiquitination of β-catenin, thus destabilizing β-catenin in the 
cytoplasm and consequently reducing its nuclear translocation. A similar mechanism of 
Wnt inhibition was previously observed with curcumin, which was reported to induce 
G2/M phase arrest and apoptosis of HCT116 colon cells through caspase-mediated 
degradation of cytoplasmic β-catenin [193, 207].  Thirdly, analogue 3-3 may be capable 
of disrupting β-catenin/TCF complexation and transcription through attenuating the 
nuclear translocation of β-catenin protein (Figure 4-2) and regulating the expression of 
several transcriptional factors such as TLE2, TCF7L1 and PITX2: TLE2 gene is a 
mammalian homologue of the Drosophila transcriptional repressor groucho which serves 
as a nuclear transcriptional co-repressor by interacting with TCF family of proteins to 
block TCF/β-catenin transcription and thus repress Wnt target oncogenes [129, 258, 259] 
while PITX2, a bicoid-related homeodomain factor [260], has been shown as a 




pathway by interacting with LEF-1 and β-catenin to activate Wnt target genes [141, 261, 
262]. Collectively, analogue 3-3 may possibly disrupt β-catenin/TCF transcriptional 
activity and complexation through up-regulating transcriptional repressor, groucho, 
inhibiting TCF7L1 and/or suppressing level of PITX2 transcription factor. In particular, 
PITX2 is required for the temporally ordered and growth factor-dependent recruitment of 
a series of specific co-activator complexes that prove necessary for cyclin D1, cyclin D2 
and c-Myc gene induction [261, 263]. Furthermore, silencing of PITX2 gene by 
hypermethylation has been closely associated with prognosis, metastasis-free survival 
and reduced risk of developing disease recurrence in breast cancer patients [264]. Most 
recently, Huang et al demonstrated that knockdown of PITX2 gene expression in human 
thyroid cancer cells and mouse in in vivo models significantly suppressed cell 
proliferation and soft-agar colony formation by down-regulating cyclin D1 and cyclin D2 
[265]. Parallel to results from our western blot analysis (Figure 4-4), we found a 
suppression of cyclin D1 mRNA level with analogue 3-3 treatment. Given that both 
PITX2 mRNA levels, as well as cyclin D1 protein and mRNA expressions, were 
suppressed in U2OS cells by analogue 3-3 treatment, it is tempting to speculate that 
attenuation of PITX2/Wnt/β-catenin pathway may have resulted in the down-regulation 
of cyclin D1 in U2OS cells, although further studies using chromatin immunoprecipitaion 
and/or reporter assays would be necessary to confirm this. 
 
Our curcumin analogues were also found to be effective in reducing osteosarcoma cell 
invasiveness by between 34.8 - 71.0 % and 63.0 - 81.6 % at 1 µM and 5 µM respectively 




MMP-9 protein expressions with curcumin analogue treatment (Figure 4-4). In addition, 
through our global analysis, we found that the most potent compound (3-3) could 
effectively suppress the mRNA expressions of several other oncogenes including WISP1 
and FOSL1 that play critical roles in promoting tumorigenesis and metastatic 
transformation in various tumor models. WISP-1, a member of the connective tissue 
growth factor that belongs to the Cry61, CTGF and Noc (CCN) super family, is involved 
in the regulation of various processes leading to tumorigenesis and malignant 
transformation including cell proliferation, migration, adhesion, angiogenesis and 
extracellular matrix formation [266]. Several lines of evidence support a role for WISP-1 
in tumorigenesis, although none has been reported with osteosarcoma. WISP-1 is over-
expressed in many tumors types, including breast, colon, cholangiocarcinoma and 
plexiform neurofibromas [267-270]. Moreover, forced expression of WISP-1 in normal 
kidney fibroblasts was sufficient to induce morphological transformation, accelerate cell 
growth and induce tumor formation in nude mice [146]. Elevated levels of WISP-1 in 
both primary breast and rectal cancers correlated with more advanced features such as 
late-stage disease, lymph node involvements and larger tumor size [269, 271]. Similarly, 
FOSL1, shown to be over-expressed in numerous cancers, promotes invasion, metastasis 
and angiogenesis [272]. For instance, Debinski at el. demonstrated that gliomas over-
express FOSL1, which is capable of modulating malignant properties in these cancer 
cells including morphology changes, anchorage-dependent growth and tumorigenic 
potential [273]. On the other hand, down-regulation of FOSL1 was reported to suppress 
breast cancer cell motility and proliferation through inhibition of tumor progression-




oncogenic properties, the potential implications of regulating WISP-1 and FOSL1 
expressions in osteosarcoma pathogenesis is highly relevant. Further studies are however 
needed to fully understand the contributory roles of these oncogenes in regulating 
osteosarcoma metastasis and tumorigenesis.  
 
Anomalous observation was made with regards to two genes, namely SFRP1 and NKD1. 
The down-regulation of mRNA SFRP1 level following treatment with analogue 3-3 is not 
unexpected since SFRP1 has been shown to be capable of increasing Wnt signaling in 
some conditions [54, 275], although it belongs to a family of five gylcoproteins (SFRP1-
5) that disrupts the pathway at the cell surface by competing with Frizzled receptors for 
Wnt ligands [55]. NKD1, a protein that binds to PDZ domain of DVL, is known for its 
function as a negative regulator of the Wnt-beta-catenin-TCF signaling pathway [106, 
276]. Our observation that NKD1 was down-regulated in U2OS cells following treatment 
with analogue 3-3 suggested that NKD1 or/and DVL-NKD1 complex could have 
mediated other unknown Wnt-independent signal transduction. We also cannot rule out 






CHAPTER 5. Role of SFRPs as tumor suppressors in human osteosarcoma 
 
5.1 Introduction  
SFRPs, a family of five glycoproteins (SFRP1-5) are the largest family of endogenous 
Wnt inhibitors. Structurally, SFRPs contain an N-terminal cysteine–rich domain (CRD) 
which share 30-50 % sequence similarity with those of the ligand binding domain of the 
FZD and a netrin (NTR) domain. The NTR domains of SFRP1, SFRP2 and SFRP5 share 
a similar pattern of cysteine spacing that is related to that of netrin 1, whereas those of 
SFRP3 and SFRP4 display a different cysteine-spacing pattern and thus a distinct pattern 
of disulphide bonds [54]. Crystallographic resolution studies revealed a number of 
different mechanisms by which SFRPs can modulate Wnt signaling: (1) sequestering 
WNT ligands through both the CRD and NTR domains; (2) functioning as a dominant-
negative form by formation of inactive complexes with FZD; (3) titrating out one 
another’s activity to favor Wnt signaling; (4) favoring Wnt-FZD interaction by binding to 
both molecules simultaneously and (5) binding of CRD to FZD [277]. 
 
Epigenetic silencing due to hypermethylation of the promoter regions of SFRP1, 2, 4 and 
5 has been found in different human cancers, suggesting tumor suppressor function of 
these SFRPs [61, 62, 278]. On the other hand, restoration of sFRP functions in these 
tumor types has been shown to effectively attenuate Wnt signaling even in the presence 
of downstream mutation [61]. Unlike the other SFRPs, SFRP3 does not have the CpG-
islands in its promoter region. Instead, chromosomal deletion and loss of heterozygosity 




that the SFRP3 gene is located at 2q where frequent deletion and loss of heterozygosity 
are observed.  
 
Differences in the biological effects of the various SFRPs have previously been reported 
in various malignancies. This is not surprising given that SFRPs do not bind to Wnt 
ligands in an equivalent manner, neither in terms of specificity and number of binding 
sites nor in terms of interaction domain. Furthermore, post-translation modifications may 
very likely confer additional differences that might further diversify the functions of 
different SFRP family members.  
 
Recently, the loss of SFRP3 expression was reported in osteogenic sarcoma biopsy 
specimens and several osteosarcoma cells lines [56]. Despite strong evidence of their 
status as tumor suppressors, the functional significance of other family members 
including SFRP1, 2, 4 and 5 in the pathogenesis of osteosarcoma has yet been reported. 
Therefore, we hypothesized that these genes function as tumor suppressors and 
restoration of these may inhibit osteosarcoma tumorigenesis and metastasis. The 
objective of this chapter is thus to examine functional roles and mechanisms of SFRPs as 
tumor suppressors in regulating osteosarcoma cell proliferation, motility and invasion. 
Understanding this may be useful in the development of SFRPs as a therapeutic strategy 
in osteosarcoma.  
 
We first examined the transcriptional expressions of SFRP genes and showed that these 




compared to human fetal osteoblasts. Using SFRPs-stably transfected U2OS cell lines, 
we further demonstrated that forced expressions of these genes effectively suppressed β-
catenin/TCF transcriptional activities and β-catenin protein levels, as well as resulted in 
redistribution of β-catenin protein from the nucleus to the membrane of U2OS cells. We 
found that ectopic expressions of SFRPs are capable of disrupting the cascade of events 
that leads to osteosarcoma tumorigenesis and/or metastasis including inhibition of 
anchorage-dependent growth rates, colony formation efficiencies, cell invasion, 
migration, as well as induction of G0/G1 cell cycle arrest and apoptosis. These tumor 
suppressing effects may be mediated though down-regulation of protein expressions of 
several Wnt responsive oncogenes such as MMP-2, cyclin D1, c-Myc and survivin. 
Furthermore, using the Human Wnt Signaling Pathway RT2 ProfilerTM PCR Array 
analysis, we identified additional Wnt target genes including WISP1, Brachyury, 
SLC9A3R1 and JUN that may account for the tumor-suppressing effects of SFRP2 and 
SFRP5 in U2OS cells. Lastly, we observed dysregulation of several Wnt signaling 
proteins when SFRP2 or SFRP5 expressions were restored in U2OS cells, suggesting that 
the molecular mechanisms of SFRP2 and SFRP5 functions may involve disruption of the 
Wnt signaling via interrupting WNT-FZD interactions, enhancing proteasomal 
degradation of cytoplasmic β-catenin, disrupting of β-catenin/TCF complexation and 
transcription, inactivating Wnt target oncogenes as well as up-regulating tumor 
suppressors genes. Taken together, our findings strongly suggest that SFRPs function as 
tumor suppressors in osteosarcoma, and that restoration of these genes in SFRPs-deficient 
osteosarcoma may be exploited as a new therapeutic approach for the treatment and 




5.2 Experimental Methods 
5.2.1 Cell culture, plasmids and stable transfection 
The human osteosarcoma cell lines CRL11226, CRL1423, OS1, OS2 and OS3 were 
kindly provided by Dr Saminathan S. Nathan (Department of Orthopaedic Surgery, Yong 
Loo Lin School of Medicine, NUS) and have been described previously [194]. 
CRL11226, CRL1423, OS1-3 cells were cultured in RPMI, McCoy’s 5A and RPMI: 
DMEM 9:1 media respectively. Human fetal osteoblasts (hFOB1.19) are a gift from Dr 
Tong Cao (Department of Dentistry, NUS) and were maintained in DMEM/F-12 medium. 
U2OS cells stably transfected with SFRPs were cultured in McCoy’s 5A medium 
supplemented with 400 µg/ml of G418. All media were supplemented with 10-15 % FBS 
(Invitrogen, Carlsbad, CA), 10U/ml penicillin G and 100μg/ml streptomycin. The cells 
were cultured in a humidified atmosphere at 37 ºC containing 5% CO2. TOPglow and 
FOPglow reporters used in the luciferase reporter gene assays were purchased from 
Upstate Biotechnology (Lake Placid, NY) while the pSV-β-galactosidase control vector 
was from Invitrogen (Carlsbad, CA). pcDNA3.1-HIS-SFRPs plasmids and pcDNA3.1-
HIS empty vector controls were generous gift from Dr. Hiromu Suzuki (Sapporo Medical 
University, Sapporo, Japan) [61]. For stable transfection, U2OS cells were transfected 
with one of the pcDNA3.1-HIS-SFRP vectors or pcDNA3.1-HIS empty vector, using 
Lipofectamin 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer’s protocol. 
Transfected cells were selected with G418 (400 µg/ml) for 14 days, starting 48 h after 







5.2.2 Western blot analysis 
Western blot analyses used to examine the protein expression levels of β-catenin, active- 
β-catenin, SFRP1, SFRP2, SFRP4, SFRP5, MMP-2, MMP-9, cyclin D1, c-Myc and 
survivin in U2OS transfectants, were carried out as previously described (section 3.2.5). 
Anti-active-β-catenin antibody (clone 8E7), which is specific for β-catenin 
dephosphorylated on Ser31 and Thr41, was purchased from Upstate (Lake Placid, NY, 
USA). Antibodies for SFRP1, SFRP2 and SFRP4 were from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA) while that of SFRP5 was purchased from ThermoFisher Scientific, 
(Waltham, MA). 
 
5.2.3 Polymerase Chain Reaction (PCR) 
Total RNA from the osteosarcoma cell lines was extracted using Qiagen’s RNeasy mini 
kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. Samples were 
treated with DNase (Ambion DNA-free kit, Applied Biosystems, Austin, TX) to remove 
genomic contaminants. RNA samples were reverse-transcribed to cDNA using iSCRIPT 
cDNA synthesis kit (BioRad, Hercules, CA), after which cDNA was amplified by PCR 
with primers specific for SFRP1, SFRP2, SFRP4, SFRP5 and GAPDH, using iTaq DNA 
polymerase kit (BioRad, Hercules, CA) and dNTP Mix (BioRad, Hercules, CA). The 
cycling conditions were as follows: 95 ºC for 3 mins, 30-35 cycles of denaturation at 95 
ºC for 30s, annealing at 55 ºC for 30s and extension at 72 ºC for 45s, followed by a 10 
mins final extension at 72 ºC. The PCR products were analyzed by electrophoresis on 3 
% agarose gels. The specific primers listed in Appendix 4 were kindly provided by Dr. 




5.2.4 Luciferase reporter gene assay 
Luciferase reporter gene assays using the U2OS transfectants were performed with 
Luciferase assay systems kit (Promega, Madison, WI) according to the manufacturer’s 
instructions, as detailed previously (section 3.2.3). Results were expressed as mean ± 
SEM of normalized ratios of luciferase and β-galactosidase activities for each triplicate 
sets. Reporter activities in U2OS/SFRPs transfectants were expressed as the percentage 
of that in U2OS/pcDNA3.1-HIS control cells.  
 
5.2.5 Immunofluorescence microscopy analysis 
U2OS stable transfectants were seeded and cultured in tissue culture-treated Lab-Tek™ 
Chambered Coverglass (Bio Laboratories, Singapore). On the following day, the cells 
were washed with PBS, fixed with 4 % formaldehyde, permeabilized with 0.5 % Triton 
X-100 and blocked in 1% Bovine Serum Albumin. The cells were then incubated with 
anti-β-catenin antibody (Santa Cruz, CA), followed by FITC-conjugated secondary 
antibody (Invitrogen, Carlsbad, CA). The cell nuclei were also counterstained with DAPI 
(Invitrogen, Carlsbad, CA). Images were acquired on an LSM 5 DUO inverted confocal 
microscope (Carl Zesis Inc, Germany).  
 
5.2.6 Anchorage-dependent MTT cell proliferation assay 
The effects of SFRPs on the proliferation of U2OS cells were assessed using MTT assays. 
U2OS transfectants were seeded into 96-well plates at a density of 10 x 103 cells/well and 
cultured over a period of 3, 5 and 7 days before cell growth was analyzed by adding 100 
μl of 1mg/ml MTT (Sigma Chemical Co., St Louis, MO). Following an incubation period 




absorbance of the formazan product was determined at λmax of 595 nm using a Tecan 
Spectra Fluor spectrophotometer (MTX Lab Systems Inc., Vienna, VA). Cell growth 
over the periods of 3, 5 and 7 days was expressed relative to that on Day 1 (set as 1.0).     
 
5.2.7 Colony formation assay 
U2OS cells were transfected with each of the pcDNA3.1-HIS-SFRP vectors or 
pcDNA3.1-HIS empty vector, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 
according to the manufacturer’s protocol. Transfected cells were then reseeded in 100-
mm culture dishes at a density of 1:20 and selected with G418 (400 µg/ml) for 14 days. 
Colonies were then fixed with 70% ethanol and stained with 0.2% w/v crystal violet 
before they were enumerated.  
   
5.2.8 Cell migration and invasion assay 
U2OS cell migration and invasion were determined using the wound healing and 
Matrigel invasion assays as previously described (section 3.2.4).  
 
5.2.9 Cell cycle analysis 
The effect of SFRPs over-expression on the cell cycle distribution was accessed by flow 
cytometry after staining the cells with PI as described earlier (section 3.2.8).  
 
5.2.10 Gene expression profiling using real-time PCR array 
The Human Wnt Signaling Pathway RT2 ProfillerTM PCR Array (SA Bioscience, MD) 




signaling transduction with forced expressions of either SFRP2 or SFRP5 in U2OS cells 
as described earlier in section 4.2.10.  
 
5.2.11 Statistical analysis 
Statistical significance for treatment groups were analyzed using the two-tailed Student’s 
t-test (SPSS, Chicago, IL). The difference between values for each treatment 
concentration and the respective controls was considered to be statistically significant 
when P < 0.05. 
 
5.3 Results 
5.3.1  Analysis of Wnt antagonist genes, SFRP1, 2, 4 and 5 in osteosarcoma cell 
lines 
Down-regulation of SFRP genes through epigenetic silencing was commonly found in 
various malignancies [58, 61, 62, 278, 279]. While the loss of SFRP3 expression has 
previously been observed in osteogenic sarcoma biopsy specimens and several 
osteosarcoma cells lines [56], the functional roles of SFRP1, 2, 4 and 5 as potential tumor 
suppressors in osteosarcoma have yet been explored. We therefore hypothesized that a 
loss of SFRP1, 2, 4 or 5 may contribute to the activation of Wnt signaling and, thus be 
implicated in the pathogenesis of osteosarcoma. To this end, we first compared the 
expression status of these Wnt genes in a panel of eight osteosarcoma cell lines against 
hFOB using PCR. As osteosarcoma is a mesenchymal neoplasm that can result from 
morphologically abnormal osteoblastic cells producing defective immature bone (osteoid), 




against osteosarcoma cell lines and tissue samples [19, 26, 56, 65]. As shown in Figure 
5-1, SFRP1, 2 and 5, but not SFRP4 mRNA were expressed in hFOB cells. Compared to 
hFOB cells, the expression of SFRP1 was down-regulated in U2OS, HOS, CRL1423 and 
OS2 cell lines and completely absent in SaOS-2 cells. We found that SFRP2 mRNA 
expression was completely absent in four of the eight osteosarcoma cell lines tested 
(U2OS, CRL11226, CRL1423 and OS3) and was down-regulated in HOS, compared to 
hFOB. While SFRP4 expression was absent in HOS and CRL11226 cell lines, the other 
cell lines showed varied expressions of SFRP4 gene: strong expression in OS1 and weak 
but detectable expressions in U2OS, SaOS-2, CRL1423, OS2 and OS3 cell lines. On the 
other hand, SFRP5 expression was markedly suppressed in all eight osteosarcoma cell 
lines tested compared to hFOB cells, and completely absent in U2OS and CRL1423 cells. 
To investigate the anti-tumor effects of SFRPs in osteosarcoma, U2OS cells were used 
for the restoration of SFRPs in subsequent studies, given that they consistently showed 
low expressions of SFRP1, 2 and 5 compared to hFOB.  
 
                                  CRL    CRL 
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Figure 5-1. Frequent inactivation of Wnt antagonist genes, SFRP1, 2, 4 and 5 in 
osteosarcoma cell lines. RT-PCR analysis of SFRP1, 2, 4 and 5 in hFOB, together with 
eight osteosarcoma cell lines. GAPDH was used as a loading control.  NTC, no template 









5.3.2  Establishment of stable transfectants of SFRP1, 2, 4 and 5 in U2OS cells 
To elucidate the role of SFRP1, 2, 4 and 5 in osteosarcoma disease progression, we stably 
transfected U2OS cells with each of the SFRPs under study and pcDNA3.1-HIS control 
vectors. The reexpressions of the SFRPs genes in stable clones were confirmed by 
western blotting and RT-PCR (Figure 5-2). U2OS/SFRP1 clone #2, U2OS/SFRP2 clone 
#7, U2OS/SFRP4 clone #1 and U2OS/SFRP5 clone #3 were selected and used for 
subsequent experiments as the mRNA and protein expressions of SFRPs in these clones 
were highly up-regulated in U2OS/SFRP cells compared with the U2OS/pcDNA3.1-HIS 
cells. Other clones were not selected as the SFRPs expressions in these clones were either 
low or totally absent.  
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Figure 5-2. Successful establishment of stable transfectants of SFRP1, 2, 4 and 5 in 
U2OS cell. (a) Successful selection of several stable clones, verified by western blots 
using antibodies against the respective SFRPs. α-Tubulin was used as a loading control. 
(b-c) Selected stable clones to be used for subsequent experiments, with SFRPs protein 
and mRNA expressions verified using (b) western blot analysis and (c) RT-PCR analysis 







5.3.3  Restoration of SFRPs expression decreased β-catenin production and 
inhibited TCF-dependent transcriptional activity 
Activation of the Wnt/β-catenin signaling pathway results in phosphorylation of GSK-3β 
and stabilization of cytosolic β-catenin leading to activation of TCF-mediated 
transcriptional activity [35]. To evaluate the effects of SFRP1, 2, 4 and 5 on the 
downstream  β-catenin/TCF transcriptional activity in osteosarcoma cells, U2OS/SFRP1, 
U2OS/SFRP2, U2OS/SFRP4  and  U2OS/SFRP5 stable transfectants were transiently co-
transfected with reporter plasmids containing either wild-type (TOPGlow) or mutant 
(FOPGlow) consensus TCF/LEF binding elements and pSV-β-galatosidase control vector 
for normalization of transfection efficiency. As shown in Figure 5-3a, β-catenin/TCF 
transcriptional activities were significantly suppressed in all the stable transfectants. 
Compared to the U2OS/pcDNA3.1-HIS control cells, TCF-mediated transcription were 
inhibited by approximately 88 %, 57 %, 49 % and 62 % in the U2OS/SFRP1, 
U2OS/SFRP2, U2OS/SFRP4 and U2OS/SFRP5 cells respectively. Transcriptional 
activity for FOPGlow remained low at all instances. Consistently, the suppression of β-
catenin/TCF transcriptional activities in the U2OS/SFRPs transfectants were 



















































Figure 5-3. SFRPs over-expression inhibited TCF-dependent transcriptional activity 
and decrease β-catenin protein. (a) Luciferase reporter gene assays by using either 
reporter gene TOPGlow or a negative control with mutant TCF-4 binding sites 
(FOPGlow) was used to analyze TCF-dependent transcriptional activity. Results were 
expressed as mean ± SEM of normalized ratios of luciferase and β-galactosidase 
activities for each triplicate sets. Reporter activities in U2OS/SFRPs transfectants were 
expressed as the percentage of that in U2OS/pcDNA3.1-HIS control cells. ** P>0.01, 
compared with U2OS/pcDNA3.1-HIS control group. (b) Western blot analysis of total β-
catenin protein expression in U2OS/SFRPs stable transfectants. α-Tubulin was used as a 
loading control. 
  
5.3.4  Ectopic expressions of SFRP1, 2, 4 and 5 decreased nuclear β-catenin and 
facilitated the translocation of β-catenin protein to the cell membrane 
Using immunofluorescence microscopy analysis, we next examined whether over-
expression of SFRPs were associated with changes in the localization of β-catenin protein. 




reduction in nuclear β-catenin immunofluorescence signal and a corresponding increase 
in membranous β-catenin localization compared to the control vector pcDNA3.1 U2OS 
cells, suggesting that restoration of SFRPs resulted in β-catenin translocating from the 
nucleus to adherent junctions of the cell membrane in U2OS cells.   
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Figure 5-4. Immunofluorescence microscopy analysis of β-catenin protein 
localization in U2OS cells over-expressing SFRPs. The cells were incubated with anti-
β-catenin antibody and the nuclei were also counter stained with DAPI. Representative 
images from three independent experiments shown were acquired on an LSM 5 DUO 
inverted confocal microscope.  
 
5.3.5  Over-expression of SFRPs suppressed both anchorage-dependent cell 
growth, colony formation and disrupted cell cycle progression through 
affecting  proliferation-associated Wnt-responsive genes expressions in U2OS 
cells 
Previous studies have reported that disruption of Wnt/β-catenin signaling using DN-
LRP5 inhibited both in vitro and in vivo osteosarcoma growth [52]. We have also 
recently demonstrated that PKF118-310, a specific Wnt/β-catenin antagonist, induced 
apoptosis and G2/M phase cell cycle arrest but suppressed osteosarcoma cell proliferation 
[195]. Given that β-catenin/TCF signaling and its gene products such as cyclin D1, c-




distribution and apoptosis, we next investigated the effects of SFRP1, 2, 4 and 5 on the 
expressions of these Wnt responsive oncogenes such as cyclin D1, c-Myc and survivin 
[97, 98]. 
 
As shown in Figure 5-5a, we observed a significant decrease in cyclin D1 protein 
expression in all the SFRPs transfectants. Survivin protein expression was also down-
regulated with over-expression of SFRP2, 4 and 5 while the protein expression for c-Myc 
was markedly suppressed by the restoration of SFRP2, but up-regulated by ectopic 
expressions of SFRP4 and SFRP5. Given the observations, we further asked if the 
perturbation of cyclin D1, c-Myc and survivin protein expressions correlated with anti-
proliferation and pro-apoptotic effects with over-expression of SFRPs antagonist in 
U2OS cells.  
 
Anchorage-dependent growth of each transfectant was determined using the MTT cell 
proliferation assay, Figure 5-5b showed correspondingly lower rate of growth over a 
period of 7 days in SFRPs transfected U2OS cells compared to that of U2OS/pcDNA3.1-
HIS control cells. Specifically, transfection with SFRP1, 2, 4 and 5 exhibited 
approximately 1.5-, 2.0-, 2.7- and 1.6-fold lower rate of anchorage-dependent growth 
than the U2OS/pcDNA3.1-HIS control cells after 7 days of cell seeding respectively.  
 
Consistent with both the suppression of proliferation-associated Wnt responsive targets 
and the inhibition of anchorage-dependent growth, results from the colony formation 
assay demonstrated that restoration of SFRP1, 2, 4 and 5 attenuated anchorage-




U2OS/pcDNA3.1-HIS control cells, transfection of SFRP-1, 2, 4 and 5 resulted in 88.7 %, 
83.2 %, 65.6 % and 72.9 % reduction in the number of colonies formed respectively.   
 
To examine if SFRPs could exert their anti-proliferative effects through disruption of cell 
cycle progression and/or apoptosis, we performed flow cytometry analysis. Our results 
revealed that over-expression of SFRP4 and SFRP5 significantly induced the rate of 
apoptosis (Sub-G1 phase) by 229.3 % and 249.2 % respectively, compared to the 
U2OS/pcDNA3.1-HIS control cells (Figure 5-5d). We also found that restoration of 
SFRP1, 2 and 5 resulted in an increase in the number of cells in the G0/G1 phase (66.3 % 
in control vs. 72.8 %, 74.8 % and 68.5 % respectively), with a corresponding decrease in 
the number of cells in the G2/M phase (17.2 % in control vs. 10.7 %, 12.6 % and 10.6 % 
respectively), suggesting an induction of G0/G1 phase arrest. On the other hand, a G2/M 
phase arrest was observed for over-expression of SFRP4, as indicated by the 
accumulation of cells in the G2/M phase (51.06 %), but a reduction in the number of cells 
in the G0/G1 phase (6.6 %). Taken together, our studies showed that restoration of 
SFRPs in U2OS cells resulted in the suppression of both anchorage-dependent (Figure 
5-5b) and -independent growth (Figure 5-5c), possibly through disruptions of the cell 
cycle progression (Figure 5-5d) and alterations of proliferation-associated Wnt target 
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Figure 5-5. Over-expression of SFRP1, 2, 4 and 5 suppressed anchorage-dependent 
cell growth and colony formation, disrupted cell cycle progressions through down-
regulating proliferation-associated Wnt-responsive genes in U2OS cells. (a) Western 
blot analysis of proliferation-associated Wnt target oncogenes such as cyclin D1, c-Myc 
and survivin in U2OS/SFRPs stable transfectants. α-Tubulin was used as a loading 
control. (b) Anchorage-dependent growth over periods of 3, 5 and 7 days were evaluated 




as 1.0). (c) Representative images from three independent experiments showing a 
decrease in the number of colonies formed with U2OS cells stably transfected with 
SFRP, compared to pcDNA3.1-HIS control vector, after selection with G418 (400µg/ml) 
for 14 days. Relative colony formation was expressed as the percentage of colonies 
formed with U2OS transfected with empty vector, pcDNA3.1-HIS. ** P<0.01, compared 
with the pcDNA3.1-HIS control vector group. (d) Cell cycle distribution of the U2OS 
transfectants was measured by flow cytomerty analysis and the results were plotted as the 
percentage of cell in each cell cycle phase. Data were presented as mean ± S.E.M from 
three independent experiments. ** P<0.01, indicated the difference in the various cell 




5.3.6  Restoration of SFRPs expression inhibited U2OS cell invasion and migration 
through regulating MMP-2 and MMP-9 proteins 
Our group and several others have recently shown that inhibition of Wnt/β-catenin 
signaling using either PKF118-310, a specific antagonist of the pathway or endogenous 
inhibitors such as DN-LRP5 and DKK-3 could result in the suppression of cell 
invasiveness and motility of osteosarcoma cells [52, 63, 195]. Given these observations, 
we also examined the in vitro invasiveness and motility of U2OS cells expressing SFRP1, 
SFRP2, SFRP4, SFRP5 or pcDNA3.1-HIS vector control in Matrigel invasion and 
wound healing assays. As shown in Figure 5-6a, the capacity of SFRP1, SFRP2, SFRP4 
and SFRP5-transfected U2OS cells to invade through the Matrigel-coated inserts over a 
period of 24 h were significantly decreased (80.3 %, 53.4 %, 73.9 % and 83.0 % 
respectively) compared with control cells (100 %). Except for SFRP4, over-expressions 
of SFRP1, 2 and 5 resulted in a parallel reduction in cell motility in U2OS cells using the 
wound healing assay (Figure 5-6b). 
 
MMPs play important roles in the degradation of extracellular matrix to facilitate cancer 




matrix degradation enzymes associated with enhanced osteosarcoma tumor invasion and 
metastasis [217-219], we examined whether reduced invasion with ectopic expression of 
SFRP1, 2, 4 and 5 correlated with MMP-2 and MMP-9 protein expressions in U2OS cells. 
Western blot analysis showed that restoration of SFRP1 and SFRP4 resulted in a decrease 
in both MMP-2 and MMP-9 protein expressions (Figure 5-6c). On the other hand, with 
over-expression of SFRP2, we observed a reduction in MMP-9 expression but an 
unexpected increase in MMP-2 protein expression. SFRP5 did not have any effects on 
both the MMP-2 and MMP-9 protein expressions, although the invasive capacity and 
motility of U2OS cells were markedly reduced with ectopic expression of this Wnt 
antagonist gene. Altogether, our results suggest that restoration of SFRPs in U2OS cells 
significantly inhibited U2OS cell invasiveness (Figure 5-6a) and/or motility (Figure 5-6b), 
and that other metastasis-associated genes, besides MMP-2 or MMP-9, may be involved 






















      HIS
**
















 (c)  
 
Figure 5-6. SFRPs over-expression inhibited OS cell metastasis through suppressing 
MMP-2 and MMP-9 protein. (a) Inhibition of U2OS cell invasion by SFRPs over-
expression. Cells invaded through to the lower surface of the Matrigel-coated inserts over 
a period of 24 h were captured on a light microscope at 200 x magnification after staining 
pcDNA3.1-HIS  
 0h                       
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with crystal violet. Ten random fields were enumerated and data were presented as means 
± SEM of three independent experiments. Cell invasion in U2OS/SFRP transfectants 
were expressed as the percentage of invasion in U2OS/pcDNA3.1-HIS. ** P>0.01, 
compared to the U2OS/pcDNA3.1-HIS group. (b) Representative images from three 
independent experiments showing differential wound closure rates of U2OS cells stably 
transfected with SFRPs or empty vector, pcDNA3.1-HIS, captured using microscope at 
10 x objective. (c) Western blot analysis of MMP-2 and MMP-9 protein expressions in 
U2OS/SFRPs stable transfectants. α-Tubulin was used as a loading control. 
 
 
5.3.7 Changes in gene expression profile induced by over-expression of SFRP2 or 
SFRP5 in U2OS cells 
To identify critical targets of Wnt inhibition, we next examined the global changes in 
gene expression of 84 genes related to Wnt-mediated signal transduction in U2OS cells 
over-expressed with either SFRP2 or SFRP5 using the Human Signaling Pathway RT2 
ProfilerTM PCR arrays. Expressions of selected genes that were significantly up- or down-
regulated (p-value < 0.05) were presented in (Table 5-1) while the others were reported in 
Appendix 5 and 6. As shown in Table 5-1, over-expression of SFRP2 resulted in the 
significant up-regulation of several endogenous Wnt antagonists such as DKK1, WIF-1 
and SFRP1 while the transcription levels of DKK1 and FRZB were elevated with 
restoration of SFRP5. With ectopic expression of SFRP2, the levels of several Wnt 
ligands and receptors including WNT 5a, WNT 5b, WNT 11, FZD2, FZD4, FZD6 and 
FZD7 were significantly suppressed. In contrast, those of WNT 1, WNT 2, WNT 2b, 
WNT 3, WNT 7a, WNT 8a, WNT 9a, WNT 16, FZD3, FZD5 and FZD8 were up-
regulated. The expressions of a different set of Wnt ligands and receptors were 
perturbated with over-expression of SFR5: Compared with pcDNA3.1 HIS control U2OS 




while those of WNT 10a, WNT 16, WNT 2b and FZD3 were up-regulated in U2OS cells 
over-expressing SFRP5. 
 
Furthermore, the transcriptional expressions of several Wnt signaling components that 
play important roles in facilitating the phosphorylation-dependent ubiquitination of 
cytoplasmic β-catenin including APC, β-TrCP, CSNK1G1, FBXW2 and FBXW11 and 
were significantly up-regulated in both SFRP2 and SFRP5 over-expressed U2OS cells 
(Table 5-1). Forced expression of SFRP5 also resulted in a significant up-regulation of 
SENP2 mRNA levels. The expressions of other Wnt signaling components necessary for 
ubiquitination of cytoplasmic β-catenin such as CSNK1D, GSK-3β and FBXW4 were 
enhanced with restoration of SFRP2, but remained unchanged in U2OS cell over-
expressing SFRP5.  
 
We also found perturbations in several genes that play critical roles in TCF/β-catenin 
transcription when SFRPs are over-expressed in U2OS cells. Our gene array analysis 
showed a 2.2-fold increased in AES gene which encodes groucho, a nuclear 
transcriptional co-repressor that blocks TCF/β-catenin transcription with ectopic 
expression of SFRP5 in U2OS cells (Table 5-1). The expressions of transcriptional co-
repressor proteins such as CTBP2 and TLE1 were up-regulated 2.03- and 2.00-fold 
respectively, while levels of LEF transcriptional factor was significantly suppressed with 





In addition, forced expressions of both SFRP2 and SFRP5 resulted in the suppression of 
oncogene WISP1 but induced levels of T tumor suppressor gene. The expressions of 
other Wnt target oncogenes such as JUN and c-Myc were also significantly down-
regulated in U2OS cells stably transfected with SFRP2 and SFRP5 respectively. 
Consistent with results from the western blot analysis Figure 5-5a, we further observed 
that the cyclin D1 transcriptional levels were suppressed by approximately 2-fold in 
SFRP2 stable transfectants, but an increased in cyclin D2 mRNA was also observed.  
Much to our surprise, we found up-regulations in the gene expressions of several 
activators of the Wnt/β-catenin/TCF signaling pathway such as DVL1 and DVL2 while 
NKD1, a dishevelled-binding protein was significantly suppressed with restoration of 
either SFRP2 or SFRP5. Unexpectedly, TCFL1 expression was found to be up-regulated 
in U2OS cells over-expressing SFRP5.  
 
Taken together, we identified several novel Wnt signaling components and target genes 
that may possibly explain the mechanism of Wnt inhibition and tumor suppressive effects 





Table 5-1. Wnt signaling components and target genes that significantly dysregulated with over-expression of SFRP2 or SFRP5 
in U2OS cells.   
  SFRP2 over-expression SFRP5 over-expression 
Gene           
(Gene Symbol) 
Function  Fold  
change 









enhancer of split 
(AES) 
Mammalian homologue of the Drosophila 
groucho which serves as a nuclear 
transcriptional co-repressor by interacting 
with TCF family of proteins to block 
TCF/β-catenin transcription and thus 
repress Wnt target oncogenes 





Tumor suppressor gene which facilitates 
the degradation of β-catenin by binding it 
and recruiting it to the APC-Axin-GSK-3β 
β-catenin destructive complex as well as 
by exporting nuclear β-catenin 




A component of an E3 ubiquitin ligase 
complex, which functions in 
phosphorylation-dependent ubiquitination 
of cytoplasmic β-catenin, thus destabilizes 
it. 
1.23 0.011 ↑ 1.79 0.040 ↑ 
Cyclin D1 Wnt target oncogene that stimulates tumor 
cell proliferation and cell cycle 




(CCND1) progression in the G1/S phase.  
Cyclin D2 
(CCND2) 
Wnt target oncogene that stimulates tumor 
cell proliferation and cell cycle 
progression in the G1/S phase, 
compensatory increase in cyclin D2 was 
observed with cyclin D2 knockdown  
2.63 0.000076 ↑ - - - 
Casein kinase 1, 
delta       
(CSNK1D) 
Facilitate phosphorylation and 
destabilization of cytoplasmic β-catenin 
1.96 0.0010 ↑ - - - 
Casein kinase 1, 
gamma 1 
(CSNK1G1) 
 3.47 0.00026 ↑ 2.05 0.00046 ↑ 
C-terminal binding 
protein 2    
(CTBP2) 
A transcriptional co-repressor that function 
as a scaffold protein to recruit chromatin-
modifying enzymes to TCF/LEF family of 
DNA-binding transcriptional factors, thus 
facilitating the transcriptional repression 
activity of TCF/LEF, as well as 
antagonizing the activity of p300 co-
activator complex  
2.03 0.00054 ↑ - - - 
Dickkopf 1 
(DKK1) 
Endogenous Wnt antagonist that attenuates 
Wnt signaling by binding to LRP and 
Kremen receptors, and sterically hindering 
Wnt interaction with LRPs 
3.32 0.000005 ↑ 1.178 0.037 ↑ 




homolog 1 (DVL1) that functions to release β-catenin from 
ubiquitin-dependent degradation 
Dishevelled 
homolog 2  
(DVL2) 
 2.24 0.0011 ↑ 1.395 0.046 ↑ 





A member of the F-box protein family that 
constitutes one of the four subunits of 
ubiquitin protein ligase complex called 
SCFs (SKP1-cullin-F-box), which function 
in phosphorylation-dependent 
ubiquitination. 
3.78 0.0010 ↑ 2.76 0.019 ↑ 





 1.66 0.0061 ↑ - - - 





 1.49 0.0030 ↑ 1.44 0.0066 ↑ 
Frizzled receptor 2 
(FZD2) 
Member of the 'frizzled' gene family 
encode 7-transmembrane domain proteins 
receptors that interacts with Wnt signaling 
proteins to initiate Wnt signaling. 
1.87 0.0052 ↓ - - - 
Frizzled receptor 3 
(FZD3) 




Frizzled receptor 4 
(FZD4) 
 2.70 0.0037 ↓ 2.55 0.016 ↓ 
Frizzled receptor 5 
(FZD5) 
 2.63 0.00032 ↑ - - - 
Frizzled receptor 6 
(FZD6) 
 5.02 0.000032 ↓ - - - 
Frizzled receptor 7 
(FZD7) 
 3.72 0.00062 ↓ 1.34 0.052 ↓ 
Frizzled receptor 8 
(FZD8) 
 1.62 0.0013 ↑ - - - 
Glycogen synthase 
kinase 3β   
(GSK3β) 
A component of Axin-GSK-3β β-catenin 
destructive complex which function in 
phosphorylation-dependent ubiquitination 
of cytoplasmic β-catenin, thus destabilize 
it.  
1.48 0.0016 ↑ - - - 
Jun oncogene 
(JUN) 
A Wnt target oncogene that is over-
expressed in osteosarcoma, and its 
suppression inhibited growth and 
metastasis of osteosarcoma in an 
orthotopic spontaneously metastasizing 
neoplasia model 
1.72 0.00039 ↓ - - - 
Lyphoid enhancing 
factor 1        
Member of TCF/LEF transcription factors 
that function as mediator of the Wnt/β-
catenin transcription, also a Wnt target 








homolog       
(MYC) 
 
A multifunctional, nuclear phosphoprotein 
that is frequently over-expressed in various 
malignancies, and plays a role in cell cycle 
progression, apoptosis and cellular 
transformation, as well as functions as a 
transcription factor that regulates 
transcription of specific target genes. 
- - - 2.81 0.047 ↑ 
Naked cuticle 
homolog 1  
(NKD1) 
A Dishevelled-binding protein that 
functions as a negative regulator of the 
Wnt/β-beta-catenin/TCF signaling 
pathway 
1.63 0.0048 ↓ 1.61 0.016 ↓ 
Frizzled-related 
protein 1    
(SFRP1) 
Belongs to a family of five glycoprotein 
(SFRP1-5) that competes with Frizzled 
receptors for bind Wnt ligands and 
silencing of this tumor suppressor gene is 
implicated in several malignancies  
1.49 0.0026 ↑ - - - 
Frizzled-related 
protein 3      
(FRZB) 





Axin-binding protein that promotes β-
catenin ubiquitination and degradation 
- - - 1.66 0.052 ↑ 
Solute carrier 
family 9 (sodium/ 
β-catenin-associating protein that 
potentiates β-catenin/TCF-dependent 






member 3 regulator 
1         
(SLC9A3R1) 
transcription, and function as a tumor 
suppressor to regulate anti-cancer activities 
T, brachyury 
homolog             
(T) 
 
Epigenetic silencing of this tumor 
suppressor is implicated in non-small-cell 
lung cancer 
1.62 0.0048 ↑ 1.44 0.027 ↑ 
T-cell specific 
transcription factor 
7-like 1    
(TCF7L1) 
Member of TCF/LEF transcription factors 
that function as mediator of the Wnt/β-
catenin transcription  
- - - 1.36 0.0073 ↑ 
Transducin-like 
enhancer of split 1 
(TLE1) 
Mammalian homologue of the Drosophila 
groucho which serves as a nuclear 
transcriptional co-repressor by interacting 
with TCF family of proteins to block 
TCF/β-catenin transcription and thus 
repress Wnt target oncogenes 
1.97 0.00030 ↑ - - - 
WNT inhibitor 
factor 1 (WIF1) 
 
A Wnt antagonist that is frequently 
silenced in many tumors including 
osteosarcoma, and restoration of this 
tumor suppressor gene suppressed cell 
proliferation, invasiveness and in vivo 
lung metastasis in many cancers  






protein 1     
(WISP1) 
A member of the connective tissue growth 
factor that is frequently over-expressed in 
various tumors, and is involve in the 
regulation of various processes leading to 
tumorigenesis and malignant 
transformation including cell proliferation, 
migration, adhesion, angiogenesis and 
extracellular matrix formation. 




member 1   
(WNT1) 
Secreted signaling protein that are 
implicated in oncogenesis and in several 
developmental processes 




member 2   
(WNT2) 


































































 3.32 0.000005 ↑ 1.57 0.041 ↑ 
 
Selected genes that are involved in the Wnt/β-catenin signaling with forced expression of SFRP2 in U2OS cells were listed. The gene 
symbol, gene function, fold-change, p-value, status of transcription has been described for each gene. The fold-changes in gene 






5.4  Discussion  
The Wnt/β-catenin pathway was first linked to cancer formation when it was found to be 
chronically activated in spontaneous forms of colon cancer. Approximately 90 % of 
colon cancers showed aberrant Wnt signaling, usually as a result of mutation in APC 
(80 %) [79-81], and less frequently due to mutations in β-catenin [76, 77] or Axin [85, 
86]. On the other hand, mutations in APC and β-catenin are rare in osteosarcoma, despite 
accumulation of β-catenin protein [73, 74]. Instead, epigenetic silencing of genes 
encoding upstream components seemed to be the preferred route to chronic Wnt signaling 
dysfunction in osteosarcoma. Attention has therefore been focused on the contributory 
role of Wnt upstream components in osteosarcoma pathogenesis. 
 
Indeed, over-expressions of numerous upstream membrane-bound Wnt components 
including Wnt ligands (Wnt 1, 4, 5a, 7, 10b, 11) [47, 48], Frizzled receptors (FZD1-10) 
[47] and LRP5 co-receptor [47, 51, 52] have been implicated in osteosarcoma 
tumorigenesis and metastasis. Epigenetic silencing of genes encoding endogenous Wnt 
pathway cell surface inhibitors such as DKK3 [63] and WIF-1 [65, 149] were observed to 
promote osteosarcoma disease progression. Furthermore, it has been previously reported 
that SFRP3 transcription was severely suppressed in osteogenic sarcoma biopsy 
specimens and several osteosarcoma cells lines [56], while the forced expression of 
SFRP3 inhibited in vivo tumor growth and lung metastasis [232]. However, the molecular 
functions of other members of the SFRPs family in the pathogenesis of osteosarcoma 




Therefore, we hypothesized that SFRP1, 2, 4 or 5 function as tumor suppressor genes and 
restoration of these may inhibit osteosarcoma tumorigenesis and metastasis.  
 
To test our hypothesis, we first established the constitutive levels of SFRPs in 
osteosarcoma cells by PCR. In general, SFRPs expressions in osteosarcoma cells are 
down-regulated compared hFOB cell lines (Figure 5-1). However, we did not detect 
mRNA expression of SFRP4 in hFOB cells. In agreement with our observations, several 
studies have previously reported undetectable mRNA levels of one or more SFRPs levels 
in normal human tissues or cell lines such as normal breast, lung and mesothelioma [58, 
280]. Despite lacking abundant expression in hFOB, SFRP4 may nevertheless bear 
crucial tumor-suppressive functions that only become effective under certain tumorigenic 
circumstances. This speculation is supported by a study which found that low levels of 
SFRP5 was readily inducible by activating Wnt signaling through forced expression of 
Wnt-1 or treatment with LiCl [281]. Effective inhibitions of the Wnt/β-catenin pathway 
by restoration of SFRPs in U2OS cells were subsequently shown by marked suppression 
of both β-catenin/TCF transcriptional activities (Figure 5-3a) and total β-catenin protein 
levels (Figure 5-3b), as well as re-distribution of β-catenin protein from the nucleus to the 
cell membrane (Figure 5-4) using luciferase reporter assays, western blotting and 
immunofluorescence confocal microscopy analyses respectively.  
 
Upon restoration of the SFRPs, anchorage-dependent (Figure 5-5b) and –independent 
(Figure 5-5c) growths of osteosarcoma cells were found to be negatively regulated. 




expressions of SFRP1, 2 and 5 resulted in G0/G1 mitosis exit abnormity while a G2/M 
phase delay was observed with over-expression of SFRP4 in U2OS cells, accounting for 
the anti-proliferation effects of SFRPs in U2OS (Figure 5-5d). High apoptotic rate in 
SFRP4 and SFRP5 over-expressing cells might contribute additionally to cell 
proliferation suppression in U2OS cells (Figure 5-5d). Our western blot results 
demonstrated that perturbations of protein expressions of several Wnt target proliferation-
associated oncogenes including cyclin D1, c-Myc and survivin [234-241], correlated with 
anti-proliferation and pro-apoptotic effects with over-expression of SFRPs antagonist in 
U2OS cells. 
 
Interestingly, we observed an up-regulation of c-Myc protein expression in U2OS over-
expressing SFRP4 or SFRP5. Consistent with these results, c-Myc mRNA level was also 
significantly induced 2.8-fold in U2OS cell over-expressing SFRP5 (Table 5-1). c-Myc is 
known to play multiple roles in cell cycle progression, apoptosis and cellular 
transformation, and is regulated in a multi-factorial and tissue specific manner [98]. Our 
observation that restoration of SFRP4 and SFRP5 up-regulated c-Myc protein expression, 
but induced anti-proliferative and pro-apoptotic effects in U2OS cell, is thus not 
unexpected. A similar phenomenon was reported previously by Thompson et al. who 
found that both a decrease and increase of c-Myc led to apoptosis [282]. In another study, 
a decreased expression of c-Myc was found in human colorectal adenocarcinoma cells 
over-expressing β-catenin [283]. Furthermore, c-Myc may be positively or negatively 
regulated based on combinatorial interactions involving E2F transcriptional factors and 




Besides their anti-proliferative effects, SFRPs may function as anti-invasive agents in 
osteosarcoma by inhibiting U2OS cell invasion and motility. As shown in Figure 5-6, we 
found that ectopic expressions of SFRP1, 2 and 5 decreased the invasiveness and motility 
of U2OS. On the other hand, restoration of SFRP4 inhibited U2OS cell invasion but had 
no effect on U2OS cell migration, suggesting that SFRP4 has less effects on motility in 
U2OS cells than the other members of the SFRPs family of Wnt antagonists. Reduction 
in MMP-2 and MMP-9 protein was observed only in SFRP1 and SFRP4 transfectants, 
suggesting that other invasion-associated genes may be involved in regulating 
osteosarcoma cell invasion and migration. In agreement with our observations, Zhao et al 
also found no significant correlation between SFRP5 expression and MMP-2 or MMP-9 
expressions in gastric cancer cells, however, both MMP-7 and MT1-MMP mRNA 
expressions correlated inversely with SFRP5 expressions in these cell lines [285]. Further 
experiments are necessary to investigate the roles of other members of the MMP family, 
such as MMP-1 [286], MMP-3 [287] MMP-7 [288] , MMP-13 [289], MMP-26 [101], 
MT1-MMP [290], MT3-MMP [231], that may be affected through direct or indirect Wnt 
activation. 
 
As a means to elucidate novel targets that can mediate the anti-tumor effects of SFRPs 
restoration, we examined changes in the global expressions of 84 Wnt signaling 
components and target genes expression profile induced by SFRP2 and SFRP5 over-
expressions in U2OS stable transfectants using the Human Wnt Signaling Pathway RT2 
ProfilerTM PCR Array. SFRP2 and SFRP5 were chosen for Wnt array analysis over 




members of the SFRPs family; (2) Both SFRP2 and SFRP5 are markedly down-regulated 
in U2OS cells and in many other osteosarcoma cell lines while the suppression of the 
other SFRPs was less obvious (Figure 5-1) and (3) To test our hypothesis that Novel Wnt 
target genes, besides MMPs (Figure 5-6), may play a more significant role in regulating 
the anti-metastatic effects of SFRP2 or SFRP5. 
 
Firstly, based on the RT-PCR array data, we observed suppressions of mRNA 
expressions of specific frizzled receptors (SFRP2: FZD2, FZD 4, FZD6, FZD7; SFRP5: 
FZD4, FZD7) and Wnt ligands (SFRP2: WNT 5a, WNT 5b, WNT 11; SFRP5: WNT 5a, 
WNT 11), suggesting that restoration of SFRP2 or SFRP5 may disrupt specific WNT-
FZD interactions and thus block signal initiation at the membranous level. Up-regulation 
of expressions of other endogenous antagonists such as DKK-1, SFRP1, SFRP3 and/or 
WIF-1 by SFRP5 and SFRP2 over-expression respectively may additionally prevent or 
reduce Wnt signaling by binding competitively to the LRP5 and/or FZD receptors. 
Notably, these Wnt antagonists function as tumor suppressor genes and were previously 
reported to inhibit both in vitro and in vivo cell proliferation, invasion, migration, 
angiogenesis as well as induce apoptosis in several malignancies such as osteosarcoma 
[56, 65, 149], prostate [232], liver multiple myeloma [279, 291], breast [62] and kidney 
[292]. Given that epigenetic silencing of SFRP3 and WIF-1 have been implicated in the 
pathogenesis of osteosarcoma [56, 65] and that restoration of WIF-1 and DKK3 have 
been shown to inhibit in vivo lung metastasis and invasiveness of osteosarcoma cells 
respectively [63], our findings suggest that SFRP2 or SFRP5 may offer a clinically 




WIF-1 in osteosarcoma to achieve effective therapy. However, further studies are needed 
to examine the specific effects for the disruption of the native WNT-FZD complexes by 
SFRP2 and SFRP5. 
 
Secondly, it is tempting to speculate that over-expressions of SFRP2 or SFRP5 could 
have attenuated Wnt signaling in U2OS cells through enhancing the phosphorylation-
dependent ubiquitination and destabilization of cytoplasmic β-catenin, given that 
restorations of SFRP2 and SFRP5 both resulted in a collective up-regulations of signaling 
components that are responsible for these processes such as APC, CSNK1G1, CSNK1D, 
GSK3β, β-TrCP, FBXW2, FBXW4, FBXW11 and SENP2. As shown in Table 5-1, over-
expression of SFRP2 or SFRP5 increased the mRNA expression of APC, a tumor 
suppressor which plays critical roles in facilitating the degradation of β-catenin by 
binding and recruiting it to the APC-Axin-GSK-3β β-catenin destructive complex as well 
as by exporting nuclear β-catenin [109, 131, 293]. Furthermore, as proposed by Ha et al. 
who found that the subsequent phosphorylation of APC by CSNK slowed the release of 
β-catenin from the destructive complex [294], the up-regulation of CSNK observed with 
ectopic expressions of SFRP2 and SFRP5 may possibly further enhance ubiquitination of 
β-catenin in U2OS cells. Phosphorylated β-catenin is then recognized by and associates 
with specific member of the SCF (SKP1-cullin-F-box) family of the E3 ubiquitin ligase 
complex, the Beta-transducin repeat containing and F-box proteins before it gets 





Thirdly, SFRP2 may be capable of disrupting β-catenin/TCF complexation and 
transcription through attenuating the nuclear translocation of β-catenin protein by 
redistribution to the cell membrane (Figure 5-4) and regulating the expression of several 
transcriptional factors such as TLE1, LEF1, and CTBP2. TLE1 gene is a mammalian 
homologue of the Drosophila transcriptional repressor groucho which serves as a nuclear 
transcriptional co-repressor by interacting with TCF/LEF family of proteins to block 
TCF/β-catenin transcription and thus repress Wnt target oncogenes [129, 258, 259]. As a 
co-repressor, CTBP2 primarily functions as a scaffold protein to recruit chromatin-
modifying enzymes, including HDACS, histone methyltranferases and polycomb group 
proteins, to TCF/LEF family of DNA-binding transcriptional factors, thus facilitating the 
transcriptional repression activity of TCF/LEF [296, 297] and antagonizing the activity of 
p300 co-activator complex [298]. Notably, mutations which affect the CTBP2 interaction 
with TCF/LEF have been reported to contribute to carcinogenesis [93, 299]. Given that 
LEF1, a DNA binding transcriptional factor, has been shown to be a bona fide target gene 
[300, 301], down-regulation of LEF may possibly reduce the magnitude of Wnt 
activation since a smaller amount of LEF protein would be available for complex 
formation with β-catenin. Taken together, SFRP2 may possibly disrupt β-catenin/TCF 
transcriptional activity and complexation through up-regulating transcriptional repressors 
such as groucho and CTBP2, while suppressing the level of LEF1 transcription factor. On 
the other hand, SFRP5 may be capable of disrupting β-catenin/TCF transcription by up-






Lastly, ectopic expression of both SFRP2 and SFRP5 were found to effectively suppress 
the mRNA expressions of oncogene WISP1 but induced expression of tumor suppressor 
T gene, Brachyury. Both WISP1 and Brachyury genes play critical roles in regulating 
tumorigenesis and metastatic transformation in various tumor models. Indeed, several 
lines of evidence support a role for WISP-1 in tumorigenesis: WISP-1, a member of the 
connective tissue growth factor that belongs to the Cry61, CTGF and Noc (CCN) super 
family, has been shown to promote cell proliferation, migration, adhesion, angiogenesis 
and extracellular matrix formation [266, 302]. WISP-1 is over-expressed in many tumors 
types, including breast, colon, cholangiocarcinoma and plexiform neurofibromas [267-
270] and its over-expression correlated with more advanced features such as late-stage 
disease, lymph node involvements and larger tumor size in both primary breast and rectal 
cancers [269, 271]. In in-vivo mouse models, forced expression of WISP-1 in normal 
kidney fibroblasts were found to induce morphological transformation, accelerate cell 
growth and induced tumor formation [146]. On the other hand, Brachyury was recently 
identified as a tumor suppressor gene in non-small-cell lung cancer [303] whereas other 
members of the T-box family genes that share T box motif with Brachyury such as TBX2 
and TBX3, are known to be transcriptional repressors that inhibit cell proliferation and 
oncogenic transformation [304]. Since our earlier results from the western blot analysis 
showed that protein expressions of MMP-2 and MMP-9 remained unaltered and did not 
correspond to the reduction in invasive capacity of SFRP5 over-expressing U2OS cells, it 
is tempting to speculate that other metastasis-associated Wnt target genes including 
WISP1 and Brachyury might play a significant contributory role in regulating 




siRNA or forced expressions of these genes would be necessary to fully elucidate their 
effects in regulating osteosarcoma cell invasion by SFRP5.    
 
Furthermore, we observed suppressions of several other Wnt target oncogenes such as 
SLC9A3R1, JUN and cyclin D1 with forced expression of SFRP2. Parallel to results 
from the western blot analysis (Figure 5-5a), we found a reduction of cyclin D1 mRNA 
level in U2OS cell over-expressing SFRP5. On the other hand, we observed an up-
regulation of cyclin D2 in these cells. Such compensated effects of cyclin D2 with the 
knockdown of cyclin D1 was previously observed in mantle lymphoma cells as well as in 
an in vivo mouse model, but more studies are required to explain these observed 
phenomenon. SLC9A3R1, a β-catenin-associating protein that potentiates β-catenin/TCF-
dependent transcription [305] was found to be up-regulated in breast cancer [306], 
schwannoma [307] and hepatocellular carcinomas [305] compared to their non-tumor 
counterparts. Elevated level of SLC9A3R1 is closely associated with the invasive 
behavior of malignant glioma cells in vivo and in vitro, and when silenced, tumor cells 
exhibited reduced migratory activity, leading to an increased susceptibility to 
chemotherapy [308]. Furthermore, SLC9A3R1 has been reported to regulate formation of 
invadopodia-cell structures that mediate tumor cell migration and invasion [309]. 
Another Wnt target gene, JUN has been found to be over-expressed in many cancers 
including osteosarcoma [310-312]. Indeed, JUN plays a critical role in the tumorigenesis 
and metastasis of osteosarcoma as reported recently by Dass et al. who demonstrated that 
knockdown of JUN using a c-jun DNAzyme, encapsulated within a novel cationic multi-




orthotopic spontaneously metastasizing model of the disease [313]. Consistent with our 
results, JUN was suppressed in breast cancer cells that ectopically expressed SFRP2 
[314]. While the suppression of WISP1, Brachyury, SLC9A3R1 and JUN in U2OS cells 
over-expressing SFRP2 correlated with inhibition of U2OS cell proliferation, invasion 
and migration, further studies are needed to fully understand the contributory roles of 
these oncogenes in regulating osteosarcoma metastasis and tumorigenesis. Nevertheless, 
the potential implications of regulating WISP-1 and Brachyury expressions by either 
over-expression of SFRP2 or SFRP5 in osteosarcoma pathogenesis are highly relevant 
and deserve in-depth investigation, given their oncogenic properties. 
 
Much to our surprise, we observed significant up-regulations in the gene expressions of 
several activators of the Wnt/β-catenin/TCF signaling pathway such as DVL 1 and 2, as 
well as TCFL1 while suppression of NKD1, a dishevelled-binding protein with forced 
expressions of either SFRP2 or SFRP5. The expressions of several Wnt ligands and 
receptors were also induced with restoration of either SFRP2 or SFRP5 in U2OS cells. A 
possible explanation to the discordant results is that external stimuli such as the forced 
expression of SFRP2 or SFRP5 may have induced a protective auto-regulatory positive 
feedback mechanism to enhanced Wnt signaling in U2OS cells. Other reasons to these 
aberrant effects may include the presence of unclassified biphasic functions of these 
signaling components in Wnt signaling and their multiple roles in regulating other cross 





Taken together, we identified several novel Wnt signaling components and target genes 
that possibly explain the mechanism of Wnt inhibition and tumor suppressive effects of 
SFRP2 or SFRP5 in U2OS cells. Further studies are however needed to gain a 
comprehensive understanding of the underlying mechanism of Wnt inhibition by these 
secreted proteins in U2OS cells. Nevertheless, our findings supplemented the limited 
existing knowledge in understanding the interactions of SFRPs with the various 
molecular Wnt targets, which are essential for designing more effective SFRPs-based 
therapeutics for the treatment of osteosarcoma.  
 
At present, we cannot rule out the fact that tumor-suppressive functions of SFRPs may be 
mediated through both Wnt/β-catenin-dependent and -independent signaling. In fact, 
restoration of SFRP4 expression in both β-catenin-dependent and β-catenin-deficient cell 
mesothelioma cell lines have been shown to promote apoptosis, suppress cancer cell 
growth and down-regulate Wnt signaling [315]. Another study showed that ectopic 
expression of SFRP1 reduced cell proliferation even though β-catenin/TCF is not 
activated in prostate cancer cells [316]. Recently, Shih et al. also found that β-catenin-
deficient SK-Hep1 hepatoma cell treated with SFRP1 shRNA showed enhanced cell 
growth, implicating involvement of Wnt-independent signaling [317]. Furthermore, 
analysis of global expression reveled that over-expression of SFRP2 repressed numerous 
genes that are implicated in Wnt/β-catenin-dependent signaling. More experiments 
involving the knockdown of the individual SFRPs in β-catenin-deficient osteosarcoma 











CHAPTER 6. Conclusions and Perspective  
 
The overall aim of this thesis is to develop novel Wnt-targeted therapeutics for the 
treatment of osteosarcoma. We tested the hypothesis of disrupting the Wnt/β-catenin 
signaling pathway as an effective therapeutic strategy in preventing osteosarcoma 
progression. The hypothesis was investigated using a two-pronged approach: The first 
approach builds on novel identification of small molecule compounds derived from 
natural sources as potent inhibitors of the Wnt pathway. Using curcumin as a lead 
compound, a series of 43 functionalized curcumin analogues were chemically 
synthesized to determine if structural modification would result in more potent Wnt 
antagonists. This part of the study also aimed at identifying critical structural motifs for 
Wnt inhibitory activity and understanding the underlying mechanism of Wnt inhibition of 
the most potent curcumin analogue. The second approach focuses on understanding the 
functional roles and mechanisms of SFRPs as tumor suppressors in regulating 
osteosarcoma cell proliferation, motility and invasion.    
 
In aim (1), several natural occurring small molecule compounds such as curcumin and 
PKF118-310 were successfully identified as effective Wnt antagonists in osteosarcoma 
(Chapter 3). We showed that curcumin significantly inhibited Wnt/β-catenin signaling 
and reverses Wnt/β-catenin-induced cell invasiveness and MMP-9 expression in U2OS 
cells. Furthermore, PKF118-310 inhibited osteosarcoma cell invasion, migration and 
proliferation, as well as induced apoptosis and G2/M phase cell cycle arrest, through 





In aim (2), functionlization of curcumin was found to be an attractive approach of 
enhancing the potency of Wnt inhibitory activity (Chapter 4). Modification of the 
curcumin structure was made to the central linker between the terminal phenyl rings and 
various permutations centered on the OH/OCH3 groups as ring substitutions. Despite 
these simple structural modifications, we identified six analogues (2-3, 3-3, 4-3, 2-6, 3-6, 
4-6) that were more potent than parental curcumin in suppressing β-catenin/TCF 
transcriptional activities and inhibition of U2OS cell invasiveness. These analogues were 
approximately 6.5- to 60-fold more potent than parental curcumin. SAR analysis of the 
whole panel of 43 curcumin analogues provided four important observations relating to 
the Wnt inhibitory activity (Figure 4-5): Firstly, reducing the flexibility of the 
intermediate linker joining the terminal phenyl rings improved inhibitory activity. 
Incorporating the linker as part of a ring structure like those represented in Series 3 
(dibenzylidene-cyclohexanone) and Series 4 (dibenzylidene-cyclopentanone) resulted in 
several compounds with outstanding activities. Secondly, the flexibility of the 
intermediate side chain influenced the substitution on the terminal phenyl rings that were 
required for good activity. Thirdly, specifically for Series 3 and 4 analogues, the 
preferred substituents were deduced to be electron donating. Lastly, ring substitutions 
with limited size requirements are favored if sited at the 3’ position.  
 
In aim (3), we investigated the functional role of SFRP1, 2, 4 and 5 and found that these 
secreted Wnt antagonists differentially suppressed anchorage-dependent growth, colony 




activities were mediated through down-regulations of Wnt responsive oncogenes 
including matrix metalloproteinases-2, cyclin D1, c-Myc and survivin. Lastly, using the 
Human Wnt Signaling Pathway RT2 ProfilerTM PCR Array, we identified additional Wnt 
target genes such as WISP1, Brachyury, SLC9A3R1 and JUN that might play significant 
contributory role in regulating osteosarcoma tumorigenesis and metastasis. By analyzing 
significant perturbations of Wnt signaling components mRNA levels, we also identified 
potential critical targets for Wnt inhibition by the restoration of SFRP2 or SFRP5 or 
treatment of analogue 3-3 in U2OS cells.  
 
The present work has raised several issues to be pursued in future investigations. In 
Chapter 4, we evaluated a set of curcumin analogues with improved potency and high 
selectivity as Wnt/β-catenin antagonists. An important outcome of this study is the 
recognition of the curcumin backbone as a potential lead for compounds with potent Wnt 
inhibitory activity. Additional analogues with the symmetrical terminal phenyl rings 
substituted with electron-donating groups such as N(OCH3)2  (σp N(OCH3)2 , -0.63 ; σm 
N(OCH3)2, -0.10) and NH2  (σp NH2 , -0.57 ; σm NH2, -0.09) would be required to 
confirm our findings that Wnt inhibitory activity is favored by the absence of electron-
withdrawing groups at these phenyl rings. In addition, the structural modifications 
described here have been fairly limited and there is ample scope for further exploration 
with more structurally diverse curcumin analogues. These proposed modifications are 
summarized in Figure 6-1. For example, would tri- or multiple-substitutions of the phenyl 
rings with electron-donating groups further improve Wnt inhibitory activity? How would 




aromatic rings such as furan, thiophene, pyrrole or naphthalene? Would incorporation of 
other aromatic rings as part of the linker and varying the substitutions on these rings lead 





of ring A with electron
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Figure 6-1. Proposed modifications of curcumin template for improved Wnt 
inhibitory activity. 
 
Another objective of this thesis is to examine the underlying mechanism of Wnt 




mRNA levels of several Wnt targeted genes following treatment with either the most 
potent analogue (3-3) or U2OS cells over-expressing SFRP2 or 5 collectively suggest that 
3-3 and forced expressions of SFRP2 or 5 attenuated the Wnt/β-catenin signaling 
pathway at various critical nodal points of the pathway. However, further experiments are 
needed to verify and confirm our results: (1) Perturbations were observed on the mRNA 
levels, thus these findings needs to be validated at the protein levels using 
immunohistochemistry or western blotting; (2) Anti-sense and siRNA strategies against 
tumor-suppressor genes including Brachyury and WIF1 that are up-regulated with our 
treatments would be essential to verify their contributory roles in regulating osteosarcoma 
growth and metastasis; (3) On the other hand, additional experiments using forced 
expressions of other oncogenes including WISP1, FOSL1, JUN and cyclinD2 that are 
down-regulated are necessary to further elucidate their effects in inhibiting various anti-
tumor activities in osteosarcoma; (4) Further immunoprecipitation assays needs to be 
performed to investigate protein interactions of the various components of the APC-
Axin-GSK-3β-β-catenin complex to fully elucidate its role in enhancing phosphorylation-
dependent ubiquitination of β-catenin following treatment with analogue 3-3 and 
restoration of SFRP2 or 5 respectively; (5) Lastly, it would be interesting to examine the  
specificities for disruption of the native WNT-FZD complexes interacts by over-
expression of SFRP2 or 5 using appropriate binding assays and X-ray crystallography.  
 
Our results suggest that manipulating this pathway through new small molecule 
compounds or recombinant/therapeutic molecules is of great promise for osteosarcoma 




subset of osteosarcoma tumors since only a few osteosarcoma cell lines were studied. 
Future studies with a wider range of osteosarcoma cell lines, primary tumors and patient 
tissue samples are required to confirm and supplement our findings and to better clarify 
the implication of canonical Wnt signaling pathway in osteosarcoma tumorigenesis and 
metastasis. Furthermore, our in vitro results may be encouraging but the true therapeutic 
potential of the Wnt/β-catenin inhibitors will only become evident when their in vivo 
efficacies as anti-tumor agents are rigorously tested in nude mice tumor models.  
 
Other challenges remain to be overcome before Wnt therapeutics becomes a reality for 
osteosarcoma treatment. Given that the Wnt/β-catenin signaling pathway is also involved 
in normal developmental processes such as the regulation of tissue regeneration and stem 
cell renewal in the bone marrow and gut, persistent inhibition of this signaling pathway 
may result in potential fatal side effects including anemia, immunosuppression and 
gastrointestinal damages. The challenge of this study will therefore be to ensure both 
therapeutic strategies of using small molecule antagonists and SFRPs secreted inhibitors 
result in sufficient selectivity to avoid these detrimental side effects resulting from 
inappropriate disruption of Wnt signaling in normal tissues. Finally, Wnt/β-catenin 
signaling pathway does not occur in isolation from other signaling pathways, and there is 
considerable evidence suggesting that other cross-talk pathways can cooperate in 
unexpected ways in the pathogenesis of osteosarcoma. The mechanism by which this 
combinatorial signaling occurs and whether it is functionally significant in osteosarcoma 




different pathways with Wnt therapeutics for osteosarcoma treatment needs further 
attention.   
 
Most recently, Cai et al. reported that canonical Wnt/β-catenin signaling appear to be 
inactive in osteosarcoma and concluded that silencing of Wnt signaling may contribute to 
osteosarcoma tumorigenesis [318]. They found that β-catenin expression was localized to 
the cytoplasm and cell membrane, rather than the nucleus. They also demonstrated that a 
GSK3β inhibitor, GIN, inhibited osteosarcoma cell growth and stimulated markers of 
osteoblast differentiation. In contrast to their findings, we found the majority of the β-
catenin protein localized in the nucleus of U2OS cells (Figure 5-4). The effects of GIN on 
osteosarcoma should be verified using a specific Wnt antagonist, especially since GSK3β 
kinase plays multiple roles in cellular processes, aside from those linked to β-catenin. In 
addition, there are no examples of signaling pathways that have been identified where 
gain-in-function clearly results in tumor suppression in one tumor type, but stimulate 
tumor formation in others. Therefore, the findings from this isolated report need further 
confirmation.  
 
In this thesis, we have proven the hypothesis that osteosarcoma tumorigenesis and 
metastasis may be delayed by small molecule Wnt inhibitors or restoration of endogenous 
antagonist SFRPs. The contributory role of aberrant canonical Wnt/β-catenin signaling in 
osteosarcoma disease progression has been demonstrated by enhanced U2OS cell 
invasion with forced expression of β-catenin (Figure 3-10b). In Chapter 3, we further 




Wnt/β-catenin inhibitors to delay osteosarcoma progression and metastasis (Aim 1). In 
Chapter 4, we evaluated and identified curcumin analogues with enhanced Wnt inhibitory 
potency and reported critical structural motifs for Wnt inhibitory activity using structure-
activity–relationship analysis (Aim 2).  Lastly, we demonstrated the role of SFRPs as 
tumor suppressors in delaying osteosarcoma disease progression (Chapter 5, Aim 3). All 
in all, our findings strongly supported the prevailing view that activated Wnt/β-catenin 
signaling is critical in the pathogenesis of osteosarcoma and that Wnt targeted 
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Appendix 1: Table of structures of synthesized compounds and their physiochemical 
properties  
a C log P/molecular weight values were determined on ChemDraw Ultra 10.0, 
CambridgeSoft, Cambridge, MA. 
b No. of rotatable bonds/No. of hydrogen bond donors and acceptors values were 




R1(3’) R2(4’) Moleculara 
weight 




















OCH3 OH 368.38 7  2 4 2.94 
1-2 OCH3 OCH3 396.43 9 0 4 3.89 
1-3 OH OCH3 368.38 7 2 4 2.94 
1-4 H H 276.33 5 0 0 4.58 
1-5 OCH3 H 336.38 7 0 2 4.41 
1-6 H OH 308.33 5 2 2 3.24 
1-7 F F 348.29 5 0 0 5.01 
 





2-1 OCH3 OH 326.34 6 2 5 2.64 
2-2 OCH3 OCH3 354.40 8 0 5 3.59 
2-3 OH OCH3 326.34 6 2 5 2.64 
2-4 H H 234.39 4 0 1 4.28 
2-5 OCH3 H 294.34 6 0 3 4.11 
2-6 H OH 266.29 4 2 3 2.94 










3-1 OCH3 OH 366.41 4 2 5 3.70 
3-2 OCH3 OCH3 394.46 6 0 5 4.65 
3-3 OH OCH3 366.41 4 2 5 3.70 
3-4 H H 274.36 2 0 1 5.33 
3-5 OCH3 H 334.41 4 0 3 5.17 
3-6 H OH 306.36 2 2 3 4.00 
3-7 F F 346.32 2 0 1 5.76 
3-8 2’F  310.34 2 0 1 5.62 
3-9 F H 310.34 2 0 1 5.62 
3-10 H F 310.34 2 0 1 5.62 
 
Series 4 Analogues 
 
 
4-1 OCH3 OH 352.38 4 2 5 3.14 
4-2 OCH3 OCH3 380.43 6 0 5 4.09 
4-3 OH OCH3 352.38 4 2 5 3.14 
4-4 H H 260.33 2 0 1 4.77 
4-5 OCH3 H 320.38 4 0 3 4.61 
4-6 H OH 292.33 2 2 3 3.44 
4-7 F F 332.29 2 0 1 5.20 
4-8 2’F  296.31 2 0 1 5.06 
4-9 F H 296.31 2 0 1 5.06 
4-10 H F 296.31 2 0 1 5.06 
 








5-2 OCH3 OCH3 328.36 7 0 5 3.18 
5-3 OH OCH3 300.31 5 2 5 2.50 
5-4 H H 208.26 3 0 1 3.62 
5-5 OCH3 H 268.31 5 0 3 3.77 
5-6 H OH 240.25 3 2 3 2.83 








Appendix 2: Characterization of compounds in Series 1-5 
 
Compound 1-1(Curcumin): C21H20O6. Yellow-orange crystals. Melting point: 183°C. 
1H-NMR (300 MHz, CDCl3) δ: 3.95 (6H, s, OCH3 × 2), 5.80 (1H, s, COCH=C), 6.48 (2H, 
d, J=16Hz, CHCO ×2), 6.93 (2H, d, J=8Hz, Ar-H), 7.05 (2H, s, Ar-H), 7.12(2H, d, J= 
8Hz, Ar-H), 7.59 (2H, d, J = 16Hz, Ar-CH=C ×2 ). 13C-NMR (75 MHz, CDCl3) δ: 
55.928, 101.089, 109.626, 114.800, 121.769, 122.828, 127.677, 140.491, 
140.491,146.755, 147.823, 151.915, 183.229. MS (APCI) m/z: 369.0 (M+1)+. Anal calcd 
for C17H14O5: C, 68.45; H, 4.73; Found: C, 68.03; H, 4.78. 
 
Compound 1-2: Orange powder. C23H24O6. Melting point: 130-131°C. 1H-NMR (300 
MHz, CDCl3) δ: 3.92 (6H, s, OCH3 ×2), 3.93 (6H, s, OCH3 ×2), 5.82(1H, s, COCH=C), 
6.50 (2H, d, J=16Hz, CHCO ×2), 6.88 (2H, d, J=8  Hz, Ar-H), 7.10 (4H, m, Ar-H), 
7.61(2H, d, J=16 Hz, Ar-CH=C ×2). 13C-NMR (75 MHz, CDCl3) δ: 55.843, 55.912, 
76.642, 77.066, 77.490, 101.274, 109.754, 111.096, 121.967, 122.578, 128.002, 140.334, 
149.173, 150.992, 183.204. MS (APCI) m/z: 396.9 (M+1)+. HPLC (MeOH: H2O=80:20) 
tR (min): 9.394. PHPLC/ %: 97.50. HPLC (ACN: H2O=80:20) tR (min): 2.931. PHPLC/ %: 
100.00.  
 
Compound 1-3: Orange powder. C21H20O6. Melting point: 192°C. 1H-NMR (300 MHz, 
CDCl3) δ: 3.92(6H, s, OCH3 ×2), 5.82 (1H, s, COCH=C), 6.48 (2H, d, J=16 Hz, CHCO 
×2), 6.87 (2H, d, J= 8Hz, Ar-H), 7.04 (2H, d, J=8Hz, Ar-H),7.15 (2H, s, Ar-H), 7.53 (2H, 
d, J=16 Hz,  Ar-CH=C ×2 ). 13C-NMR (75 MHz, CDCl3) δ:  MS (APCI) m/z: 369.0 
(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 2.450. PHPLC/ %: 95.97. HPLC (ACN: 
H2O=80:20) tR (min): 1.849. PHPLC/ %: 95.48  
 
Compound 1-4: Yellow powder. C19H16O2. Melting point: 138-140°C. 1H-NMR (300 
MHz, DMSO-d6) δ: 6.209 (1H, s, COCH=C), 6.953 (2H, d, J=16 Hz, CHCO ×2), 7.442 
(6H, s, Ar-H ), 7.688 (2H, s, Ar-H ),7.719 (2H, m, Ar-H). 13C-NMR (75 MHz, DMSO-
d6) δ: 101.752, 124.194, 128.237, 128.878, 13.200, 134.551, 140.264, 183.092 . MS 
(APCI) m/z: 277.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 9.281. PHPLC/ %: 99.86. 
HPLC (ACN: H2O=70:30) tR (min): 12.003. PHPLC/ %: 98.50 
 
Compound 1-5: Brownish-orange powder. C23H24O4. Melting point: 59-60°C. 1H-NMR 
(300 MHz, CDCl3) δ: 3.85 (6H, s, OCH3 ×2), 5.86 (1H, s, COCH=C), 6.62 (2H, d, 
J=16Hz, -CHCO-×2), 6.88 (2H, d, J=2Hz, Ar-H), 6.95 (2H, d, J=10 Hz, Ar-H), 7.08 (2H, 
s, Ar-H),7.30 (2H, s, Ar-H), 7.633 (2H, d, J= 16 Hz, Ar-CH=C ×2). 13C-NMR (75 MHz, 
CDCl3) δ: 55.289, 101.794, 113.037, 115.908, 120.794, 124.328, 129.882, 136.329, 
140.543, 159.889, 183.230 . MS (APCI) m/z: 337.0 (M+1)+. HPLC (MeOH: H2O=80:20) 
tR (min): 1.784. PHPLC/ %: 95.81. HPLC (ACN: H2O=80:20) tR (min): 1.608. PHPLC/ %: 
97.30 
 
Compound 1-6: Orange-red crystals. C19H16O6. Melting point: 229-230°C. 1H-NMR 
(300 MHz, DMSO-d6) δ: 6.03 (1H, s, COCH=C), 6.65 (2H, J = 16 Hz, -CHCO-×2), 6.83 
(4H, d, J = 8.4 Hz, Ar-H), 7.53-7.57 (m, 6H, Ar-H + Ar-CH=C ×2), 10.2 (2H, s, OH). 




159.893, 183.325 MS (APCI) m/z: 369.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 
5.055. PHPLC/ %: 96.85. HPLC (ACN: H2O=80:20) tR (min): 1.670. PHPLC/ %: 99.14 
 
Compound 1-7: Yellow powder. C19H12F4O. Melting point: 229-230°C. 1H-NMR (300 
MHz, DMSO-d6) δ: 5.82 (1H, s, COCH=C), 6.53 (2H, J = 16 Hz, -CHCO-×2), 7.14-7.41 
(m, 7H, Ar-H + Ar-CH=C ×2), 7.57 (2H, d, 8Hz, Ar-H). 13C-NMR (75 MHz, DMSO-d6) 
δ: 76.5764, 77.0000, 77.2022, 77.4236, 78.3575, 102.1870, 116.0418, 117.7460, 
117.9771, 124.8419, 132.1689, 138.4753, 182.7933. MS (APCI) m/z: 309.2 (M+1)+. 
HPLC (MeOH: H2O=80:20) tR (min): 14.846. PHPLC/ %: 99.85. HPLC (ACN: 
H2O=70:30) tR (min): 2.198. PHPLC/ %: 98.68 
 
Compound 2-1: Greenish-yellow powder. C19H18O5. Melting point: 106°C. 1H-NMR 
(300 MHz, CDCl3) δ: 3.96 (6H, s, OCH3 ×2), 6.90-6.95 (4H, m,  Ar-H + COCH= ×2), 
7.09-7.17 (m, 4H, Ar-H), 7.68 (2H, d, J=16 Hz, Ar-CH= ×2). 13C-NMR (75 MHz, 
DMSO-d6) δ: 55.689, 111.350, 115.632, 122.965, 123.334, 126.306, 142.754, 149.942, 
188.015 MS (APCI) m/z: 326.9 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 1.794. 
PHPLC/ %: 95.81. HPLC (ACN: H2O=70:30) tR (min): 1.608. PHPLC/ %: 97.40 
 
Compound 2-2: Orange-yellow solid. C21H22O5. Yield: 52.0%. Melting point: 93-95°C. 
1H-NMR (300 MHz, CDCl3) δ: 3.93(6H, s, OCH3 ×2), 3.95(6H, s, OCH3 ×2), 6.89 (2H, d, 
J =8.1 Hz, Ar-H), 6.96 (d, J = 16 Hz, COCH= ×2), 7.14-7.21 (m, 4H, Ar-H), 7.69 (d, J = 
16 Hz, Ar-CH= ×2). 13C-NMR (75 MHz, CDCl3) δ: 55.845, 55.892, 109.840, 111.035, 
123.033, 123.530, 127.763, 142.984, 149.156, 151.252, 188.629 MS (APCI) m/z: 355.0 
(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 3.129. PHPLC/ %: 95.49. HPLC (ACN: 
H2O=70:30) tR (min): 2.762. PHPLC/ %: 94.59 
 
Compound 2-3: Yellow powder. C19H18O5. Yield: 33.27%. Melting point: 189-190°C. 
1H-NMR (300 MHz, DMSO-d6) δ: 3.77 (s, 6H, OCH3 ×2), 6.93 (d, 2H, J = 8 Hz, Ar-H), 
7.03 (d, J = 16 Hz, COCH= ×2), 7.14-7.17 (m, 4H, Ar-H), 7.57 (d, J = 16 Hz, 2H, Ar-
CH= ×2). 13C-NMR (75 MHz, DMSO-d6) δ:  56.0, 112.592, 114.706, 122.818, 123.919, 
128.057, 143.757, 147.087, 150.906, 189.454 MS (APCI) m/z: 327.0 (M+1)+. HPLC 
(MeOH: H2O=80:20) tR (min): 3.129. PHPLC/ %: 95.49. HPLC (ACN: H2O=70:30) tR 
(min): 2.762. PHPLC/ %: 94.59 
 
Compound 2-4: Yellow crystals. C17H14O. Yield: 28.3%. Melting point: 113°C. 1H-
NMR (300 MHz, CDCl3) δ: 7.09 (d, J= 16 Hz, 2H, COCH= ×2), 7.26-7.42 (m, 6H, Ar-H), 
7.60-7.63 (m, 4H, Ar-H), 7.75 (d, J = 16 Hz, 2H, Ar-CH= ×2). 13C-NMR (75 MHz, 
CDCl3) δ: 125.327, 128.310, 128.872, 130.411, 134.964, 143.206, 188.805 MS (APCI) 
m/z: 235.3 (M+1)+.PHPLC/ %: 95.37. HPLC (ACN: H2O=80:20) tR (min): 3.075. PHPLC/ %: 
99.72 
 
Compound 2-5: Yellow solid. C19H18O3. Yield: 45.7%. Melting point: 50-51°C. 1H-
NMR (300 MHz, CDCl3) δ: 3.847 (6H, s, CH3-O x2), 6.959(2H, d, J=3.15Hz, Ar-H), 
7.056(4H, m, Ar-H), 7.208 (2H, d, J=16Hz, -COCH= x2), 7.326(2H, t, J=8Hz, Ar-H), 
7.699(2H, d, J=16Hz, Ar–CH=Cx2). 13C-NMR (75 MHz, CDCl3) δ:  55.100, 113.127, 




159.751, 188.641 MS (APCI) m/z: 295.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 
6.637. PHPLC/ %: 96.48. HPLC (ACN: H2O=80:20) tR (min): 3.040. PHPLC/ %: 96.71 
 
Compound 2-6: Dark yellow powder. C17H14O3. Yield: 24.26%. Melting point: 236-
239°C. 1H-NMR (300 MHz, DMSO-d6)  δ: 6.837 (4H, m, Ar-H x4 ), 7.099(2H, d, 
J=16Hz, -COCH= x2), 7.644 (6H, m, Ar-H=x4 + Ar–CH=Cx2), 10.062(2H, s, OH). 13C-
NMR (75 MHz, DMSO-d6)  δ: 115.836, 122.656, 125.821, 130.443, 142.400, 159.821, 
188.047. MS (APCI) m/z: 267.2 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 2.738. 
PHPLC/ %: 99.42. HPLC (ACN: H2O=70:30) tR (min): 1.793. PHPLC/ %: 99.67 
 
Compound 2-7: Yellow crystals. C17H10F4O. Melting point: 132-133°C. 1H-NMR (300 
MHz, DMSO-d6)  δ: 6.955(2H, d, J=7.95, Ar-H), 7.199(2H, t, J=8.9Hz, Ar-H), 7.332(2H, 
d, J= 16Hz, -COCH= x2), 7.443(2H, m, Ar-H), 7.637 (2H, d, J=16Hz, Ar–CH=Cx2). MS 
(APCI) m/z: 306.9 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 2.728. PHPLC/ %: 99.28. 
HPLC (ACN: H2O=70:30) tR (min): 1.793. PHPLC/ %: 99.67 
 
Compound 2-9: C17H12F2O Melting point: 147-149°C. 1H-NMR (300 MHz, DMSO-d6)  
δ: 6.981(4H, m, Ar-H), 7.248 (6H, m, Ar-H, -COCH= x2), 7.564 (2H, d, J=16Hz, Ar–
CH=Cx2). 13C-NMR (75 MHz, CDCl3) δ:  114.261, 114.550, 117.515, 130.417, 130.523, 
136.829, 136.935, 139.640, 142.124, 161.342, 164.616, 188.252 MS (APCI) m/z: 271.0 
(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 5.418. PHPLC/ %: 99.08. HPLC (ACN: 
H2O=80:20) tR (min): 3.195. PHPLC/ %: 97.59 
 
Compound 2-10: C17H12F2O. Melting point: 149-150°C 1H-NMR (300 MHz, DMSO-d6)  
δ: 7.231(6H, m, Ar-H), 7.781 (6H, m, Ar-H, -COCH= x2, Ar–CH=Cx2) 13C-NMR (75 
MHz, CDCl3) δ:  114.936, 115.225, 124.006, 124.034, 129.166, 129.282, 129.908, 
141.018, 161.324, 164.655, 187.397 MS (APCI) m/z: 271.2 (M+1)+. HPLC (MeOH: 
H2O=80:20) tR (min): 3.373 . PHPLC/ %: 99.16. HPLC (ACN: H2O=80:20) tR (min): 3.228. 
PHPLC/ %: 95.74 
 
Compound 3-1: Yellow solid. C22H22O5. Melting point: 177-178°C. 1H-NMR (300 MHz, 
DMSO-d6)  δ: 1.72 (s, 2H, -CH2-), 2.88 (s, 4H, =C-CH2- × 2), 3.81 (s, 6H, OCH3 × 2), 
6.85 (d, J = 8.1 Hz, 2H, Ar-H), 7.03 (d, J = 8.4 Hz, 2H, Ar-H), 7.11 (s, Ar-H), 7.57 (s, 2H, 
CH=C × 2), 9.52 (br s, 2H, OH). 13C-NMR (75 MHz, CDCl3)  δ:   55.289, 76.574, 
76.994, 77.421, 101.794, 113.037, 115.908, 120.794, 124.328, 129.882, 136.329, 
140.543, 159.889, 183.230. MS (APCI) m/z: 367.0 (M+1)+. HPLC (MeOH: H2O=80:20) 
tR (min): 3.351. PHPLC/ %: 97.88. HPLC (ACN: H2O=80:20) tR (min): 3.209. PHPLC/ %: 
99.31.  
 
Compound 3-2: Yellow crystals. C24H26O5. Melting point: 149-151°C. 1H-NMR (300 
MHz, CDCl3)  δ: 1.830(2H, m, J=6Hz ,-CH2-), 2.95(4H, t, J=5Hz =C-CH2- x2), 
3.914(6H, s, CH3-O x2), 3.924 (6H, s, CH3-O x2), 6.911(2H, d, J=8.4Hz, Ar-H), 
7.023(2H, s, Ar-H), 7.114(2H, d, J=4.2Hz, Ar-H),7.753(2H, s,-CH=C- x2). 13C-NMR (75 
MHz, CDCl3) δ: 23.022, 28.503, 55.909, 76.725, 77.150, 77.754, 110.897, 113.714, 




(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 5.691. PHPLC/ %: 100.00. HPLC (ACN: 
H2O=80:20) tR (min): 2.750. PHPLC/ %: 97.80.   
 
Compound 3-3: Brownish-yellow powder. C22H22O5. Yield: 31.09%. Melting point: 
189°C. 1H-NMR (300 MHz, DMSO-d6)  δ: 1.72 (t, J =5Hz, 2H), 2.86 (s, 4H), 3.81 (s, 
OCH3 × 2), 6.99-7.01(m, 6H, Ar-H + CH=C × 2), 7.48 (s, 2H, Ar-H), 9.18 (br s, 2H, 
OH). 13C-NMR (75 MHz, DMSO-d6) δ: 22.237, 27.847, 55.504, 111.911, 117.060, 
122.884, 129.172, 133.957, 135.691, 146.173, 148.483, 188.514 S MS (APCI)  m/z: 
367.3 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 4.810. PHPLC/ %: 100.00. HPLC 
(ACN: H2O=80:20) tR (min): 1.747. PHPLC/ %: 99.83.    
 
Compound 3-4: Yellow crystals. C20H18O. Melting point: 116-120°C. 1H-NMR (300 
MHz, CDCl3)  δ: δ: 1.79 ( t, J=6 Hz , 2H -CH2-), 2.93 (4H, t, J=5 Hz, -CH2- ×2), 7.25-
7.48 (10H, m, Ar–H), 7.80 (2H, s,-CH=C- ×2). 13C-NMR (75 MHz, DMSO-d6) δ: 22.994, 
28.429, 76.579, 77.002, 100.686, 128.356, 128.556, 130.340, 135.963, 136.175, 136.916, 
190.373  . MS (APCI) m/z: 275.1 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 12.149. 
PHPLC/ %: 98.71. HPLC (ACN: H2O=80:20) tR (min): 5.549. PHPLC/ %: 98.60.     
 
Compound 3-5: Yellow crystals. C22H22O3. Yield: 41.1%. Melting point: 59-60°C. 1H-
NMR (300 MHz, CDCl3)  δ: 1.68 (2H, t, J=5Hz, -CH2-), 2.86(4H, s, =C-CH2-x2), 
3.835(6H, s, CH3-O), 6.96 (d, J=8 Hz, 2H, ArH), 7.05-7.10 (m, 4H, ArH), 7.32-7.38 (m, 
2H, ArH), 7.60 (s, 2H, CH=C- ×2). 13C-NMR (75 MHz, DMSO-d6) δ: 22.287, 27.780, 
55.023, 114.502, 115.474, 122.449, 129.459, 135.636, 136.404, 159.109, 188.80 MS 
(APCI) m/z: 335.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 5.049. PHPLC/ %: 95.43. 
HPLC (ACN: H2O=80:20) tR (min): 4.033. PHPLC/ %: 96.79.     
 
Compound 3-6: Brownish-yellow powder. C20H18O3. Yield: 25.44%. Melting point: 270-
271°C. 1H-NMR (300 MHz, DMSO-d6)  δ: 1.71(2H, t, J=6 Hz, -CH2-), 2.85(4H, t, 
J=5.4Hz, -CH2- ×2), 6.84 (4H, d, J=4Hz, ArH), 7.40(4H, d, J=4 Hz, ArH),7.53 (2H, s, 
Ar–CH=C ×2), 9.96 (2H, br s, OH ×2). 13C-NMR (75 MHz, DMSO-d6) δ: 22.476, 27.912, 
115.464, 126.393, 132.390, 133.242, 135.731, 158.250, 188.443 MS (APCI) m/z: 307.0 
(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 7.542. PHPLC/ %: 98.28. HPLC (ACN: 
H2O=80:20) tR (min): 3.075. PHPLC/ %: 97.68.     
 
Compound 3-7: Yellow crystals. C20H14F4O Yield: 12.5%. Melting point: 105-106°C. 
1H-NMR (300 MHz, CDCl3)  δ: 1.79-1.87 (m, 2H, -C-CH2-), 2.89 (4H, t, J=5.7Hz, -C-
CH2- ×2), 7.18-7.31 (m, 6H, ArH), 7.67 (2H, s, Ar–CH=C ×2). 13C-NMR (75 MHz, 
DMSO-d6). MS (APCI) m/z: 347.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 6.923. 
PHPLC/ %: 92.43. HPLC (ACN: H2O=80:20) tR (min): 5.013. PHPLC/ %: 96.79.     
 
Compounds 3-8: Yellow powder. C20H16F2O. Melting point: 95-96°C. 1H-NMR (300 
MHz, CHCl3) δ: 1.7821(2H, m,-CH2-), 2.8086(4H, t, J=5.67Hz =C-CH2- x2), 7.1324(4H, 
m, Ar-H), 7.3441(4H, m, Ar-H), 7.8224(2H, s,-CH=C- x2). 13C-NMR (75 MHz, DMSO-
d6) δ: 22.9383, 28.5130, 76.5764, 77.0000, 77.4236, 115.5604, 115.8589, 123.6673, 
123.7154, 123.7636, 123.9455, 129.7041, 129.7522, 130.2722, 130.3781, 130.6669, 




HPLC (MeOH: H2O=80:20) tR (min): 5.535. PHPLC/ %: 97.00. HPLC (ACN: H2O=80:20) 
tR (min): 4.435. PHPLC/ %: 95.99.  
 
Compound 3-9: Yellow powder. C20H16F2O. Melting point: 84°C. 1H-NMR (300 MHz, 
CHCl3) δ: 1.8000 (2H, m,-CH2-), 2.9128(4H, t, J=5.28Hz =C-CH2- x2), 7.2148(8H, m, 
Ar-Hx2), 7.7270(2H, s,-CH=C- x2). 13C-NMR (75 MHz, DMSO-d6) δ: 22.6206, 28.2241, 
76.5764, 77.0000, 77.4236, 115.2909, 115.5701, 116.4452, 116.7351, 126.1321, 
126.1706, 129.7619, 129.8678, 135.6254, 135.6542, 135.8577, 137.8206, 137.9265, 
160.8509, 164.1148, 189.6774. MS (APCI) m/z: 311.0 (M+1) +. HPLC (MeOH: 
H2O=80:20) tR (min): 6.683. PHPLC/ %: 99.41. HPLC (ACN: H2O=80:20) tR (min): 5.609. 
PHPLC/ %: 97.23  
 
Compound 3-10: Yellow powder. C20H16F2O. Melting point: 151°C. 1H-NMR (300 
MHz, CHCl3) δ: 1.8055 (2H, m,-CH2-), 2.8952(4H, t, J=5.28Hz =C-CH2- x2), 7.0943(4H, 
m, Ar-H), 7.4458(4H, m, Ar-H), 7.7458(2H, s,-CH=C- x2). 13C-NMR (75 MHz, DMSO-
d6) δ: 22.8709, 28.3108, 115.3583, 115.6375, 132.1689, 132.2844, 135.6928, 135.8468, 
160.9857, 164.2978, 190.0048. MS (APCI) m/z: 310.9 (M+1) +. HPLC (MeOH: 
H2O=80:20) tR (min): 5.699. PHPLC/ %: 96.45. HPLC (ACN: H2O=80:20) tR (min): 5.316. 
PHPLC/ %: 95.44 
 
Compound 4-1: Dark yellow powder. C21H20O5. Melting point: 198-202 °C. 1H-NMR 
(300 MHz, DMSO-d6) δ : 3.06 (4H, s, -CH2-CH2), 3.84 (6H, s, OCH3 ×2), 6.89 (2H, d, 
J=8 Hz, Ar-H), 7.16 (2H, d, J=8 Hz, Ar-H), 7.24(2H, s, Ar-H), 7.35 (2H, s, CH=C×2), 
9.69(2H, br s, OH ×2). 13C-NMR (75 MHz, DMSO-d6) δ: 26.914, 56.605, 115.545, 
116.922, 125.793, 128.179, 133.841, 135.768, 148.727, 149.537, 195.480. MS (APCI) 
m/z: 353.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 2.464. PHPLC/ %: 98.66. HPLC 
(ACN: H2O=70:30) tR (min): 1.953. PHPLC/ %: 100.00.  
 
Compound 4-2: Yellow powder. C23H24O5. Yield: 44.0%. Melting point: 196-199°C. 1H-
NMR (300 MHz, CDCl3) δ : 3.10 (4H, s, CH2-CH2), 3.93 (12H, s, OCH3 ×4), 6.93 (2H, 
d, J= 8 Hz, Ar-H), 7.12-7.27 (m, 4H, Ar-H), 7.53 (2H, s, CH=C×2).13C-NMR (75 MHz, 
DMSO-d6) δ: 26.387, 55.822, 55.899, 111.112, 113.409, 124.534, 128.946, 133.622, 
135.319, 148.856, 150.223, 195.946. MS (APCI) m/z: 381.0 (M+1)+. HPLC (MeOH: 
H2O=80:20) tR (min): 7.734. PHPLC/ %: 96.91. HPLC (ACN: H2O=80:20) tR (min): 2.377. 
PHPLC/ %: 96.60.  
 
Compound 4-3: Dark yellow powder. C21H20O5.  Yield: 27.19%. Melting point: 224-
225°C. 1H-NMR (300 MHz, DMSO-d6) δ : 3.02 (4H, s, CH2-CH2), 3.82 (6H, s, OCH3 
×2), 7.02 (2H, d, J= 8 Hz, Ar-H), 7.12-7.14 (m, 4H, Ar-H), 7.28 (2H, s, CH=C × 2), 9.28 
(2H, s, OH ×2). 13C-NMR (75 MHz, DMSO-d6) δ: 25.846, 55.534, 112.095, 116.836, 
123.566, 128.334, 132.410, 135.260, 146.481, 149.148, 194.795 MS(APCI) m/z: 353.0 
(M+1)+.HPLC (MeOH: H2O=80:20) tR (min): 6.566. PHPLC/ %: 99.28. HPLC (ACN: 
H2O=80:20) tR (min): 3.083. PHPLC/ %: 99.79.  
Compound 4-4: Yellow powder. C19H16O. Yield: 63.9%. Melting point: 194-195°C. 1H-
NMR (300 MHz, CDCl3) δ: 3.07 (4H, s, CH2-CH2), 7.35-7.44 (m, 6H, Ar-H), 7.56-7.58 




130.652, 133.722, 135.717, 137.212, 196.220 MS (APCI)  m/z: 381.0 (M+1)+. HPLC 
(MeOH: H2O=80:20) tR (min): 22.011. PHPLC/ %: 97.12. HPLC (ACN: H2O=80:20) tR 
(min): 4.199. PHPLC/ %: 99.28  
 
Compound 4-5: Yellow crystals. C21H20O3. Yield: 56.8%. Melting point: 144-147°C. 1H-
NMR (300 MHz, CDCl3) δ : 3.05 (4H, s, CH2-CH2), 3.82 (6H, s, MeO ×2), 6.91 (dd, J= 2 
Hz, J = 10 Hz, 2H, ArH), 7.08 (s, 2H, ArH), 7.16 (d, J= 8 Hz, 2H, ArH), 7.30-7.35 (m, 
2H, Ar-H), 7.52 (s, 2H, CH=C ×2). 13C-NMR (75 MHz, DMSO-d6) δ : 26.387, 55.154, 
114.968, 115.888, 123.179, 129.592, 133.647, 136.978, 137.405, 159.579, 196.103. MS 
(APCI) m/z: 321.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 13.048. PHPLC/ %: 
98.85. HPLC (ACN: H2O=80:20) tR (min): 4.022. PHPLC/ %: 99.09 
 
Compound 4-6: Greenish-yellow powder. C19H16O3. Yield: 31.60%. Melting point: 
314°C. 1H-NMR (300 MHz, DMSO-d6) δ : 3.02 (4H, s, CH2–CH2), 6.87 (4H, d, J= 8Hz, 
Ar–H3,5 ×2), 7.33 (s, 2H, CH=C ×2), 7.54 (4H, d, J= 8Hz, Ar–H2,6x2), 10.1 (br s, 2H, 
OH×2 ). 13C-NMR (75 MHz, DMSO-d6) δ: 26.063, 116.110, 126.800, 132.912, 134.787, 
159.078, 195.280MS 795 MS (APCI) m/z: 293.0 (M+1)+. HPLC (MeOH: H2O=80:20) tR 
(min): 3.854. PHPLC/ %: 98.60. HPLC (ACN: H2O=70:30) tR (min): 1.784. PHPLC/ %: 
99.66 
 
Compound 4-7: Yellow crystals. C19H12F4O.Yield: 38.5%. Melting point: 239-240°C. 
1H-NMR (300 MHz, CDCl3) δ : 3.10(4H, s, CH2–CH2), 7.19-7.45 (m, 6H, Ar-H), 7.50 (s, 
2H, CH=C ×2). MS (APCI) m/z: 332.9 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 
20.240. PHPLC/ %: 96.92. HPLC (ACN: H2O=70:30) tR (min): 13.712. PHPLC/ %: 98.41 
 
Compound 4-8: Yellow powder. C19H14F2O. Melting point: 210°C. 1H-NMR (300 MHz, 
CHCl3) δ: 3.0484(4H, s, CH2–CH2), 7.7.167(4H, m, Ar-H), 7.3667(2H, m, Ar-H),7.5776 
(2H, m, Ar-H),7.8111(2H, s, Ar-CH=Cx2) .13C-NMR (75 MHz, DMSO-d6) δ: 26.0771, 
76.1527, 76.5764, 77.0000, 115.3775, 115.6664, 123.3496, 123.5132, 123.6095, 
123.6577, 125.2655, 125.3329, 129.7041, 130.5802, 130.6958, 138.5041, 159.6281, 
195.1076. MS (APCI) m/z: 297.0 (M+1) +.HPLC (MeOH: H2O=80:20) tR (min): 6.816. 
PHPLC/ %: 99.89. HPLC (ACN: H2O:80=20) tR (min): 4.057. PHPLC/ %: 94.18 
 
Compound 4-9: Yellow powder. C19H14F2O. Melting point: 191-192°C. 1H-NMR (300 
MHz, CHCl3) δ: 2.9969 (4H, s, CH2–CH2), 7.0071(2H, m, Ar-H), 7.2633 (6H, m, Ar-H), 
7.4257(2H, s, Ar-CH=Cx2). 13C-NMR (75 MHz, DMSO-d6) δ: 26.3370, 76.5764, 
77.0000, 77.4236, 100.6658, 116.1863, 116.4751, 116.5907, 116.8795, 126.7001, 
126.7386, 130.1662, 130.2818, 132.7273, 132.7658, 137.6954, 137.8109, 138.0420, 
139.6595, 161.1494, 164.4229, 195.9068. MS (APCI) m/z: 297.0 (M+1) +. HPLC (MeOH: 
H2O=80:20) tR (min): 5.848. PHPLC/ %: 97.32. HPLC (ACN: H2O=80:20) tR (min): 4.303. 
PHPLC/ %: 93.77 
Compound 4-10: Yellow powder. C19H14F2O. Melting point: 239-240°C. 1H-NMR (300 
MHz, CHCl3) δ:  2.7885(4H, s, CH2–CH2), 6.8292(8H, m, Ar-H), 7.3077 (2H, s, Ar-
CH=Cx2). 13C-NMR (75 MHz, DMSO-d6) δ: 26.3274, 76.5764, 77.0000, 77.4236, 
115.8108, 116.0996, 131.9956, 132.0437, 132.5444, 132.6599, 132.7177, 136.6556, 




H2O=80:20) tR (min): 7.108. PHPLC/ %: 99.57. HPLC (ACN: H2O=80:20) tR (min): 4.387. 
PHPLC/ %: 95.02 
 
Compound 5-1: Yellow powder .C17H16O5. Yield: 34.07%. Melting point: 108-110°C. 
1H-NMR (300 MHz, DMSO-d6) δ: 3.87 (6H, s, MeO ×2), 6.82 (1H, d, J= 8 Hz, ArH), 
6.91(1H, d, J=8Hz, ArH), 7.27 (1H, d, J= 8 Hz, ArH), 7.48-7.80 (m, 5H, Ar-H + 
CH=CH), 9.62 (s, 1H, OH), 9.99 (s, 1H, OH). 13C-NMR (75 MHz, DMSO-d6) δ: 55.637, 
55.776, 111.519, 111.722, 114.848, 115.540, 118.643, 123.480, 126.445, 129.786, 
143.527, 147.711, 149.334, 151.593, 186.957 MS (APCI) m/z: 301.0 (M+1)+. HPLC 
(MeOH: H2O=80:20) tR (min): 4.252. PHPLC/ %: 97.30. HPLC (ACN: H2O=80:20) tR 
(min): 3.234. PHPLC/ %: 95.495.624 
 
Compound 5-2: Light yellow solid. C19H20O5. Yield: 69.0%. Melting point: 110°C. 1H-
NMR (300 MHz, CDCl3) δ: 6.85 (t, 2H, J = 7.8 Hz, Ar-H), 7.12 (m, 1H, Ar-H), 7.18 (d, J 
= 8.1 Hz, 1H, Ar-H), 7.38 (d, J = 15 Hz, 1H, COCH=), 7.57-7.65 (m, 2H, Ar-H), 7.71 (d, 
J = 15 Hz, 1H, Ar-CH=). 13C-NMR (75 MHz, CDCl3) δ:  55.788, 55.854, 109.768, 
110.044, 110.616, 110.954, 119.404, 122.732, 127.858, 131.334, 143.937, 149.026, 
151.084, 152.935, 188.401 MS (APCI)   m/z: 329.0 (M+1)+. HPLC (MeOH: H2O=80:20) 
tR (min): 7.043. PHPLC/ %: 99.34. HPLC (ACN: H2O=80:20) tR (min): 3.742. PHPLC/ %: 
99.12 
 
Compound 5-3: Yellow powder. C17H16O5. Melting point: 144-147°C. 1H-NMR (300 
MHz, CDCl3) δ: 3.94 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 6.86 (d, J= 8 Hz, 1H, ArH), 
6.93 (d, J= 8 Hz, 1H, ArH), 7.13 (dd, J = 1.8 Hz, J = 10 Hz, 1H, ArH), 7.27-7.28 (m, 1H, 
ArH), 7.39 (d, J = 16 Hz, 1H, COCH=), 7.61-7.63 (m, 2H, ArH), 7.72 (d, J = 16 Hz, 1H, 
ArCH=). 13C-NMR (75 MHz, DMSO-d6) δ:  56.197, 56.288, 111.821, 112.542, 114.804, 
115.151, 119.781, 122.406, 122.779, 128.088, 131.317, 144.265, 146.882, 147.027, 
150.793, 152.766, 188.593 MS (APCI) m/z: 301.0 (M+1)+. HPLC (MeOH: H2O=80:20) 
tR (min): 3.366. PHPLC/ %: 99.40. HPLC (ACN: H2O=80:20) tR (min): 2.934. PHPLC/ %: 
99.91 
 
Compound 5-4: Light yellow crystals. C15H12O. Yield: 66.1%. Melting point: 53-55°C. 
1H-NMR (300 MHz, CDCl3) δ: 7.41-7.79 (m, 10H, Ar-H + -CH=CH-), 8.03 (d, J = 7.5 
Hz, 2H, Ar-H). 13C-NMR (75 MHz, CDCl3) δ: 121.980, 128.358, 128.407, 128.530, 
128.862, 130.450, 132.689, 134.781, 138.104, 144.714, 190.393 MS (APCI) m/z: 209.0 
(M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 8.273. PHPLC/ %: 100.00. HPLC (ACN: 
H2O=70:30) tR (min): 4.465. PHPLC/ %: 99.27 
 
Compound 5-5: Yellow liquid. C17H16O3. Yield: 15.8%. Liquid state. 1H-NMR (300 
MHz, CDCl3) δ: 3.85 (s, 3H, OMe), 3.88 (s, 3H, OMe), 6.97 (d, J = 8 Hz, 1H, ArH), 
7.12-7.61 (m, 8H, Ar-H + COCH=), 7.77 (d, J=16 Hz, 1H, Ar-CH=). 13C-NMR (75 MHz, 
CDCl3) δ: 121.980, 128.358,55.038, 55.156, 112.704, 113.263, 116.053, 118.978, 
120.818, 120.857, 122.060, 129.343, 129.696, 135.993, 144.437, 159.650, 159.700, 
189.781 MS (APCI) m/z: 241.2 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 6.073. 





Compound 5-6: Pale yellow powder. C15H12O3. Yield: 12.05%. Melting point: 190-
195°C. 1H-NMR (300 MHz, DMSO-d6) δ: 6.80-6.88 (m, 4H, ArH), 7.56-7.62 (m, 4H, 
ArH + -CH=CH-), 7.94 (d, J = 8 Hz, 2H, Ar-H).  MS (APCI) m/z: 241.2 (M+1)+. HPLC 
(MeOH: H2O=80:20) tR (min): 3.326. PHPLC/ %: 99.69. HPLC (ACN: H2O=70:30) tR 
(min): 2.941. PHPLC/ %: 99.69 
 
Compound 5-7: White crystals. C15H8F4O. Yield: 14.3%. Melting point: 132-134°C. 1H-
NMR (300 MHz, CDCl3) δ: 7.18-7.39 (m, 4H, Ar-H + COCH=), 7.45-7.51 (m, 1H, Ar-
H), 7.73 (d, J = 16 Hz, 1H, Ar-CH=), 7.79-7.90 (m, 2H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δ:  55100.711, 116.482, 116.715, 117.508, 117.742, 117.894, 117.978, 118.127, 
121.670, 121.694, 125.335, 125.403, 131.783, 131.841, 134.884, 143.229, 148.946, 
152.249, 187.095 MS (APCI) m/z: 280.9 (M+1)+. HPLC (MeOH: H2O=80:20) tR (min): 









Appendix 3: Effects of curcumin analogue 3-3 on 84 related Wnt components and 
target genes in U2OS cells using Human Wnt signaling real time PCR array analysis. 
The gene symbol, gene description, fold-change and p-value were reported for each gene. 
Genes that are significantly dysregulated (p-value < 0.05) are bold and indicated with *.  
 
Gene 




Genes that are up-regulated with cucrumin analogue 3-3 treatment 
 
BTRC * Beta-transducin repeat containing 1.540 0.0475 
CCND2 Cyclin D2 1.099 0.7502 
CTBP2 C-terminal binding protein 2 1.012 0.9960 
DKK1 Dickkopf homolog 1 (Xenopus laevis) 1.602 0.0663 
FGF4 
Fibroblast growth factor 4 (heparin secretory 
transforming protein, Kaposi sarcoma 
oncogene) 1.000 0.9596 
FRZB Frizzled-related protein  1.307 0.3766 
KREMEN1 Kringle containing transmembrane protein 1 1.031 0.8588 
MYC 
V-myc myelocytomatosis viral oncogene 
homolog (avian) 1.606 0.0821 
TLE2 * 
Tranducin-like enhancer of split 2 (E(sp1) 
homolog, Drosophila) 2.406 0.000526 
WNT2B 
Wingless-type MMTV integration site 
family, member 2B 1.206 0.3665 
 
Genes that are down-regulated with curcumin analogue 3-3 treatment 
 
AES Amino-terminal enhancer of split 1.932 0.1798 
APC Adenomatosis polyposis coli 1.663 0.0798 
AXIN1 Axin 1 1.050 0.8786 
BCL9 B-cell CLL/lymphoma 9 1.498 0.2007 
FZD5 Frizzled homolog 5(Drosophila) 1.047 0.8533 
CCND1 * Cyclin D1 1.461 0.0421 
CCND3 Cyclin D3 1.146 0.6529 
CSNK1A1 Casein kinase 1, alpha 1 1.901 0.1223 
CSNK1D Casein kinase 1, delta 1 1.385 0.4049 
CSNK1G1 Casein kinase 1, gamma 1 1.195 0.5570 
CSNK2A1 Casein kinase 1, alpha 1 polypeptide 1.211 0.1538 
CTBP1 C-terminal binding protein 1 1.832 0.2304 
CTNNB1 
Catenin(cadherin-associated protein), beta 1, 
88kDa 1.461 0.0884 
CTNNBIP1 Catenin, beta interacting protein 1 2.009 0.0682 
CXXC4 CXXC finger 4 2.651 0.0697 





DIXDC1 DIX domain containing 1 1.516 0.0675 
DVL1 Dishevelled, dsh homolog 1 (Drosophila) 1.110 0.4598 
DVL2 Dishevelled, dsh homolog 2 (Drosophila) 1.823 0.3636 
EP300 E1A binding protein p300 1.254 0.4232 
FBXW11 F-box and WD repeat domain containing 11 1.159 0.5991 
FBXW2 F-box and WD repeat domain containing 2 1.047 0.5459 
FOSL1 * FORolike antigen 1 4.574 0.0448 
FOXN1 Forkhead box N1 1.451 0.2374 
FRAT1 
Frequently rearranged in advanced T-cell 
lymphomas 1.495 0.313 
FSHB 
Follicle stimulating hormone, beta 
polypeptide 1.234 0.4260 
FZD1 Frizzled homolog 1 (Drosophila) 1.569 0.1054 
FZD2 * Frizzled homolog 2 (Drosophila) 3.776 0.0304 
FZD3 * Frizzled homolog 3 (Drosophila) 1.341 0.0153 
FZD4 * Frizzled homolog 4 (Drosophila) 2.597 0.0297 
FZD6 Frizzled homolog 6 (Drosophila) 1.357 0.5118 
FZD7 Frizzled homolog 7 (Drosophila) 1.509 0.2087 
FZD8 Frizzled homolog 8 (Drosophila) 1.097 0.7414 
GSK3A Glycogen synthase kinase 3 alpha 1.379 0.2654 
GSK3B Glycogen synthase kinase 3 beta 1.226 0.3865 
JUN Jun oncogene 1.686 0.1092 
LEF1 Lymphoid enhancer-binding factor 1 1.251 0.1993 
LRP5 
Low density lipoprotein receptor-related 
protein 5 1.198 0.6691 
LRP6 
Low density lipoprotein receptor-related 
protein 6 1.335 0.1809 
NKD1 * Naked cuticle homolog 1 (Drosophila) 2.292 0.0173 
NLK Nemo-like kinase 1.097 0.7933 
PITX2 * 
Paired-like homedomain transcription 
factor 2 3.855 0.0306 
PORCN Porcupine homolog (Drosophila) 1.026 0.8923 
PPP2CA 
Protein phosphatase 2(formerly 2A), catalytic 
subunit, alpha isoform 1.341 0.0535 
PPP2R1A 
Protein phosphatase 2(formerly 2A), 
regulatory subunit A, alpha isoform 1.678 0.2019 
PYGO1 Pygopus homolog (Drosophila) 1.184 0.2637 
RHOU Ras homolog gene family, member U 1.973 0.0833 
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 1.509 0.1791 
SFRP1 * Secreted frizzled-related protein 1 1.562 0.000628 
SFRP4 Secreted frizzled-related protein 4 1.606 0.1438 
FBXW4 F-box and WD repeat domain containing 4 1.231 0.4354 
SLC9A3R1 
Solute carrier family 9 (sodium/hydrogen 




SOX17 SRY (sex determining region Y)-box 17 1.162 0.5814 
T T, brachyury homolog (mouse) 1.289 0.2734 
TCF7 
Transcription factor 7 (T-cell specific, HMG-
box) 1.234 0.4260 
TCF7L1 * 
Transcription factor 7-like 1 (T-cell 
specific, HMG-box) 2.921 0.0307 
TLE1 
Tranducin-like enhancer of split 1 (E(sp1) 
homolog, Drosophila) 1.655 0.0699 
WIF1 WNT inhibitory factor 1 1.234 0.4260 
WISP1 * 
WNT inducible signaling pathway protein 
1 2.815 0.0276 
WNT1 
Wingless-type MMTV integration site 
family, member 1 1.234 0.4260 
WNT10A 
* 
Wingless-type MMTV integration site 
family, member 10A 3.403 0.0151 
WNT11 * 
Wingless-type MMTV integration site 
family, member 11 9.895 0.000005 
WNT16 
Wingless-type MMTV integration site 
family, member 16 1.228 0.4311 
WNT2 
Wingless-type MMTV integration site 
family, member 2 1.234 0.4260 
WNT3 
Wingless-type MMTV integration site 
family, member 3 1.437 0.2642 
WNT3A 
Wingless-type MMTV integration site 
family, member 3A 1.323 0.2490 
WNT4 
Wingless-type MMTV integration site 
family, member 4 2.292 0.1375 
WNT5A * 
Wingless-type MMTV integration site 
family, member 5A 2.549 0.0195 
WNT5B * 
Wingless-type MMTV integration site 
family, member 5B 2.357 0.0125 
WNT6 * 
Wingless-type MMTV integration site 
family, member 6 4.367 0.0295 
WNT7A * 
Wingless-type MMTV integration site 
family, member 7A 2.474 0.0397 
WNT7B * 
Wingless-type MMTV integration site 
family, member 7B 4.218 0.0115 
WNT8A * 
Wingless-type MMTV integration site 
family, member 8A 1.354 0.0055 
WNT9A 
Wingless-type MMTV integration site 





Appendix 4: Primer sequence for RT-PCR 
Gene   Sequence  Product 
size (bp) 
 
SFRP1 Sense 5'-CCAGC GAGTA CGACT ACGTG AGCTT-3' 497 
 Anti-sense 5'-CTCAGATTTCAACTCGTTGTCACAGG-3'  
SFRP2 Sense 5'-ATGAT GATGA CAACG ACATA ATG-3' 322 
 Anti-sense 5'-ATGCG CTTGA ACTCT CTCTG C-3'  
SFRP4 Sense 5'-CCAGA CATGA TGGTA CAGGA AAG-3' 380 
 Anti-sense 5'-CTTTTACTAAGCTGATCTCTCCAT-3'  
SFRP5 Sense 5'-CAGAT GTGCT CCAGT GACTT TG-3' 346 
 Anti-sense 5'-AGAAG AAAGG GTAGT AGAGG GAG-3'  
GAPDH Sense 5'-CGGAG TCAAC GGATT TGGTC GTAT-3' 307 





Appendix 5: Effects of SFRP2 on 84 related Wnt components and target genes in 
U2OS cells using Human Wnt signaling real time PCR array analysis. The gene 
symbol, gene description, fold-change and p-value were reported for each gene. Genes 
that are significantly dysregulated (p-value < 0.05) are bold and indicated with *.  
 
Gene 




Genes that are up-regulated with SFRP2 over-expression 
 
AES  Amino-terminal enhancer of split 1.774 0.0829 
APC * Adenomatosis polyposis coli 2.163 0.0019 
AXIN1 Axin 1 1.102 0.2615 
BCL9 B-cell CLL/lymphoma 9 1.050 0.4808 
BTRC * Beta-transducin repeat containing 1.226 0.0106 
CCND2 * Cyclin D2 2.627 0.000076 
CCND3 Cyclin D3 1.060 0.6606 
CSNK1D * Casein kinase 1, delta 1 1.959 0.0010 
CSNK1G1*  Casein kinase 1, gamma 1 3.466 0.00026 
CSNK2A1 Casein kinase 1, alpha 1 polypeptide 1.231 0.3178 
CTBP1 C-terminal binding protein 1 1.057 0.2074 
CTBP2 * C-terminal binding protein 2 2.028 0.00054 
CTNNBIP1 Catenin, beta interacting protein 1 1.283 0.4021 
CXXC4 CXXC finger 4 1.074 0.0945 
DIXDC1 DIX domain containing 1 1.230 0.3597 
DKK1 * Dickkopf homolog 1 (Xenopus laevis) 3.317 0.000005 
DVL1 * Dishevelled, dsh homolog 1 (Drosophila) 1.376 0.0074 
DVL2 * Dishevelled, dsh homolog 2 (Drosophila) 2.245 0.0011 
EP300 E1A binding protein p300 1.209 0.0957 
FBXW2 * F-box and WD repeat domain containing 2 3.776 0.0010 
FBXW4 * F-box and WD repeat domain containing 4 1.655 0.0061 
FBXW11 * 
F-box and WD repeat domain containing 
11 1.488 0.0030 
FGF4 
Fibroblast growth factor 4 (heparin secretory 
transforming protein, Kaposi sarcoma 
oncogene) 1.335 0.6212 
FOXN1 Forkhead box N1 1.251 0.2438 
FRZB  Frizzled-related protein  1.495 0.1817 
FSHB 
Follicle stimulating hormone, beta 
polypeptide 2.378 0.061762 
FZD3 * Frizzled homolog 3 (Drosophila) 1.811 0.00075 
FZD5 * Frizzled homolog 5(Drosophila) 2.627 0.0003 
FZD8 * Frizzled homolog 8 (Drosophila) 1.617 0.00134 
GSK3B * Glycogen synthase kinase 3 beta 1.480 0.00167 





Low density lipoprotein receptor-related 
protein 5 1.128 0.2017 
LRP6 
Low density lipoprotein receptor-related 
protein 6 1.128 0.0796 
NLK Nemo-like kinase 2.751 0.2345 
PITX2  
Paired-like homedomain transcription factor 
2 1.079 0.6196 
PPP2R1A 
Protein phosphatase 2(formerly 2A), 
regulatory subunit A, alpha isoform 1.286 0.4072 
RHOU Ras homolog gene family, member U 1.220 0.1463 
SENP2  SUMO1/sentrin/SMT3 specific peptidase 2 1.526 0.2469 
SFRP1 * Secreted frizzled-related protein 1 1.491 0.0026 
SFRP4 Secreted frizzled-related protein 4 1.149 0.4850 
    
SOX17 SRY (sex determining region Y)-box 17 1.338 0.3052 
T * T, brachyury homolog 1.625 0.0048 
TCF7  
Transcription factor 7 (T-cell specific, HMG-
box) 1.231 0.5227 
TLE1 * 
Tranducin-like enhancer of split 1 (E(sp1) 
homolog, Drosophila) 1.968 0.0003 
TLE2  
Tranducin-like enhancer of split 2 (E(sp1) 
homolog, Drosophila) 1.733 0.2065 
WIF1 * WNT inhibitory factor 1 3.317 0.000005 
WNT1 * 
Wingless-type MMTV integration site 
family, member 1 3.317 0.000005 
WNT10A  
Wingless-type MMTV integration site 
family, member 10A 1.021 0.8557 
WNT16 * 
Wingless-type MMTV integration site 
family, member 16 3.317 0.000005 
WNT2 * 
Wingless-type MMTV integration site 
family, member 2 3.317 0.000005 
WNT2B * 
Wingless-type MMTV integration site 
family, member 2B 1.159 0.0047 
WNT3 * 
Wingless-type MMTV integration site 
family, member 3 1.408 0.0369 
WNT3A 
Wingless-type MMTV integration site 
family, member 3A 1.526 0.0967 
WNT4 
Wingless-type MMTV integration site 
family, member 4 1.021 0.8764 
WNT6  
Wingless-type MMTV integration site 
family, member 6 1.289 0.2158 
WNT7A*  
Wingless-type MMTV integration site 
family, member 7B 3.379 0.0053 
WNT8A * 
Wingless-type MMTV integration site 





Wingless-type MMTV integration site 
family, member 9A 2.154 0.0034 
 
Genes that are down-regulated with SFRP2 over-expression  
 
CCND1 * Cyclin D1 1.973 0.00029 
CSNK1A1 Casein kinase 1, alpha 1 1.424 0.1171 
CTNNB1 
Catenin(cadherin-associated protein), beta 1, 
88kDa 1.099 0.1991 
DAAM1 
Dishevelled associated activator of 
morphogenesis 1 1.110 0.3138 
FOSL1  FORolike antigen 1 1.190 0.6883 
FRAT1 
Frequently rearranged in advanced T-cell 
lymphomas 1.151 0.4000 
FZD1 Frizzled homolog 1 (Drosophila) 1.260 0.0893 
FZD2 * Frizzled homolog 2 (Drosophila) 1.875 0.0052 
FZD4 * Frizzled homolog 4 (Drosophila) 2.701 0.0037 
FZD6 * Frizzled homolog 6 (Drosophila) 5.016 0.000032 
FZD7 * Frizzled homolog 7 (Drosophila) 3.724 0.00062 
GSK3α Glycogen synthase kinase 3α 1.020 0.8131 
JUN * Jun oncogene 1.721 0.00039 
LEF1 * Lymphoid enhancer-binding factor 1 1.434 0.0533 
MYC  
V-myc myelocytomatosis viral oncogene 
homolog (avian) 1.077 0.5938 
NKD1 * Naked cuticle homolog 1 (Drosophila) 1.628 0.0048 
PORCN Porcupine homolog (Drosophila) 1.257 0.3911 
PPP2CA 
Protein phosphatase 2(formerly 2A), catalytic 
subunit, alpha isoform 1.140 0.2990 
PYGO1 Pygopus homolog (Drosophila) 2.357 0.0806 
SLC9A3R1 
* 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1  1.146 0.0118 
TCF7L1  
Transcription factor 7-like 1 (T-cell specific, 
HMG-box) 1.162 0.1494 
WISP1 * 
WNT inducible signaling pathway protein 
1 7.569 0.00025 
WNT11 * 
Wingless-type MMTV integration site 
family, member 11 11.210 0.00025 
WNT5A * 
Wingless-type MMTV integration site 
family, member 5A 1.853 0.0022 
WNT5B * 
Wingless-type MMTV integration site 
family, member 5B 1.519 0.0054 
WNT7B 
Wingless-type MMTV integration site 





Appendix 6: Effects of SFRP5 on 84 related Wnt components and target genes in 
U2OS cells using Human Wnt signaling real time PCR array analysis. The gene 
symbol, gene description, fold-change and p-value were reported for each gene. Genes 
that are significantly dysregulated (p-value < 0.05) are bold and indicated with *.  
 
Gene 




Genes that are up-regulated with SFRP5 over-expression 
 
AES * Amino-terminal enhancer of split 2.163 0.0410 
APC * Adenomatosis polyposis coli 1.794 0.0380 
AXIN1 Axin 1 1.141 0.4515 
BTRC * Beta-transducin repeat containing 1.798 0.0404 
FZD5 Frizzled homolog 5(Drosophila) 1.289 0.2411 
CCND3 Cyclin D3 1.060 0.6979 
CSNK1D Casein kinase 1, delta 1 1.045 0.5434 
CSNK1G1*  Casein kinase 1, gamma 1 2.052 0.00046 
CTBP1 C-terminal binding protein 1 1.060 0.6914 
CTBP2 C-terminal binding protein 2 1.089 0.5701 
CTNNB1 
Catenin(cadherin-associated protein), beta 1, 
88kDa 1.372 0.1697 
CTNNBIP1 Catenin, beta interacting protein 1 1.023 0.8274 
CXXC4 CXXC finger 4 1.055 0.5615 
DAAM1 
Dishevelled associated activator of 
morphogenesis 1 1.043 0.7656 
DIXDC1 DIX domain containing 1 1.220 0.2515 
DKK1 * Dickkopf homolog 1 (Xenopus laevis) 1.178 0.0373 
DVL1 * Dishevelled, dsh homolog 1 (Drosophila) 1.447 0.0193 
DVL2 * Dishevelled, dsh homolog 2 (Drosophila) 1.395 0.0458 
EP300 E1A binding protein p300 1.401 0.2063 
FBXW2 * F-box and WD repeat domain containing 2 2.757 0.0186 
FBXW11 * F-box and WD repeat domain containing 11 1.437 0.0066 
FGF4 
Fibroblast growth factor 4 (heparin secretory 
transforming protein, Kaposi sarcoma 
oncogene) 1.181 0.5367 
FOSL1  FORolike antigen 1 1.461 0.1373 
FOXN1 Forkhead box N1 1.502 0.1666 
FRZB * Frizzled-related protein  2.445 0.00968 
FZD1 Frizzled homolog 1 (Drosophila) 1.263 0.2806 
FZD3 * Frizzled homolog 3 (Drosophila) 1.811 0.0445 
FZD8 Frizzled homolog 8 (Drosophila) 1.226 0.1030 
GSK3B Glycogen synthase kinase 3 beta 1.120 0.4285 
LEF1 Lymphoid enhancer-binding factor 1 1.043 0.8003 






V-myc myelocytomatosis viral oncogene 
homolog (avian) 2.809 0.0473 
NLK Nemo-like kinase 1.115 0.5519 
PPP2CA 
Protein phosphatase 2(formerly 2A), catalytic 
subunit, alpha isoform 1.464 0.1466 
PPP2R1A 
Protein phosphatase 2(formerly 2A), 
regulatory subunit A, alpha isoform 1.069 0.6371 
SENP2 * SUMO1/sentrin/SMT3 specific peptidase 2 1.659 0.0524 
SFRP4 Secreted frizzled-related protein 4 1.505 0.0686 
FBXW4 F-box and WD repeat domain containing 4 1.272 0.1951 
SLC9A3R1 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1  1.040 0.6586 
SOX17 SRY (sex determining region Y)-box 17 1.526 0.2289 
T * T, brachyury homolog (mouse) 1.441 0.0265 
TCF7 * 
Transcription factor 7 (T-cell specific, 
HMG-box) 1.357 0.00737 
TLE2  
Tranducin-like enhancer of split 2 (E(sp1) 
homolog, Drosophila) 1.209 0.1542 
WNT10A * 
Wingless-type MMTV integration site 
family, member 10A 1.659 0.00149 
WNT16 * 
Wingless-type MMTV integration site 
family, member 16 1.566 0.0407 
WNT2B * 
Wingless-type MMTV integration site 
family, member 2B 1.366 0.0107 
WNT3 
Wingless-type MMTV integration site family, 
member 3 1.283 0.3457 
WNT3A 
Wingless-type MMTV integration site family, 
member 3A 1.128 0.6488 
WNT4 
Wingless-type MMTV integration site family, 
member 4 1.072 0.6682 
WNT5B  
Wingless-type MMTV integration site family, 
member 5B 1.117 0.1867 
WNT6  
Wingless-type MMTV integration site family, 
member 6 1.198 0.4048 
WNT7B  
Wingless-type MMTV integration site family, 
member 7B 1.107 0.7392 
WNT8A  
Wingless-type MMTV integration site family, 
member 8A 1.385 0.0757 
WNT9A 
Wingless-type MMTV integration site family, 
member 9A 1.278 0.2706 
 
Genes that are down-regulated with SFRP5 over-expression 
 




CCND1  Cyclin D1 1.278 0.2336 
CCND2 Cyclin D2 1.128 0.4163 
CSNK1A1 Casein kinase 1, alpha 1 1.002 0.8883 
CSNK2A1 Casein kinase 1, alpha 1 polypeptide 1.107 0.4711 
FRAT1 
Frequently rearranged in advanced T-cell 
lymphomas 1.326 0.3332 
FSHB 
Follicle stimulating hormone, beta 
polypeptide 1.016 0.9750 
FZD2  Frizzled homolog 2 (Drosophila) 1.094 0.8241 
FZD4 * Frizzled homolog 4 (Drosophila) 2.549 0.0156 
FZD6 Frizzled homolog 6 (Drosophila) 1.354 0.1132 
FZD7 * Frizzled homolog 7 (Drosophila) 1.341 0.0517 
GSK3A Glycogen synthase kinase 3 alpha 1.141 0.4442 
JUN Jun oncogene 1.170 0.6445 
KREMEN1 Kringle containing transmembrane protein 1 1.115 0.1604 
LRP5 
Low density lipoprotein receptor-related 
protein 5 1.149 0.7137 
NKD1 * Naked cuticle homolog 1 (Drosophila) 1.613 0.0158 
PITX2  
Paired-like homedomain trnascription factor 
2 1.079 0.5783 
PORCN Porcupine homolog (Drosophila) 1.089 0.3624 
PYGO1 Pygopus homolog (Drosophila) 1.014 0.8092 
RHOU Ras homolog gene family, member U 1.434 0.0734 
SFRP1  Secreted frizzled-related protein 1 1.587 0.1410 
TCF7L1  
Transcription factor 7-like 1 (T-cell specific, 
HMG-box) 1.016 0.9750 
TLE1 
Tranducin-like enhancer of split 1 (E(sp1) 
homolog, Drosophila) 1.263 0.0800 
WIF1 WNT inhibitory factor 1 1.016 0.9750 
WISP1 * 
WNT inducible signaling pathway protein 
1 2.848 0.00205 
WNT1 
Wingless-type MMTV integration site 
family, member 1 1.016 0.9750 
WNT11 * 
Wingless-type MMTV integration site 
family, member 11 5.566 0.00044 
WNT2 
Wingless-type MMTV integration site 
family, member 2 1.016 0.9750 
WNT5A * 
Wingless-type MMTV integration site 
family, member 5A 1.471 0.0218 
WNT7A 
Wingless-type MMTV integration site 
family, member 7A 1.411 0.1683 
 
